Prolonging the exposure to anti-cancer agents by Soepenberg, O. (Otto)
Prolonging the exposure to 
anti-cancer agents 
Otto Soepenberg 
Cover: 
Lay out: 
Opsonized liposomes uptake by macrophage; metaphor for evidence 
based medicine 
lr. C.S.R.R. Renard 
ISBN 90-9017633-0 
NUR 878 
© 2004 1 0. Soepenberg 
Prolonging the exposure to anti-cancer agents 
This PhD thesis was performed at the Department of Medical Oncology, 
Erasmus MC- Daniel den Hoed Oncology Center, Rotterdam, the Netherlands 
Publication of this thesis was financially supported by: 
Daiichi Pharmaceuticals UK Ltd. (main sponsor), Amgen Europe BY, AstraZeneca 
BY, Aventis Pharma BY, Bayer BY, Bristol-Myers Squibb BY, GlaxoSmithKline BY, 
Novartis Pharma BY, Ortho Biotech/ Janssen-Cilag BY, Roche Nederland BY en 
Sanofi-Synthelabo BY. 
All rights reserved. No parts of this thesis may be reproduced or transmitted in any 
form by any means electronic or mechanical, including photocopying, recording or any 
information storage and retrieval, without the written permission from the publisher 
Printed by: PrintPartners lpskamp, Enschede 
Prolonging the exposure to anti-cancer agents 
Verlenging van de expositieduur van antikankermiddelen 
Proefschrift 
Ter verkrijging van de graad van doctor aan 
de Erasmus Universiteit Rotterdam 
op gezag van de Rector Magnificus 
Prof. dr. S.W.J. Lamberts 
en volgens besluit van het College van Promoties 
De openbare verdediging zal plaatsvinden 
op woensdag 18 februari 2004 om 15.45 uur 
door 
Otto Soepenberg 
geboren te Enschede 
Promotiecommissie: 
Promotoren: Prof. dr. J. Verweij 
Prof. dr. G. Stater 
Overige leden: Prof. dr. A.M.M. Eggermont 
Prof. dr. A.T. van Oosterom 
Prof. dr. P. Sonneveld 
Oasis solum facit venenum [Paracelsus] 
Aan mijn ouders 


Introduction to the thesis 11 
Chapter 1 
Chapter 2 
Chapter 3 
Chapter 4 
Chapter 5 
Chapter 6 
Modulation of camptothecin analogs in the treatment of 
cancer: a review 
Anti-Cancer Drugs 2001, 12: 89-105 
19 
Phase I, pharmacokinetic, food effect, and pharmacogenetic 55 
study of oral irinotecan given as semi-solid matrix capsules 
in patients with solid tumors 
Submitted 
Phase I and pharmacokinetic study of oral irinotecan given 83 
once daily for 5 days every 3 weeks in combination with 
capecitabine in patients with solid tumors 
Submitted 
Liquid chromatographic assays for DE-310, a novel 
camptothecin analog, and two major enzymatic products 
in human matrices 
107 
J Chromatogr B Analyt Techno[ Biomed Life Sci 2004, 799: 15-22 
Phase I and pharmacokinetic study of DE-31 0, a 
macromolecular prodrug of the topoisomerase I inhibitor 
exatecan (DX-8951f), administered once every 2 or 6 weeks 
in patients with advanced solid tumors 
Submitted 
Real-time pharmacokinetic guiding clinical decisions: 
Phase I study of a weekly schedule of liposome 
encapsulated paclitaxel in patients with solid tumours 
fur J Cancer 2004, in press 
127 
151 
Summary and conclusions, Samenvatting en conclusies 171 
Publications 189 
Dankwoord 195 


Introduction to the thesis :::J 
M' 
.., 
0 
a. 
s::::: 
n 
M' 
.... 
0 
:::J 
Introduction to the thesis 
Approximately half a century ago, thousands of natural products were chemically 
screened in a program initiated by the National Cancer Institute USA to evaluate 
naturally-occuring substances for antitumor activity. This program led to the 
discovery by Wall and coworkers of camptothecin - isolated from the stem 
wood of the Chinese tree Camptotheca acuminata -, and paclitaxel - isolated 
from the Western yew Taxus Brevifolia - as potential cytotoxic agents [1· 31. The 
development of both classes of agents had in common that early phase 1/11 clinical 
trials showed unpredictable severe adverse events [4·71, which limited the initial 
enthusiasm and led to the suspension of research of these antineoplastic agents 
during the next two decades. After the recognition of the unique mechanisms of 
cytotoxic action of both camptothecin and paclitaxel, renewed interest in the 
further development of these cytotoxic agents was heralded [8-101. 
Camptothecin belongs to the class of topoisomerase I inhibitors, which results 
in the inhibition of the nuclear enzyme DNA topoisomerase I and are active in 
the S-phase of the cell cycle. DNA topoisomerases are essential enzymes for cell 
growth and proliferation. The enzyme makes a transient single-strand break in the 
supercoiled DNA duplex resulting in relaxation of supercoiled DNA. Camptothecin 
stabilizes the covalent cleavable DNA-topoisomerase I complex, which causes 
arrest of the replication fork, resulting in inhibition of DNA synthesis and finally 
cell death [9-111. 
The initial failure encountered in the clinical development of the first 
generation camptothecins was partly related to the poor aqueous solubility of 
the agent, which necessitated novel alkaline pharmaceutical formulations for 
intraveneous administration. Drug-research efforts led to the identification and 
development of new semi-synthetic derivatives with improved water solubility 
while maintaining the drug's unique mechanism of cytotoxic action. One of 
the second generation camptothecin analogs is irinotecan, which is at present 
registered for use in colorectal cancer, whilst other third generation analogs 
(e.g., exatecan, diflomotecan) are currently in clinical development. A variety 
12 of different strategies is being used to modulate the systemic delivery of the 
camptothecin analogs, frequently in order to increase antitumor activity and/ or 
reduce experienced side effects. An overview of pharmaceutical modulation 
of formulation vehicles as well as modulation of routes of administration and 
considerations on infusion duration of these analogs is discussed in Chapter 1. 
Related to theirS-phase specificity, the cytotoxicity of topoisomerase I inhibitors 
in preclinical models increases with duration of exposure. Long-term exposures 
to low concentrations are more effective than short-term exposures to high 
concentrations [121. Although, this concept established greater tumor efficacy 
compared with bolus administration in experimental studies, the optimal 
treatment and dosing regimens, such as continuous intravenous infusion, long-
term oral delivery, or polymerized drug formulations have to be more crystallized 
in further clinical investigations. 
Oral administration of irinotecan is an approach for continuous drug administration 
facilitating sustained exposure of the drug. The results of a phase I study of oral 
irinotecan, formulated as semi-solid matrix (SSM) capsules, are presented in 
Chapter 2. In addition, the results of a phase I study of the oral combination of 
irinotecan and capecitabine are described in Chapter 3. 
An alternative approach for continuous drug administration is to make use 
of a macromolecular drug-delivery system, which can comprise an active 
topoisomerase I inhibitor linked to a polyalcohol polymer. Macromolecular 
carriers have been shown to alter drug pharmacokinetics at the whole organism 
and cellular level and facilitate controlled drug-release at the tumor site. This 
concept is based on the principle that macromolecular carriers will accumulate 
and be retained preferentially in tumor tissue by a phenomenon, termed 
enhanced permeability and retention (EPR) effect introduced by Hiroshi Maeda in 
1986, which is thought to be due to tumor vasculature displaying a discontinuous 
endothelium, that allows macromolecular extravasation into tumor tissues, 
and also the lack of effective lymphatic drainage in tumors, which prevents 
efficient clearance of such accumulated macromolecules [13·161. To study the 
biodistribution of DE-310, a novel macromolecular prodrug of the topoisomerase 
I inhibitor exatecan (DX-8951f), and its two major enzymatic products in human 
matrices (i.e., erythrocytes and saliva), we developed and validated high liquid 
chromatographic assays as described in Chapter 4. In Chapter 5 we reported 
the results of a phase I and pharmacokinetic study of DE-310. In addition, 
pharmacokinetic analysis was performed in normal skin and superficial tumor 
tissue. 
The taxane diterpenoid, paclitaxel, belongs to the class of anti-microtubulin 
agents, which acts by promoting and stabilizing tubulin polymers against 13 
depolymerisation resulting in inhibition of the dynamic process of reorganization 
of microtubuli and ultimately cell death [171. Due to its poor solubility in aqueous 
solution, paclitaxel is formulated in a mixture of Cremophor EL (polyoxyethylated 
Castor oil 35) and ethanol. Cremophor EL contributes to the nonlinear 
pharmacokinetic behavior of paclitaxel and to severe side effects, including 
hypersensitivity reactions and pheripheral neurotoxicity [18·201. To overcome 
these problems associated with the current formulation of paclitaxel, a variety 
of strategies are being explored to optimize the chemotherapeutic treatment 
with this agent [21 1. One of the strategies is delivery of the drug by encapsulation 
in liposomes [221. Liposomes are also macromolecular carriers, which are able 
to leak in tumor tissues by the proposed EPR effect [23 ,241. Another issue for 
paclitaxel is to optimize its dose and schedule. Preclinical data have suggested 
that duration of exposure is an important factor in the cytotoxic activity of this 
drug [251. This has been preliminarily confirmed by the activity of prolonged (96-
hours) infusions of paclitaxel in patients with metastatic breast cancer having 
previously failed taxane therapy [26,271, and by data comparing 3-hour versus 
24-hour infusion of high dose paclitaxel in breast cancer patients [281. Another 
method to achieve extended cumulative exposure is frequent, repetitive dosing, 
such as by a weekly schedule [29-311. We performed a phase I study of liposome 
encapsulated paclitaxel (LEP) administered six-times weekly in a period of eight 
weeks as reported in Chapter 6. 
In summary, this thesis includes clinical and pharmacological studies, aiming 
at prolongation of the exposure to anti-cancer agents belonging to the class of 
topoisomerase I inhibitors, either by oral administration (i.e., oral irinotecan, 
formulated as semi-solid matrix (SSM) capsules, and the oral combination of 
irinotecan and capecitabine), or by administration as macromolecular drug-
delivery system (i.e., DE-310), as well as an anti-microtubulin agent (taxane) by 
liposomal encapsulation (i.e., LEP). 
References 
[1] Wall ME. Camptothecin and taxol: discovery to clinic. Med Res Rev 18: 299-
314, 1998 
[2] Wall ME, Wani MC, Cook CE, et al. Plant antitumor agents. I. The isolation 
and structure of camptothecine, a novel alkaloidal leukaemia and tumor 
inhibitor from Camptotheca acuminata. J Am Chern Soc 88: 3888-3890, 
14 1966 
[3] Wani M, Taylor HL, Wall ME, et al. Plant antitumor agents. VI. The isolation 
and structure of taxol, a novel antileukemic and antitumor agent from 
Taxus brevifolia. JAm Chern Soc 93: 2325-2327, 1971 
[4] Muggia FM, Creaven PJ, Hansen HH, et al. Phase I clinical trial of weekly 
and daily treatment with camptothecin (NSC-1 00880): correlation with 
preclinical studies. Cancer Chemother Rep 56: 515-521, 1972 
[5] Moertel CG, SchuttAJ, Reitemeier RJ, et at. Phase II study of camptothecin 
(NSC-1 00880) in the treatment of advanced gastrointestinal cancer. Cancer 
Chemother Rep 56: 95-101, 1972 
[6] Schaeppi U, Fleischman RW, Cooney DA. Toxicity of camptothecin (NSC-
1 00880). Cancer Treat Rev 20: 73-96, 1994 
[7] Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro 
by taxol. Nature 277:665-667, 1979 
[8] Rowinsky EK, Cazenave LA, Donehower RC. Taxol: a novel investigational 
antimicrotubule agent. J Natl Cancer lnst 82:1247-1259, 1990 
[9] Hsiang YH, Hertzberg R, Hecht S, et at. Camptothecin induces protein-
linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260: 
14873-14878, 1985 
[1 0] Hsiang YH, Liu LF. Identification of mammalian DNA topoisomerase I as an 
intracellular target of the anticancer drug camptothecin. Cancer Res 48: 
1722-1726, 1988 
[11] Hsiang YH, Lihou MG, Liu LF. Arrest of replication forks by drug-stabilized 
topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by 
camptothecin. Cancer Res 49:5077-5082, 1989 
[12] Houghton PJ, Cheshire PJ, Hallman JD, et at. Efficacy of topoisomerase 
I inhibitors, topotecan and irinotecan, administered at low dose levels 
protracted schedules to mice bearing xenografts of human tumors. Cancer 
Chemother Pharmacal 36:393-403, 1995 
[13] Matsumura Y, Maeda H. A new concept for macromolecular therapeutics 
in cancer chemotherapy; mechanism of tumoritropic accumulation of 
proteins and the antitumor agent SMANCS. Cancer Res 6:6387-6392, 1987. 
[14] Maeda H, Matsumura Y. Tumouritropic and lymphotropic principles of 
macromolecular drugs. CRC Crit Rev Ther Drug Carrier Syst 6:193-210, 
1989 
[15] Maeda H. The enhanced permeability and retention (EPR) effect in 
tumor vasculature: the key role of tumor-selective macromolecular drug 
targeting. Adv Enzyme Regul41:189-207, 2001 
[16] Maeda H, Wu J, Sawa T, et at. Tumor vascular permeability and the EPR 
effect in macromolecular therapeutics: a review. J Control Release 65:271-
284, 2000 
[17] Parness J, Horwitz SB. Taxol binds to polymerized tubulin in vitro. J Cell 
Biol 91 :479-87, 1981 
[18] Henningsson A, Karlsson MO, Vigano L, et at. Mechanism-based 
pharmacokinetic model for paclitaxel. J Clin Oneal 19:4065-4073, 2001 
:;-
....... 
""' 0 Q 
r:: 
(') 
....... 
c;· 
:::J 
15 
[19] Szebeni J, Muggia FM, Alving CR. Complement activation by Cremophor EL 
as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. 
J Natl Cancer lnst 90:300-306, 1998 
[20] ten TijeAJ, Verweij J, Laos WJ, et al. Pharmacological effects offormulation 
vehicles: implications for cancer chemotherapy. Clin Pharmacokinet 42: 
665-685, 2003 
[21] Nuijen B, Bouma M, Schellens JH, et al. Progress in the development of 
alternative pharmaceutical formulations of taxanes. Invest New Drugs 19: 
143-153,2001. 
[22] Straubinger RM, Sharma A, Murray M, et al. Novel Taxol formulations: 
Taxol-containing liposomes. J Natl Cancer lnst Monogr 15:69-78, 1993 
[23] Drummond DC, Meyer 0, Hong K, et al. Optimizing liposomes for delivery 
of chemotherapeutic agents to solid tumors. Pharmacal Rev 51:691-743, 
1999 
[24] Harrington KJ. Liposomal cancer chemotherapy: current clinical 
applications and future prospects. Expert Opin lnvestig Drugs 10:1045-
1061,2001 
[25] Lopes N, Adams E, Pitts T, et al. Cell kill and cell cycles effects of Taxol on 
human and hamster ovarian cell lines. Cancer Chemother Pharmacal 32: 
235-242, 1993 
[26] Chang A, Boros L, Garrow G, et al. Paclitaxel by 3-hour infusion followed by 
96-hour infusion on failure in patients with refractory malignant disease. 
Semin Oncol22:124-127, 1995 (suppl 6) 
[27] Seidman A, Hochhauser D, Gollub M, et al. Ninety-six-hour paclitaxel 
infusion after progression during short taxane exposure: a phase II 
pharmacokinetic and pharmacodynamic study in metastatic breast cancer. 
J Clin Oncol14:1877-1884, 1996 
[28] Smith RE, Brown AM, Mamounas EP, et al. Randomized trial of 3-hour 
versus 24-hour infusion of high-dose paclitaxel in patients with metastatic 
or locally advanced breast cancer: National Surgical Adjuvant Breast and 
Bowel Project Protocol B-26. J Clin Oncol17:3403-3411, 1999 
16 [29] Gianni L. Theoretical and practical aspects of paclitaxel scheduling. Ann 
Oncol6:861-863, 1995 
[30] Akerley W, Glantz M, Choy H, et al. Phase I trial of weekly paclitaxel in 
advanced lung cancer. J Clin On col 16:153-158, 1998 
[31] Seidman AD, Hudis CA, Albanel J, et al. Dose-dense therapy with weekly 
1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J 
Clin Oncol16:3353-3361, 1998 
--------------------------------------------------------------------------------------------------------------------------

Modulation of camptothecin analogs 
in the treatment of cancer: A review 
Diederik Kehrer 
Otto Soepenberg 
Walter Loos 
Jaap Verweij 
Alex Sparreboom 
Department of Medical Oncology, 
Erasmus MC- Daniel den Hoed, Rotterdam, the Netherlands 
Anti-Cancer Drugs 2001, 12: 89-105 
Abstract 
The topoisomerase I inhibitors reviewed in this paper are all semisynthetic 
analogs of camptothecin. Modulation of this intranuclear enzyme translates 
clinically in antitumor activity against a broad spectrum of tumors and is 
therefore subject of numerous investigations. We present preclinical and clinical 
data on camptothecin analogs that are already being used in clinical practice 
[i.e., topotecan and irinotecan (CPT-11 )] or are currently in clinical development 
(e.g., 9-aminocamptothecin, 9-nitrocamptotecin, lurtotecan, OX 8951f and BN 
80915), as well as drugs that are still only developed in a preclinical setting 
(e.g. silatecans, polymer-bound derivates). A variety of different strategies is 
being used to modulate the systemic delivery of this class of agents, frequently 
in order to increase antitumor activity and/ or reduce experienced side effects. 
Three principal approaches are being discussed, including (i) pharmaceutical 
modulation of formulation vehicles, structural alterations and the search 
for more water soluble prodrugs, (ii) modulation of routes of administration 
and considerations on infusion duration, and (iii) both pharmacodynamic and 
pharmacokinetic biomodulation. 
Introduction 
Camptothecin (CPT), a plant alkaloid isolated from Camptotheca acuminata, was 
first identified in the late 1950's [11. Due to severe and unpredictable toxic side 
effects in early clinical studies, including myelosuppression, severe diarrhea and 
hemorrhagic cystitis, the clinical development of CPT was halted in the 1970's [2-
51. In the early 1980's several important events occurred that resulted in renewed 
interest in this agent; (i) the molecular target of CPT, viz. the nuclear enzyme 
topoisomerase I, was identified. This topoisomerase I was described as an enzyme 
involved in transient scission and relegation of DNA during the replication and 
transcription phases. Binding of CPT to the topoisomerase I-DNA complex 
20 (cleavable complex) and interference with the relegation step of this process was 
recognized as the primary mechanism of action of CPT, finally leading to a double 
stranded DNA break and, ultimately, cell death [6·81. Subsequent investigations 
indicated overexpression of this topoisomerase I enzyme in various types of solid 
tumors, including ovarian and colon cancer [9,101. (ii) At the same time, it was 
shown that the failures encountered in the clinical development of CPT were 
related, at least partially, to the drug's poor water solubility, which necessitated 
pharmaceutical formulation in alkaline solutions for i. v. administration. This not 
only led to chemical modification of the original structure into an entity lacking 
antitumor activity, but also induced profound alterations in the toxicological 
behavior of the agent [11 1. 
These two key findings then boosted drug-research efforts aimed at identifying 
and developing new [(semi-)synthetic] analogs with improved aqueous solubility 
while maintaining CPT's unique mechanism of action. Some of these agents are 
currently in clinical development, whilst irinotecan (CPT-11) and topotecan are 
now registered for use in colorectal cancer [121, and ovarian and lung cancer [131, 
respectively. Both topotecan and CPT-11 underwent extensive clinical evaluation 
in phase II and Ill trials and data suggested that both drugs are also active in 
various other tumor types in addition to the indications mentioned [14, 151. 
Unlike most other CPT analogs, CPT-11 is a prodrug with very little inherent 
antitumor activity. To form the active metabolite SN-38, which is 100- to 
1 000-fold more active than the parent compound [161, CPT-11 is hydrolyzed by 
a carboxylesterase [171. SN-38 in its turn can be metabolized further by UDP 
glucuronosyltransferase 1A1 to form an inactive ~-glucuronide derivative (SN-38-
G) [181. In in vitro studies, topoisomerase I inhibitors showed more pronounced 
antitumor efficacy with protracted exposure to low concentrations. In animal 
models, low-dose prolonged exposure also resulted in less toxicity [19-231. It should 
be noted that for several reasons, including species differences in drug disposition 
and tolerability as well as intrinsic differences in tumor sensitivity, in vitro and 
animal models have been shown to be poor predictors of clinical efficacy and 
toxicity. Nonetheless, most clinical studies have focussed on low-dose exposure 
to topoisomerase I inhibitors in cancer patients [24-291. Meanwhile, numerous 
researchers are unravelling the clinical pharmacodynamics and pharmacokinetics 
of the different analogs. This has lead to an explosion in publications on this 
subject. The present review is focussed on chemical and pharmacologic aspects 
of CPT analog development, with special emphasis on the choice of routes of 
delivery and on intrinsic differences in toxicity profiles of the various analogs and 
possible ways to modulate these either pharmacodynamically or -kinetically. 
Chemical properties 
Structure-activity relationships 
Most of the currently known CPT analogs share a basic five-ring structure with 
a chiral center located at C20 in the terminal E-ring. Extensive studies on the 
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Figure 1. Structure-activity relationships of camptothecins. 
synthesis of CPT analogs and the development of structure-activity relationships 
have been carried out over recent years and some important general relationships 
have emerged l30l. While these relationships will clearly be refined in the years 
to come, current knowledge is potentially adequate for the design of improved 
analogs of CPT. This current knowledge is here summarized in Figure 1 rather 
than being described exhaustively. Structure-activity studies have also shown 
a close correlation between the ability to inhibit topoisomerase I and overall 
cytotoxic potency l31 l. For the purpose of this review, a number of regions in the 
CPT structure is particularly relevant: 
(i) It has been shown that the topoisomerase I inhibitory activity of these 
22 agents is stereospecific, with the naturally occurring ($)-isomer being 
many-fold more potent that the (R)-isomer l7 ,9l. 
(ii) In general, substitutions at C7, C9 and C1 0 tend to increase topoisomerase 
I inhibition and sometimes increase water solubility, whereas substitutions 
at C12 decrease antitumor activity l16l. 
(iii) Similarly, the formation of certain additional ring structures, e.g_ between 
C7 and C9 or C1 0 and C11 increases activity [32-351_ 
(iv) One of the principal chemical features of this class of agents is the 
presence of a lactone functionality in theE-ring, which is not only essential 
for antitumor activity, but it also confers a degree of instability to these 
agents in aqueous solutions [361. All known camptothecins can undergo a 
pH-dependent reversible interconversion between this lactone form and a 
ring-opened carboxylate (or hydroxy acid) form (Figure 2), of which only 
the lactone form is able to diffuse across cell membranes, and exert the 
characteristic topoisomerase I inhibitory activity. At neutral or physiologic 
pH, the equilibrium between the two species favors the carboxylate form 
for all the camptothecins. As outlined, an understanding of this hydrolysis 
reaction helps to explain several observations in the early development 
of these agents. Because CPT was administered as the more water-
soluble sodium salt, patients were exposed to high concentrations of the 
relatively inactive carboxylate species, whereas large amounts of drug 
were excreted in urine, where the low pH favored closure of the lactone 
ring with resulting hemorrhagic cystitis [Z,4l. The equilibrium between the 
lactone moiety ring and the carboxylate form of the camptothecins is not 
solely dependent on the pH, but also on the presence of specific binding 
proteins in the biological matrix, most notably human serum albumin (HSA). 
Following establishment of equilibration at 3T C in phosphate buffered 
saline (PBS), equal amounts of the various CPT analogs are present in the 
pharmacologically active lactone form, with values of 17, 19, 15, 13 and 
15% for CPT, 9-aminocamptothecin (9-AC), topotecan, CPT-11 and SN-38, 
respectively [371. Addition of 40 mg/ml HSA shifts the equilibrium for CPT 
and 9-AC towards the carboxylate form, with approximately 1% present 
in the lactone form at equilibrium [37,381. In contrast to HSA, addition of 
murine serum albumin to 9-AC leads to approximately 35% existing in the 
lactone form at equilibrium [381. As opposed to CPT and 9-AC, HSA actually 
stabilizes the lactone moiety of CPT-11 and SN-38, with values of 30 
and 39%, respectively, present in the lactone form at equilibrium, while 
almost no effect was seen for topotecan [371. It has been proposed that the 
differences in the percentiles present in the lactone form at equilibrium 23 
is related to sterical considerations of the various substituents at the R1 
and R2 positions (Figure 2A). For some of the more recently developed CPT 
analogs, the substituents cause sterical hindrance and prevent binding of 
the carboxylate forms to HSA, and so drive the equilibrium towards the 
lactone species. 
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Figure 2A and 2B. Chemical structures of camptothecin analogs 
Conventional drug formulations 
The inherent instability of the lactone form and the inactivity of the carboxylate 
form have posed a specific challenge to the development of a suitable dosage 
form of CPT analogs. Since the lactone form is strongly favored by an acidic 
pH, as outlined above, the currently registered agents topotecan and CPT-11 
have both been formulated in buffered dosage forms. Topotecan is available 
as a powder containing topotecan hydrochloride and tartaric acid, yielding an 
aqueous solution for infusion of pH 2.5-3.5 after reconstitution. This solution 
is stable for at least 12 hours at room temperature, whereas the dry powder 
is stable for at least 2 years at room temperature. The pharmaceutical dosage 
form of CPT-11 is similarly based on formulation of the hydrochloride form of the 
drug in an aqueous solution, containing a lactic acid-sodium hydroxide buffer 
system of pH 3.5-4.5. Current shelf-life studies have shown that the injection 
concentrate is stable for at least 3 years at room temperature when protected 
from light. 
Pharmaceutical modulation 
Alternative formulations 
In recent years, a variety of alternative pharmaceutical formulations have been 
or are currently being evaluated. Important properties of these alternatives 
will be that they allow drug doses to be delivered at levels (at least) similar to 
those achieved with the conventional formulations, and that the drugs should be 
stable for several hours in order to be handled in a clinical setting. Despite the 
tremendous efforts invested so far, only very few of the alternatives have fulfilled 
the requirements to justify clinical testing. The rationale for re-formulation of 
CPT or its analogs has been either to stabilize the lactone moieties or to induce 
sustained release combined with specific tumor targeting of these agents. An 
example of the first approach has been the formulation of CPT, CPT-11 or 10-
hydroxy-CPT in microspheres composed of poly-D,L-lactic acid or poly(D,L-lactic-
co-glycolic acid) [39-421. The influence of various encapsulation procedures on the 25 
release of these agents has been extensively examined and has shown stabilization 
of the lactone form due to an acidic microclimate of the microspheres combined 
with enhanced pharmacokinetic characteristics in animal models [431. Although 
from a theoretical perspective the modulation of CPT in this prolonged release 
system could be attractive by reducing local toxicity and improving therapeutic 
efficacy, no phase I studies have been performed so far. 
Alternatively, substantial progress has been made recently toward liposomal 
formulation of a number of important CPT analogs. Liposomes are microparticulate 
carriers that consist of one or more lipid bilayer membranes enclosing an internal 
aqueous phase. The most common constituents are synthetic or naturally 
occurring phospholipids and cholesterol. Although several reports address the 
considerations in choosing the specific liposome constituents and their physical 
properties (e.g. for CPT [21 1, topotecan [44,451 and CPT-11 [46,471), relatively little 
information has been presented on toxicity profiles and antitumor activity. A 
recent study reported, however, that liposomal topotecan, encapsulated in 
sphingomyelin/ cholesterol liposomes using an ionophore-generated proton 
gradient, was eliminated from the plasma much more slowly than the free 
drug, resulting in a 400-fold increase in systemic exposure [481. The liposomal 
preparation also protected topotecan from lactonolysis and increased antitumor 
activity in both murine and human tumor models. Likewise, data have been 
generated demonstrating that unilamellar liposomal formulations of lurtotecan 
(NX 211 [491 and SPI-355 [501) have significant therapeutic advantage over free drug 
and that the increased activity is consistent with increased systemic exposure 
and enhanced tumor-specific delivery of the drug. Based on these exciting 
data, several phase I clinical trials have been initiated with NX 211 given to 
cancer patients in either weekly or 3-weekly regimens, and preliminary findings 
corroborate the preclinical pharmacological profile of this agent [51 1. 
CPT and a number of analogs, notably topotecan, have also been formulated 
in solid-lipid nanoparticles [composed of stearic acid, soybean lecithin 
and polyoxyethylene-polypropylene copolymer (Poloxamer 188)] [521 and 
dimethyl-B-cyclodextrin to stabilize the lactone form [531. Although these systems 
are promising sustained release and drug-targeting systems in various preclinical 
models, their clinical merit has not yet been evaluated. 
Synthetic derivatives 
26 9-Aminocamptothecin 
9-AC is a semisynthetic CPT derivative which showed outstanding preclinical 
activity against a wide spectrum of tumor types, including those of breast, 
colon, lung and prostate and melanoma [541. In clinical trials, the drug has been 
very extensively studied using two different formulations based on the use of 
dimethylacetamide/polyethylene glycol400 or a colloidal dispersion preparation, 
which enhances solubility and stability. Clinical phase I investigations have been 
conducted using a variety of i. v. administration schedules, including a 30-min 
infusion given daily for 5 days every 3 weeks, and more prolonged infusion 
schedules using 24-hour, 72-hour, 96-hour and 7-day or 21-day continuous dosing 
repeated every 4 weeks [55-61 1. All of the studies report neutropenia as the dose-
limiting toxicity, while thrombocytopenia is also frequent and sometimes severe. 
Gastrointestinal toxicity is the second most reported, though not dose limiting. 
Other toxicities are considered mild to moderate. Numerous multi-institutional 
phase II studies have been conducted in several disease types, and overall, 9-AC 
shows only very modest single-agent activity and its further evaluation does not 
seem indicated [59• 62-641. It has been suggested that the lack of clinically relevant 
antitumor efficacy relates to substantial inactivation of the agent due to the 
unfavorable lactone/ carboxylate ratio in patients [381. 
Homocamptothecins 
In the search for more stabile CPT analogs, the synthetic preparation of 
derivatives bearing a ?-membered E-ring, the so-called homocamptothecins has 
been described (Figuur 2) [651. The lactone ring is stabilized by modification of 
the naturally occurring 6-membered a-hydroxylactone ring into a ?-membered~­
hydroxylactone ring by insertion of a methylene spacer between the alcohol and 
the carboxyl moiety. The lead compound in this series, i.e. homocamptothecin 
(hCPT), has been shown to be more stable than CPT, remains a highly potent 
inhibitor of both cell growth with superior topoisomerase I inhibitory activity as 
compared to CPT [66 -681 and, most interestingly, changes the sequence-specificity 
of the drug-induced DNA cleavage by topoisomerase I [691. Indeed, in contrast 
to CPT which shows a rapid hydrolysis of the lactone moiety until a pH- and 
protein-dependent equilibrium has been reached, hCPT displays a slow and 
irreversible hydrolytic lactone ring opening [?OJ. After a 3 h incubation of CPT and 
hCPT in human whole blood at 3T C, the fraction present in the lactone form was 
6% in the case of CPT and 80% in the case of hCPT. This remarkable difference is 
not only due to the slower ring opening of hCPT, but also to a higher affinity of 
hCPT for red blood cells [711. Based upon this promising feature of hCPT, a series of 
derivatives of this agent was developed that combine enhanced plasma stability 27 
and potent topoisomerase !-mediated cytotoxicity. Various fluorinated analogs 
were subsequently found to have potent cytotoxic activity against several cell 
lines, including those overexpressing a functionally active P-glycoprotein [721. 
Figure 2 (B) shows the chemical structure of BN 80915, one of the most promising 
fluorinated hCPT analogs, which recently has entered clinical phase I testing. 
Silatecans 
Using a cascade radical annulation route to the CPT family, a novel series of 
CPT analogs, viz. 7-silylcamptothecins or silatecans, have been synthesized that 
exhibited potent inhibition of topoisomerase I, dramatically improved blood 
stability and sufficient lipophilicity to favor blood-brain barrier transit [731. 
Preliminary evaluation in preclinical mouse models indicate that silatecans may 
hold significant promise for the treatment of high-grade gliomas and provide a 
rationale for proceeding with further (pre)clinical evaluation of their efficacy 
and safety versus commercially available CPT derivatives, including topotecan 
and CPT-11. 
Hexacyclic camptothecins 
Two representative agents of the hexacyclic CPT analogs are currently under 
investigation. The first of these, lurtotecan (also known as Gl147211 or GG211 ), 
is a water-soluble, totally synthetic derivative with a dioxalane moiety between 
C1 0 and C11 [741. This agent has been evaluated clinically in various phase I and 
phase II trials using a 30-min i. v. infusion given daily for 5 consecutive days or as a 
72-hour continuous i. v. infusion [75·771. The dose-limiting toxicity in both schedules 
was myelosuppression, including severe neutropenia and thrombocytopenia. 
Nonhematological toxicities were various and only mild to moderate. Because 
the oral bioavailability was highly variable and as low as 10% [781, alternative ways 
of drug administration are currently being developed, including a new liposomal 
formulation (NX 211; see above). 
The second agent, DX-8951f or exatecan mesylate, is a new water-soluble, CPT 
analog with an amino group at C1 and a fluorine at C5 [791. DX-8951f showed 
superior and a broader spectrum of antitumor activity in vitro and in vivo 
in comparison with the other CPT analogs tested [80•811. Recently, the results 
of a phase I evaluation of DX-8951f have become available, with the drug 
administered as a 30-min i. v. infusion given daily for 5 days every 3 weeks 
[82•831. Brief, noncumulative neutropenia was the most common toxicity, and was 
seen consistently at doses greater than 0.5 mg/m2/day. Other nonhematologic 
28 toxicities were mild to moderate in severity. Various other schedules, including 
a once every 3 weeks regimen with 30-min i. v. infusions [84•851 and one based on 
continuous i.v. infusions of 5 to 21 days are presently under investigation [861. 
The 30-min infusion regimen with daily administration for 5 consecutive days 
is now being tested in clinical phase II trials in various disease types, including 
non-small cell lung cancer [871, pancreatic cancer [881, ovarian cancer [891, and 
colorectal cancer [901. 
Prod rugs 
Because of the poor aqueous solubility of some CPT analogs, some major efforts 
have been put into the design and synthesis of more water-soluble prodrugs that 
could be more readily formulated than the parent drug. Many of the synthesized 
compounds have shown only marginal improvements in solubility or are too 
unstable to allow administration in a clinical setting. The instability of prodrug 
forms of, for example, CPT is particularly problematic, since the product of 
degradation (generally the parent drug) is insoluble and precipitates in aqueous 
solutions. Other synthetic approaches have produced fairly stable prodrugs, but 
the rate of active drug liberation proceeds at a too slow and variable rate. To 
date, two approaches in prodrug design have yielded agents that have progressed 
to clinical evaluation, viz. the 9-nitro derivative of CPT and polymer-coupled 
derivatives of CPT and DX-8951f. 
C9-Substituted derivatives 
One of the most extensively studied agents of this class is 9-nitrocamptothecin 
(9-NC), which acts as a partial prodrug of 9-AC [91 ,921. 9-NC has a nitro radical 
in the C9-position and is highly insoluble in water, and was initially identified 
as a precursor in the semi-synthetic production of 9-AC. Since nearly all human 
cells are able to convert 9-NC to 9-AC, including tumor cells, it has been proven 
difficult to identify whether 9-NC-mediated antitumor activity is directly 
associated with the parent drug alone or with 9-AC alone or the combination 
of both [931. Preliminary evidence generated in clinical phase II trials suggests 
that 9-NC may be potentially be useful in the treatment of advanced pancreatic 
cancer and refractory ovarian cancer using a daily times 4 or 5 per week schedule 
with the drug given orally [941. An extensive clinical phase II program is currently 
being conducted to test the efficacy of this agent against various malignant 
diseases [95 ,961. 
Polymer-bound derivatives 
One of the possible ways to modulate anticancer agents is the use of its 
attachment to macromolecules because these high molecular weight prodrug 29 
carriers can lead to reductions in systemic toxicity, longer retention time within 
the body, alterations in biological distributions and possible improvements in 
therapeutic efficacy [97,981. Its use is dependent on the concept of the enhanced 
permeability and retention (EPR) effect in solid tumors [991. This EPR effect is 
based on four general characteristics of tumor tissues in comparison with normal 
tissues: (i) hypervascularity, (ii) hyperpermeability, (iii) defective vascular 
architecture, and (iv) less efficacious drainage due to hypoplastic or minimally 
effective lymphatic system [991. The pharmacokinetic characteristics of CPT were 
the starting point to modulate its structure in this way. As indicated, CPT is highly 
insoluble in water, and by converting the C20-0H moiety into an ester coupled 
to an amino acid spacer to allow better solubilization in aqueous environments, 
several macromolecular prodrugs of CPT have been generated in recent years 
[1001. Two of these, MAG-CPT and PEG-CPT, have progressed to clinical evaluation 
[97,1001. The former consists of CPT covalently bound to a soluble polymer [N-(2-
hydroxypropyl)-methacrylamide (HPMA)] through a glycyl-aminohexanoyl-glycyl 
spacer, whereas the latter is a macromolecule derived through conjugation of 
chemically modified polyethyleneglycol with CPT at the C20-0H position. A variety 
of preclinical studies with MAG-CPT and PEG-CPT, have shown stabilization and 
sustained release of CPT, and also prolonged drug retention within experimental 
tumors [97,1011. Recently, the preliminary results of clinical phase I studies of PEG-
CPT [1021 and MAG-CPT (also referred to as PNU 166148) [1031 have been reported, 
and indicate substantially prolonged exposure times to the active species as 
compared to administration schedules of the free drugs. 
In an effort to prolong exposure times of DX-8951f to tumor tissues that might 
increase cytotoxic properties and antitumor efficacy, a prodrug has recently 
been generated by linking the agent to a biodegradable carrier via a peptide 
spacer (DE-310). Clinical evaluation of this prodrug to examine this hypothesis is 
currently being conducted. 
Routes of delivery 
Intravenous dosing and considerations of infusion duration 
I. v. administration of CPT analogs is currently the most commonly used route of 
delivery. The advantages of this route are many, including the fact that the total 
amount and duration of the administered drug can be controlled. As mentioned 
earlier, this has the advantage of controlled prolonged delivery of the drug. In 
30 this regard, most of the studies have been done with topotecan [51, and several 
of the most promising regimens have been selected to enter phase II testing, 
viz. a daily-times-five every 3 weeks 30-min schedule [104,1051, weekly or 3-weekly 
24-hour infusion [106,1071 and a 21-day continuous low-dose infusion administered 
every 4 weeks [13,25 ,27, 29,1081. Besides proposed schedule dependency on antitumor 
activity, toxicity also appears to vary considerably. Overall, the dose-limiting 
toxicity is myelosuppression, consisting primarily of neutropenia, whereas in 
some continuous infusion schedules thrombocytopenia was more pronounced 
[25,1041. Anemia and nonhematological side effects, including nausea, vomiting, 
diarrhea, fatigue, asthenia, alopecia and mucositis are common but usually 
mild, and do not seem to be schedule dependent. Most of the studies showed 
that prolonged exposure to i. v. administered topotecan is feasible. Randomized 
comparison of the daily-times-five schedule every 3 weeks and 24-h infusion 
once a week for 4 weeks repeated every 6 weeks in patients with ovarian cancer 
suggests that the daily-times-five topotecan regimen was significantly superior 
with respect to response rate [109,1101. Randomized studies between the 5-day 
schedule and the 21-day continuous infusion schedule are not yet available [111 1. 
Regarding the administration of CPT-11, different schedules are currently being 
used in Europe (350 mg/m2 as a 90-min infusion once every 3 weeks) [1121, the 
USA (125 mg/m2 given weekly as a 90-min infusion for 4 or 6 weeks) [1131 and 
Japan (100 mg/m2 given weekly as a 30-min infusion) [1141. In all these dosing 
schedules, the total amount of CPT-11 that can be tolerated in any time period 
is similar [1151. Schedules with protracted infusions that have been investigated 
vary between 96-hours weekly to 14-days continuous infusion [26 ,116,1171. The 
maximum-tolerated dose in these studies (10-30 mg/m2/day) is much lower then 
for the short-duration schedules. Surprisingly, the AUC of the active metabolite 
SN-38 reaches comparable levels as reported for the short duration regimens, 
which is not completely understood. One possible explanation would be that 
the enhanced metabolism of CPT-11 relates to saturation of carboxylesterase-
mediated conversion of CPT-11 with (high-dose) short infusion schedules. As 
for toxicity, myelosuppression and diarrhea are the dose-limiting events in all 
tested regimens. Like with topotecan, protracted low-dose schedules give more 
rise to thrombocytopenia [1161, while in shorter schedules neutropenia is more 
prominent. The influence of infusion duration of antitumor activity has not yet 
been evaluated in a randomized setting. 
Oral dosing 
As indicated, the high specificity in the mechanism of action of CPT analogs for 
the S-phase in the cell cycle has led to the recognition that the compounds may 31 
require prolonged exposure to maximize the fractional cell kill. In this regard, 
the availability of clinically useful oral formulations of currently available CPT 
analogs would provide increased convenience for the administration of chronic 
dosing regimens and the opportunity for cost-effective outpatient therapy [941. 
Since most of the CPT analogs have relatively short terminal disposition half-
lives, the use of protracted oral dosing is not necessarily the same as continuous 
i.v. infusion, although if the postulated concept of time over threshold 
concentration is a valid indication of both toxicity and efficacy, oral dosing can 
mimic continuous infusion regimens. Formal oral bioavailability studies have 
been conducted for several agents, and have yielded bioavailability values for 
topotecan of 30 to 44% [118-1201, for 9-AC of -50% depending on the formulation 
applied [121 •1221, and for lurtotecan of 11% [781. Clinical data are not yet available 
for CPT-11, although murine data show an oral bioavailability of between 10 and 
20%, depending on the dose administered [1231. 
The development toward suitable oral regimens for CPT analogs has to date been 
most extensively studied for topotecan using daily or bi-daily administration 
of 5-day [1241, 1 0-day [1251, or 21-day schedules [1261. A variety of clinical studies 
have shown that with an increase in prolonged topotecan administration by this 
route, a shift occurs in dose-limiting toxicity from hematological toxicity (mainly 
granulocytopenia) toward severe gastrointestinal side effects, most notably 
diarrhea [1271. These investigations further indicated that the schedule applied, 
rather than the applied systemic exposure per course seemed to be related to 
the type of experienced toxicity [1271. Based on these considerations, the daily-
times-five schedule has been recommended for future studies. The need for 
further clinical development of the oral topotecan formulation became even 
more important in view of recent findings that the oral formulation has similar 
efficacy in the treatment of advanced ovarian and small-cell lung cancers as 
compared to the i. v. formulation, while less hematological toxicity was observed 
[128, 1291 
Based on theoretical considerations, including the fact that carboxylesterases are 
highly expressed in human liver and the gastrointestinal tract that could result 
in presystemic metabolism to SN-38 [1301, it appears particularly attractive to 
deliver CPT-11 by the oral route. Indeed, the preliminary findings of substantially 
increased SN-38 to CPT-11 concentration ratios with oral CPT-11 administration as 
compared to i.v. administration seems to sustain this notion [131 •1321. In addition, 
oral drug administration was associated with increased persistence of circulating 
levels of the lactone form of SN-38, which might be an additional advantage with 
32 potential pharmacodynamic importance [1331. The clinical utility of oral CPT-11 
administration is currently under further investigation. 
Local drug administration 
Hepatic arterial dosing 
The narrow therapeutic window of systemic administration of CPT and its analogs 
has prompted a search toward local drug administration, with the rationale to 
obtain selectively higher activity against locally confined tumors and/ or lower 
systemic toxicity without loss of antitumor activity. The pharmacokinetic 
behavior of CPT-11 was recently compared during 5-day hepatic arterial and i. v. 
infusion in a group of cancer patients [1341. These findings indicated that arterial 
drug administration leads to significantly higher conversion of CPT-11 into the 
active metabolite as compared to the i. v. administration, although the clinical 
relevance of this observation is, as yet, unknown [1351. In recent years, various 
agents have also been used for arterial embolization in an attempt to encapsulate 
the concomitantly administered chemotherapeutic agent and, thereby, further 
enhance the local drug concentration. This concept has been tested with CPT-11 
administered with hepatic arterial chemoembolization to patients with primary 
and metastatic hepatic malignancies [1341. Further studies are clearly required 
to confirm efficacy of this treatment and should aim at measuring systemic and 
tumor tissue concentrations. 
Pulmonary delivery 
Liposomal aerosol formulations of CPT and 9-NC have recently been developed 
for nasal inhalation treatment of experimental lung tumors xenografted in nude 
mice. It was found that this preparation was strikingly effective in the treatment 
of these xenografts growing subcutaneously over the thorax at doses much lower 
than those traditionally used in preclinical models administered by other routes 
[1361. Interestingly, 9-NC aerosol therapy was also effective against established 
melanoma and osteosarcoma lung metastases [137J. Concurrent pharmacokinetic 
studies showed that this type of treatment results in a prompt pulmonary 
distribution at substantial levels that could not be achieved with conventional 
routes of delivery, including oral and intramuscular [138,1391. Overall, these data 
suggest that local delivery of CPT analogs to the respiratory tract by liposome 33 
aerosol treatment might offer advantages over existing methods in the treatment 
of some diseases. 
Intraperitoneal dosing 
Intraperitoneal (i.p.) administration has been used as a strategy for increasing 
total drug delivery to ovarian cancers confined to the peritoneal cavity. 
The pharmacokinetic behavior of topotecan suggests that a substantial 
pharmacokinetic advantage might be obtained following i.p. injection. 
Indeed, recent clinical evidence suggests very slow peritoneal clearance of 
topotecan and high peritoneal: plasma concentration ratios of >10 after i.p. drug 
administration l140l. l.p. administration of CPT-11 has also been studied recently 
in animal models and showed some potential advantages over the i.v. route. It 
appeared that the therapy was more efficient with an increase in life span and 
was less toxic as compared to the i. v. route in mice bearing C26 colon tumors. 
In addition, substantially elevated AUCs of CPT-11 and SN-38 were found in the 
peritoneum, although plasma levels were comparable to i. v. dosing [140l. The 
clinical implications of these observations have not yet been evaluated. 
Biomodulation 
Pharmacodynamic alterations 
The use of biomodulators to increase the therapeutic index of chemotherapeutic 
treatment has made a significant impact on certain diseases l141 l. A number 
of cancer chemotherapy biomodulators has been approved for clinical use 
in humans and these agents can modulate anticancer drugs through either 
pharmacodynamic or -kinetic modulations. Among extensively studied 
biomodulating agents are the class of hematopoietic growth factors to decrease 
chemotherapy-induced neutropenia and anemia. Initial attempts to increase 
topotecan dose intensity with the use of granulocyte colony-stimulating factor 
(G-CSF) failed, since thrombocytopenia and fatigue rapidly emerged as dose-
limiting effects with the daily-times-five schedule l142,143l. On the other hand, 
G-CSF administered after 5 daily infusions of topotecan permitted a 2.3-fold dose 
escalation above the maximum-tolerated dose [144,145l, although it was concluded 
that the substantial toxicity, inconvenience and costs associated with this high-
dose topotecan/G-CSF regimen does not warrant further development. Similar 
disappointing results have been obtained with topotecan or 9-AC administered 
34 by prolonged continuous infusions l146, 147l. The addition of G-CSF with CPT-11 
administration has also been advocated by some investigators l148,149l, evidence 
for increased dose intensity or clearly improved chemotherapy based on G-CSF 
support is still lacking. Therefore, the use of G-CSF outside clinical trials to 
support chemotherapeutic treatment is not recommended. 
The principal nonhematologic toxicity for all topoisomerase I inhibitors is 
gastrointestinal. Nausea and vomiting are frequent l56,75 ,104,112l, but with the 
introduction of selective serotonine antagonist of the 5HT3 -receptor, this side 
effect is adequately manageable. Diarrhea is also frequent and mild to moderate 
in severity with i. v. administration schedules. It appears to be unrelated to 
the schedule used [56 ,75 ,104,1121, except in case of CPT-11, where with the oral 
administration diarrhea becomes the prime dose-limiting toxicity especially 
when using the prolonged schedules [24,122, m,126,150J. 
In the treatment with CPT-11 two types of diarrhea can be distinguished, viz. an 
early- and a late-onset form. The early-onset diarrhea is part of a cholinergic-
like syndrome and manifests in sweating, salivation, abdominal cramping and 
diarrhea [151 1. Interestingly, this cholinergic syndrome has not been described for 
other CPT analogs. It has been argued that the unique structural features of CPT-
11, including a bipiperidino group that shows similarity with a known stimulant 
of nicotine receptors of autonomic ganglia, dimethylphenylpiperazinium iodide, 
is responsible for this phenomenon [1521. More recently, it has been found that the 
mechanism behind the transient cholinergic reaction observed clinically is more 
likely mediated through a rapid reversible inhibition of acetylcholinesterase by 
the lactone form of CPT-11 [1531. Clinical evidence indicates that this side effect 
can be adequately treated in the acute phase as well as prophylactically with the 
use of i. v. atropine. 
CPT-11-induced delayed type diarrhea has been reported to be severe (NCI-CTC 
grade 3-4) in 11-23% of the patients [113, 1541, but even the less severe diarrhea 
still might influence continuation of therapy. Moreover, diarrhea related to drug-
induced colon-mucosal damage, as observed in both rodents [1551 and humans 
[1561, can cause severe and potentially lethal illness especially during concomitant 
occurrence of neutropenia. Once delayed-type diarrhea has occurred, a high-
dose regimen loperamide renders the diarrhea manageable [1571. 
Prophylactic treatment of this frequently observed side effect has been 
investigated in numerous studies. Potential modulation of delayed-type diarrhea 
has been examined clinically with several agents, including an enkephalinase 
inhibitor [1581 and glutamine [1591, and in animal models with a lipopeptide [1601 
and interleukin-15 [1611, with different results. A recent preliminary report on 
co-treatment with thalidomide claims a good protection against diarrhea, but 35 
we still have to await pharmacokinetic results to weigh this study on its proper 
value [1621. To explain the mechanism by which CPT-11-mediated delayed-type 
diarrhea is triggered, many pharmacokinetic analyses in humans have been 
performed in order to predict the incidence of this diarrhea, with conflicting 
results. Some studies described a correlation between late-onset diarrhea and 
the systemic glucuronidation rates of SN-38 (i.e., the biliary index) l163l. Recently, 
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it was suggested from animal models, that ~-glucuronidase activity from the 
microflora in the large intestines may play a major role in the development of 
CPT-11-induced diarrhea, by mediating the hydrolysis of biliary secreted SN-
38G, thereby causing local accumulation of SN-38, which subsequently causes 
damage to the intestinal epithelium l164l. This observation has led to experiments 
in which antibiotic treatment inhibited the ~-glucuronidase activity from the 
intestinal microflora, thereby decreasing the luminal SN-38 concentration and 
subsequently reducing intestinal damage and ameliorating diarrhea l155l. A 
recent study in humans showed that antibiotic treatment with neomycin did 
not alter SN-38 pharmacokinetics in plasma, and gave protection to recurrent 
diarrhea in over 85% of the patients experiencing diarrhea in the first course 
(unpublished data, DK and AS). The expected mechanism of blocking bacterial~­
glucuronidase activity causing a subsequent rise in SN-38/SN-38G concentration 
ratio has recently been confirmed. It would be even more attractive to use an 
agent that specifically inhibits the microbial ~-glucuronidase activity. Hange-
shasin-to (also referred to as TJ14), a herbal medicine that contains the ~­
glucuronidase inhibitor baicalin, has recently been described to be a potent 
inhibitor of delayed-type diarrhea caused by CPT-11 in a rat model l165l as well as 
in humans l166l. Unfortunately there is no information yet on possible changes in 
the systemic disposition of CPT-11 and its metabolites which are likely to occur 
due to inhibition of plasma ~-glucuronidase activity by this agent, information of 
vital importance in view of antitumor activity. 
It has also been speculated based on in vitro studies, that raising pH-values in 
the intestines by intestinal alkalization might decrease reabsorption of biliary 
secreted SN-38 after i. v. CPT-11 administration and, as a result, lowers intestinal 
side effects l167l. Again, demonstration of unaltered pharmacokinetics of SN-38 
in the presence of intestinal alkalization is of crucial importance. Thus, although 
this approach might show reduced CPT-11-mediated intestinal toxicity, this may 
be a phyrric victory if a simultaneously altered metabolic clearance (by way of 
a decreased enterohepatic recirculation of SN-38) results in reduced antitumor 
activity. 
Pharmacokinetic alterations 
Intestinal metabolic systems and drug efflux pumps located in the intestinal 
mucosa represent a major limitation in the bioavailability of orally delivered 
drugs l168l. Several enzymes located in the enterocyte, like the cytochrome P450-
3A4 isoenzyme (CYP3A4), are involved in the presystemic metabolism of many 
anticancer agents, including etoposide and paclitaxel, thereby limiting the oral 
absorption of these drugs. Since CYP3A4 is involved in the metabolism of CPT-11, 
it has been proposed that the bioavailability of this agent might be substantially 
enhanced by pharmacokinetic modulation of enteric CYP3A4 activity, e.g. by 
concomitant administration of ketoconazole, erythromycin or quinidine [1691. 
Similarly, P-glycoprotein and the Breast Cancer Resistance Protein (BCRP), which 
are abundantly present in the gastrointestinal tract, have been shown recently 
to limit the intestinal absorption of various agents, including topotecan [1701. 
Combined inhibition of intestinal P-glycoprotein and BCRP by the investigational 
agent GF120918 was shown recently to increase the systemic exposure to 
topotecan in both animals and patients with the bioavailability increasing 
from a mere 30-44% to >90%, suggesting that modulation of these transporters 
simultaneously could be considered in the development of substrate anticancer 
agents given by the oral route [171 1. 
As indicated, several preclinical studies have identified CYP3A4 to form two 
pharmacologically inactive oxidation products known as APC and NPC, as one 
of the principal enzymes involved in CPT-11. In addition, it was shown that 
ketoconazole, a synthetic imidazole-type broad-spectrum antifungal agent as 
well as a potent inhibitor of CYP3A4, inhibited APC and NPC formation by 98 
and 99%, respectively, at tested concentrations as low as 1 ~M [172,1731. Previous 
investigations indicated that with standard oral doses of ketoconazole (200 
to 400 mg/day), peak plasma concentrations are in the range of 4 to 20 ~M, 
suggesting that concomitant treatment of ketoconazole is likely to substantially 
alter the disposition of CPT-11 administered i. v. to cancer patients. Indeed, a 
recent pilot pharmacokinetic study in a cancer patient receiving CPT-11 with 
or without ketoconazole indicated a substantial pharmacokinetic interaction 
between the two drugs at the level of drug metabolism, and indicated that these 
agents can not be administered together without dose adjustments (unpublished 
data, AS and JV). If confirmed in a larger group of patients, the concomitant 
administration of ketoconazole might enable CPT-11 dose reductions without 
affecting systemic exposure to the active metabolite, SN-38, and potentially 
eliminates interpatient variability in CPT-11 pharmacokinetics that arise as a result 
of (genetically-defined) patient differences in CYP3A4 expression levels [1741. 37 
There are many other potential approaches to improve the therapeutic index 
of CPT-11 through pharmacokinetic biomodulation, including modulation with 
inhibitors of biliary secretion processes mediated by P-glycoprotein and/ or 
cMOAT (e.g., cyclosporin A) and with inducers of UDP glucuronosyltransferase 
isoforms involved in SN-38 glucuronidation (e.g., phenobarbital) [175,1761. A 
clinical trial to evaluate the pharmacological and toxicological implications of 
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a combination regimen of CPT-11, cyclosporin A and phenobarbital is currently 
in progress, and preliminary findings indicate substantial antitumor activity with 
this combination without the occurrence of significant diarrhea despite a very 
low systemic exposure to SN-38 [mJ. This finding is supportive of the conjecture 
that activation of CPT-11 by intratumoral carboxylesterases might be even more 
important than circulating SN-38 concentrations [178,1791. 
Conclusions and future perspectives 
Camptothecins are among the most promising new anticancer drugs that have 
been developed in recent years. Topotecan and CPT-11 are now registered for 
the treatment of ovarian and colon cancer, respectively. The unique mechanism 
of action on topoisomerase I and activity against a broad spectrum of other 
malignancies are an ongoing stimulus for further clinical development. With the 
growing knowledge on pharmacodynamics and pharmacokinetics of the different 
campotothecin analogs, the poor water solubility and pH-dependent reversible 
interconvention between the active lactone and inactive carboxylate form, 
as well as increase in activity or stability by substitutions to specific sites on 
the molecule, much effort has and will be done to increase antitumor activity 
of this group of drugs. Meanwhile pharmacological modulation, particularly 
of CPT-11, can be of interest to reduce toxicity and to influence metabolic 
pathways. Although much effort is being put into development of new analogs, 
the question to answer remains if drugs under development will ultimately lead 
to the theoretically expected higher activity and/ or reduced toxicity. Last but 
not least, optimization of schedules, routes of administration and combination 
therapies will lead to numerous new studies in different tumor types. It is to be 
expected that in the future many new formulations and/or combinations will 
be developed. In contrast to other previously registered anticancer drugs, the 
pharmacological knowledge on how camptothecin analogs behave in humans will 
lead to a more logical and quicker development of these agents. 
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Abstract 
Purpose: To characterize the maximum-tolerated dose (MTD), recommended 
dose, dose-limiting toxicities (DLTs), pharmacokinetic profile, and food effect of 
orally administered irinotecan formulated as new semi-solid matrix capsules. 
Patients and Methods: lrinotecan was administered orally in fasted condition 
once daily for 5 consecutive days repeated every 3 weeks. Patients were 
randomly assigned to take the drug along with a high-fat, high-calorie breakfast 
for the administration at day 1 of the first or second cycle. Dosages tested were 
70 and 80 mg/m2/day. 
Results: Twenty-five patients received 101 cycles of therapy (median 2 cycles, 
range 1 - 15). During the first cycle grade 3 delayed diarrhea and grade 3 
fever were the DLTs at the dosage 80 mg/m2 I day in three out of five patients. 
Hematological and nonhematological toxicities were mild to moderate. Exposure 
to the active metabolite SN-38 was relatively high compared to intravenous 
infusion, but no relevant accumulation was observed. Food had no significant 
effect on irinotecan pharmacokinetics. One confirmed partial remission and 
ten disease stabilizations were observed in previously treated patients. No 
association was found between the UGT1 A 1 *28 genotype and the risk of severe 
irinotecan-induced toxicity. 
Conclusion: For oral irinotecan, a dose of 70 mg/m2/day for 5 consecutive days 
every 3 weeks is recommended for further studies. Delayed diarrhea was the 
main DLT as to that observed with intravenously administered irinotecan. This 
study confirms that oral administration of irinotecan is feasible and may have 
favorable pharmacokinetic characteristics. 
Introduction 
In clinical studies, irinotecan has demonstrated single-agent activity against a 
spectrum of solid tumors l1l, in particular colorectal cancer l2·9l. In two phase Ill 
56 studies, the combination of irinotecan with both bolus or infusional 5-fluorouracil 
plus folinic acid regimens for the first-line treatment of advanced and metastatic 
colorectal cancer was significantly superior over the corresponding control 
regimen in terms of response rate, time to progression and overall survival l10, 11 l. 
As a result, irinotecan has been approved for clinical use in advanced colorectal 
cancer, both as first-line therapy in combination with 5-fluorouracil and as 
salvage treatment in refractory disease l1l. 
lrinotecan requires bioactivation to form its biologically active metabolite 
SN-38 [121, that subsequently is detoxified to SN-38 glucuronide (SN-38G) by 
the polymorphic enzyme uridine diphosphate glucuronosyltransferase 1 A 1 
(UGT1A 1) [13-151_ In addition, irinotecan is metabolized by cytochrome P450 
isoenzymes CYP3A4 and CYP3A5 to form the metabolites APC and NPC [16•171. 
Furthermore, the elimination pathways of irinotecan and SN-38 are partially 
mediated by membrane-localized, energy-dependent outward drug pumps, 
belonging to the superfamily of ATP-binding cassette (ABC) transporters, like 
MDR1 P-glycoprotein (ABCB1) [18,191. 
The highest dose intensity of irinotecan is achieved with short-time infusion once 
every 2 or 3 weeks [20•21 1, and the lowest dose intensity is achieved with protracted 
continuous schedules [22•231. However, the antitumor activity of irinotecan in 
preclinical studies is dose- and schedule-dependent, with protracted low-dose 
administration being more effective and less toxic than short duration high-dose 
schedules [24•251. This is consistent with the S-phase specificity of topoisomerase I 
inhibitors. The cytotoxicity of these drugs increases with the duration of exposure 
as a consequence of the longer drug exposure allowing a greater number of cells 
to enter into, and be targeted in, the S-phase of their cycle [26•271. Therefore, 
prolonged plasma concentrations following continuous oral delivery would 
ensure therapeutic efficacy and facilitate sustained exposure of these cytotoxic 
agents. Furthermore, the high concentrations of tissue carboxylesterases in 
the liver and gastrointestinal tract may promote presystemic conversion of 
irinotecan to SN-38 [281. Finally, approximately 90% of cancer patients expressed a 
preference for oral compared with intravenous administration of chemotherapy, 
predominantly due to the convenience of administration outside a clinical setting 
of current concerns or previous problems with intravenous access, provided that 
the efficacy of the drug is not compromised [291. 
We performed this phase I study to evaluate the oral administration of irinotecan 
formulated as new SSM capsules in patients with refractory solid tumors. The 
objectives of this trial were (a) to determine the maximum-tolerated dose (MTD) 
and dose-limiting toxicities (DLTs) of irinotecan when administered once daily 
for 5 consecutive days every 3 weeks, (b) to characterize the pharmacokinetics 57 
of irinotecan and its metabolite SN-38, (c) to correlate the observed 
irinotecan-associated toxicity with genetic polymorphisms in genes involved 
in the pharmacokinetics of irinotecan, (d) to analyse the effect of food on the 
bioavailability, and (e) to evaluate preliminary antitumor activity. 
Patients and methods 
Eligibility Criteria 
Patients with a histologically confirmed diagnosis of a malignant solid tumor 
refractory to conventional chemotherapy or for whom no effective therapy 
existed were eligible. Other eligibility criteria were similar to those described 
previously l30l. Specific exclusion criteria included prior treatment with irinotecan, 
concomitant treatment with CYP3A4 inhibitors or inducers (wash-out period of at 
least 7 days since last intake), symptomatic brain metastases or leptomeningeal 
involvement, active inflammatory bowel disease, bowel (sub- )obstruction, 
chronic diarrhea, known chronic malabsorption or total colectomy or other 
major abdominal surgery that might result in substantial alteration in transit 
or absorption of oral medication. The institutional Ethical Boards approved the 
study protocol, and all patients gave written informed consent. 
Treatment and Dose-escalation 
lrinotecan was supplied as semi-solid matrix capsules, containing 5, 20 or 50 
mg of the active drug substance, and these were stored at room temperature. 
The capsules also contained lecithin and lauroyl macrogolglycerides as inactive 
ingredients and a yellowish waxy mass. The drug was supplied by Aventis Pharma 
(Antony, France) in 30 mL bottles, containing 20 capsules of the 50 mg dosage 
form and 40 capsules of the 5 mg and 20 mg dosage form. Capsules were taken 
once a day in the morning for five consecutive days with about 180 mL of water 
after an overnight fasting for at least four hours prior to the daily oral dose and 
one hour following dosing, except for the first dose of the 5-day treatment as 
described below. Compliance with the scheduled treatment was assessed at the 
end of each cycle by counting the used and returned capsules of irinotecan. 
Prophylactic anti-emetics (either metoclopramide or a serotonin 
5-hydroxytryptamine-3 receptor antagonist) were allowed one hour before 
irinotecan dosing and up to two additional times daily if necessary during all 
cycles of treatment, except for the first dose of the 5-day treatment of the first 
58 two cycles. 
For irinotecan induced delayed type diarrhea, high-dose loperamide therapy was 
administered orally consisting of a starting dose of 4 mg at the first episode of 
diarrhea followed by 2 mg every 2 hours for at least 12 hours. The patient was 
allowed to stop loperamide only after a 12 -hour diarrhea free interval. If the 
diarrhea persisted for more than 48 hours despite the recommended loperamide 
treatment, a seven days prophylactic oral antibiotic therapy (ciprofloxacine 
500 mg b. i. d.) was added in subsequent cycles. 
The effect of food on the pharmacokinetics of irinotecan and metabolite SN-38 
was assessed on the first day of the first two cycles, for which patients were 
randomly assigned to take the study drug in the fed state after a FDA-standardized 
high-fat, high-calorie breakfast, containing approximately 20% of proteins, 60% 
of lipids, and 20% of carbohydrate (approximating 1000 kcalories) l31 l, and then 
in the fasted state or to the inverse sequence. In the fed condition for the first 
dose of the 5-day treatment of either cycle 1 or 2, capsules were taken within 5 
minutes after completion of the breakfast, which was to be ingested within 30 
minutes. 
The starting dose of irinotecan, 70 mg/m2 given once daily for 5 consecutive 
days, was based on a previous phase I study with a different formulation 
involving powder-filled capsules of irinotecan l32l. Preclinical data indicated that 
the new formulation exhibited a similar absolute bioavailability of irinotecan. 
Hence, the starting dose was 10 mg/m2 /day below the MTD (80 mg/m2/day) of 
the previous study. Further dose-escalations were based on the prior dose level 
toxicity. If no significant toxicity was observed at the previous dose level, the 
dose was escalated to the next higher dose level with 10 mg/m2/day increments. 
A treatment cycle was defined as the 5 consecutive days of irinotecan 
administration plus the necessary time for the patient to recover from any 
toxicities. Cycles were to be repeated every 21 days. A minimum of 3 patients 
was to be treated at each dose level, with a minimum 1-week interval between 
the entry of the first patient and the entry of the subsequent 2 patients at any 
given dose level. Before escalation to the next dose levels all 3 patients had to 
have received at least one treatment cycle. If one of three patients experienced 
DLT, three additional patients were entered at that dose level. The MTD was 
defined as one dose level below the dose that induced DLTs in 2 out of 6 patients 
during the first cycle. DLT was defined as National Cancer Institute Common 
Toxicity Criteria (NTC-CTC) version 2.0 grade 4 neutropenia lasting for ;:: 5 
days, neutropenic fever (defined as grade 4 neutropenia with fever ;:: 38.5°(}, 
neutropenic infection (defined as grade 3-4 neutropenia with;:: grade 3 infection 
or documented infection), thrombocytopenia less than 25 x 109 /L, ;:: grade 3 
diarrhea, despite maximal loperamide support, ;:: grade 2 nausea or vomiting, 59 
failing maximal oral antiemetic therapy, or vomiting leading to discontinuation 
of the study drug intake ;:: 3 days, other ;:: grade 3 nonhematological toxicities, 
and treatment delay due to toxicities attributed to the study drug for more than 
2 weeks l33l. lntrapatient dose-escalation was not allowed. The treatment was 
resumed when the neutrophil count had recovered to ;:: 1. 5 x 1 09 I L, the platelet 
count to ;:: 100 x 109 /L, diarrhea was grade 0, and any other treatment-related 
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toxicities were ~ grade 1. Once the MTD was confirmed at least ten additional 
patients were to be enrolled at this dose level to ensure that this dose was 
feasible for phase 11/111 studies. 
Treatment Assessment 
Prior to therapy, a complete medical history was taken and a physical examination 
and clinical chemistry evaluation was performed. Weekly evaluations included 
history, physical examination, toxicity assessment. Complete blood cell counts 
were obtained twice weekly throughout cycle 1 and weekly thereafter, serum 
biochemistry was determined on day 8 and 15 of cycle 1 and weekly thereafter 
until recovery, at every subsequent cycle it was determined once every 3 
weeks. Response evaluation was performed after every two cycles and assessed 
according to RECIST [34l. Patients were treated for at least two cycles of therapy 
unless disease progression or unacceptable toxicity was encountered. 
Pharmacologic Analysis 
For pharmacokinetic analysis, blood samples were taken immediately prior to 
drug administration, and at 0.5, 1.0, 1.5, 2, 3, 4, 6, 10, 18 and 24 hours after 
administration on days 1 and 5 at cycle 1, and on day 1 at cycle 2. Urine was 
collected prior to drug administration, and at time intervals: 0- 10 hours and 10-
24 hours after administration on days 1 and 5 at cycle 1 and day 1 at cycle 2. The 
concentrations of irinotecan and SN-38 in plasma and urine were quantified by 
a validated assay based on liquid chromatography with fluorescence detection. 
The lower limits of quantitation were 1 ng/ml in plasma for both compounds and 
100 ng/ml and 25 ng/ml in urine for irinotecan and SN-38, respectively, using 
50-I.IL aliquots. 
Pharmacokinetic parameters were calculated by standard non-compartmental 
methods using WinNonlin software version 3.3 (Pharsight, Mountain View, CA, 
USA), using standard equations. Non-predicted accumulation was calculated as 
the ratio of AUC-over-one-dosing- interval (24 h) on day 5 over AUC-extrapolated-
to-infinity on day 1. 
Pharmacogenetic Data Analysis 
Genomic DNA was extracted from 200 Ill plasma using a total nucleic acid 
extraction kit on a MagnaPure LC (Roche, Mannheim, Germany). Variations 
in the ABCB1 (nucleotide 3435 C>T) [35l, CYP3A4 (CYP3A4*3, CYP3A4*17, 
and CYP3A4*18), CYP3A5 (CYP3A5*3) genes were analyzed by polymerase 
chain reaction (PCR)-restriction fragment length polymorphism as previously 
reported [36•37J· For UGT1A1*28, a 35 cycle PCR (1 min 94°C, 1 min 60°C, and 
1 min 72 ° C) was performed using primers 5' -FAM-AAG TGA ACT CCC TGC TAC 
CT-3' and 5' -AAA GTG AAC TCC CTG CTA CC-3'. The number of TA-repeats in the 
253 bp PCR product was determined using capillary electrophoresis on an ABI 
310 (Applied BioSystems, Foster City, USA) [14•151. Genetic polymorphisms were 
correlated with pharmacokinetic parameters obtained in fasted condition cycles 
in 23 patients. 
Statistical Analysis 
Pharmacokinetic parameters from the various treatment groups were compared 
statistically using SAS version 8.2 (SAS Institute Inc., Cary, NC, USA). To compare 
the pharmacokinetic parameters with the genetic polymorphisms a Kruskal-
Wallis test (SPSS version 10.1, Paris, France) was used or a non-parametrical 
trend analysis (Stata version 7.0; Stata Corp., College Station, TX, USA) [151. All 
tests results with a P < .05 were regarded as statistically significant. 
Results 
Patient Characteristics 
A total of 25 patients (10 male and 15 female), with a median age of 53 years 
(range, 31 - 76 years) was enrolled into the study (Table 1 ). All patients were 
eligible, treated and evaluable for toxicity and DLT. All patients, except four, 
had received prior chemotherapy and/ or radiotherapy. A total of 101 cycles of 
treatment were given. Dose levels studied were 70 mg/m2 /day, and 80 mg/m2 / 
day daily-times-five every 3 weeks. Twenty-one patients were assessable for 
response. Three patients, who were not assessable for response, withdrew from 
the study before the first scheduled tumor reassessment, and one patient had a 
response, which was not properly assessed. A total of 16 patients were evaluable 
for the food effect, whereas nine patients were not evaluable for the food effect 
because of vomiting within one hour after the meal. 
Dose-Limiting Toxicity 
At the starting dose of 70 mg/m2 /day 3 patients were treated. Because no 
DLT was observed, the next dose level of 80 mg/m2 /day was explored. After 
determination of a DLT consisting of grade 3 delayed diarrhea in one out of three 
patients, this cohort was expanded (Table 2). One additional patient at this 
dose level experienced grade 3 fever, regarded as a DLT because no infection 
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was documented and other causes were not found. Subsequently, the dose of 70 
mg/m2/day was further explored with 3 additional patients. None of these three 
patients experienced DLT. Therefore, the recommended dose for phase II trials 
was set at 70 mg/m2/day for 5 consecutive days every 3 weeks, and fourteen 
additional patients were enrolled at this dose to fully assess feasibility and the 
food effect. One of these patients experienced DLT (i.e., grade 3 fatigue and 
grade 3 anorexia). 
Hematologic Toxicity and Nonhematologic Toxicity 
Hematologic and nonhematologic toxicities were mild to moderate (Table 3 and 
4, respectively). The majority of patients (68%) developed grade 1 or 2 anemia. 
The nonhematologic toxicities consisted mainly of nausea, vomiting, diarrhea, 
stomatitis, anorexia and asthenia. Most (76%) patients experienced grade 1 to 
2 nausea, and 13 out of 25 patients (52%) experienced grade 1 to 2 vomiting at 
both dose levels. Prophylactic anti-emetics either metoclopramide or serotonine 
antagonists were used to manage nausea and vomiting. Since almost every 
patient experienced vomiting during the feasibility step (dose level 70 mg/m2 / 
day), it was recommended to use oral 5-HT3-blockers from the first intake of 
oral irinotecan capsules. Grade 3 delayed diarrhea was observed in five (20%) 
patients at the 70 and 80 mg/m2 I day dosages, although was not considered 
DLTs in three patients due to suboptimal supportive treatment with loperamide. 
Grade 1 to 2 diarrhea was noted in all other patients and was easily manageable 
with loperamide support and if necessary with use of ciproxin. Grade 1 and 2 
anorexia was noted in seven (28%) patients, mostly at dose level 70 mg/m2/day. 
A grade 3 anorexia was observed in one patient at dose level 80 mg/m2/day at 
subsequent cycle and was coincidenced by inadequate anti-emetic treatment of 
severe nausea and vomiting. A grade 1 to 2 asthenia was observed in eleven (44%) 
patients at both dose levels. Four patients experienced mild alopecia (grade 
1) and one patient moderate alopecia (grade 2). Finally, a mild cholinergic 
syndrome was observed in two patients (one in cycle 1 and the other in cycle 2). 
No patient received prophylatic atropine for this adverse event. 
Characteristic 
For Dose-Limiting Toxicity 
For Food Effect 
For Efficacy 
No. of ~ycles/patient 
Median 
Ra~nge 
Gender, male : female 
.. ~~~0:11~E: ... 
WHO performance status 
0 
1 
2 
::; 2 prior regimens 
~ 3 prior re~imens 
Radiotherapy only 
Both 
None 
Tumqr .!YPE:S 
Lung 
Gastric 
.... (jyn0:ecologic 
Unknown primary tumor 
. §~i!C?llr:ii1C:l)' 
Miscellaneous 
2 
53 
Abbreviations: no., number; WHO, World Health Organization. 
No. of Patients 
25 
25 
16 
21 
10: 15 
7 
17 
13 
8 
4 
3 
2 
6 
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No. of Patients 
Dose level . With one dose: With one . [ . 1. 2/d ] ·· No. of pts. ·' d d ! . l d l d No. of cycles mg m. ay re u.ce 1 eye e e aye : 
70 20 2a 2 89 
80 5 2b 2 12 
TOTAL 25 4 4 101 
First cycle 
1120 
2/5 
Chapter 2 
Patients with DLT 
3/20 
2/5 
DLT Events at 1st cycle 
grade 3 asthenia and grade 3 
anorexia [N=1] 
grade 3 diarrhea [N=1]; 
and grade 3 fever [N=1] 
Note: 3 dose reduction from 70 mg/m2/day to 60 mg/m2/day; bdose reduction from 80 mg/m2/day to 70 mg/m2/day. 
Abbreviation: no., number; pts., patients. 
Anemia Leukocytopenia 
Grades 
Dose level No. of 1 2 3-4 1 [mgfm2fd] No. of pts. cycles 2 3 4 
70 20 89 7 6 0 1 2 0 0 
80 5 12 0 2 0 1 1 0 0 
Note: a not considered a DLT at subsequent cycle according to protocol definitions. 
Abbreviation: d, day; no., number; pts., patients. 
O'> 
U1 
1 
1 
0 
Neutropenia Thrombocytopenia 
2 3 4 1 2 3-4 
0 1a 0 0 0 0 
2 0 0 0 1 0 
z JaJdDLfJ 
Dose level No. 
[mg/m2/d] of pts. 
70 20. 
80 5 
0' 
0' 
No. of 
cycles 
89 
12 
1 
11 
1 
Diarrhea Nausea 
2 3 1 2 3 1 
7 2a,b 12 5C 0 7 
1 3a,e 1 1C 3C 1 
Chapter 2 
Vomiting Stomatitis Anorexia Asthenia 
Grades 
2 3 1 2 3 1 2 3 1 2 3 
3C 0 1 0 0 4 I ! 2 
1a 5 4 2d 
2C 2c 0 1 0 1 0 1f 1 3 0 
Note: a considered a DLT at first cycle in 1 pt., b not considered a DLT at first cycle in 1 pt. due to insufficient supportive treatment 
with loperamide, c not considered a DLT at first or subsequent cycles due to insufficient supportive treatment with anti-emetics, 
d considered DLTs at first and subsequent cycle, e not considered DLTs at first and subsequent cycle in 2 pts. due to insufficient 
supportive treatment with loperamide, r not considered a DLT at subsequent cycle. 
Abbreviation: d, day; no., number; pts., patients. 
lrinotecan SN-38 
No. Cycle 1 
of 
Cycle 2 Cycle 1 Cycle 2 
Parameters pts. Day 1 Day 5 Day 1 Day 1 Day 5 Day 1 
Dose: 70 mg/m2/day 
cmax [ng/ml] 81.3 ± 38.3 [47] 136 ± 88 [65] 101 ± 86 [86] 10.7 ± 6.0 [56] 10.0 ± 6.2 [62] 9.3 ± 4.9 [53] 
--------
---- -
Median T max [h] [range] 3 [1-6] 2 [0.5-6] 3 [1-6} 3 [1-6] 1.5 [1.5-3] 3 [1..5·4] 
---
- --
--- -·- --- --·-
AUC<0•24hl [ng·h/ml] 601 ± 241 [40] 1029 ± 814 [79] 689 ± 493 [72] 69.8 ± 52.0 [75] 77.8 ± 53.5 [69] 66.3 ± 49.3 [74] 20a 
AUC [ng·h/ml] 735 ± 400 [54] 1181 ± 940 [80] 758 ± 542 [71] i 89,6C ± 55.9 [62] 81.1C ± 50,5 [62] • 93,9 ± 68;1 [73] 
Tv. [h] 8.1 ± 4.0 [50] 8.3 ± 2.1 [25] 6.8 ± 1.7 [25] 10,6C ± 13.3 [125] 16.8C ± 21,6 [128] 11,6 ± 11.8 [102] 
- -- --------- ---- ------
------- - - ----- ---
Metabolic ratio i 0.14 ± 0.08 [57} 0.08 ± 0.04 [46} i 0.20 ± 0.22 [113] - -
- -- -
'i 
Dose: 80 mg/m2/day 
cmax [ng/ml] 86 ± 48.0 116±61 [53] !78.0 ± 79.3 [102] 6.3 ± 3.4 [53] 6.2 ± 2.2 [36] r 5.8 ± 3.7 [64] [56] 
Median T max [h] [range] 3 [0.5-6] 2 [2-4] 4 [3-6] 3 [2-3] 3 [1.5·6] 3 [2·4] 
AUC<0•24hl [ng·h/ml] 5b 656 ± 223 [34] 864 ± 562 [65] : 718 ± 560 [78] i 46.2 ± 29.2 [63] 49.8 ± 31.4 (63] 41.2. ± 38.1 [92] 
AUC [ng·h/ml] 794 ± 335 [42] 1003 ± 652 [65] 792 ± 600 [76] 88.7 ± 78.9 [89] 54.4d ± 25.5 [47] 70.6d ± 31.1 [44] 
Tv, [h] 8.7 ± 3.6 [41] 9.0 ± 1.4 [16] 6.9 ± 0.7 [10] 18.2 ± 20.2 [111] 8.9d ± 8.7 [97] 5;2d ± 1.8 [34] 
Metabolic ratio - - 0.11 ± 0.09 [80] 0.08 ± 0.08 [101 J 0.07 ± 0.01 [17] 
Note: AUC0_24h corresponding to AUC0_t on day 1 at cycle 1 and cycle 2; a PK parameters were calculated in 16 pts. out of 20 pts. on day 1 at 
cycle 2; b PK parameters were calculated in 3 pts. out of 5 pts. on day 1 at cycle 2; c Ty, and AUC were calculated in 19 pts.; d T Yz and AUC 
were calculated in 4 pts; metabolic ratio is defined as the AUC ratio of SN-38-to-irinotecan. 
Abbreviations: SD, standard deviation; CV, coefficient of variation; no., number; pts., patients; AUC, area under the plasma concentration· 
time curve; (max' peak plasma concentration; T max' time to Cmax; T112 , half-life of terminal phase. 
"' '-I z JaJdDLfJ 
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··,~ ~~t)l~ 6[~ E:ffe~tottoc:lq on irthotecal) .·pharmacokinetics: AVC ra..tio fqr oralacJ~iJ11~tratjqn 9fter a high-fat, high" 
~alol"i§!rpr~9~f9-st compa.red to fasting state 
Parameter lrinotecan SN-38 
Mean[%] 132 77 
cmqx 90% Cl [%] 94- 187 60- 98 
p-value 0.172 0.075 
----
Mean[%] 113 117 
AUC 90% Cl [%] 86 148 88- 155 
p-value 0.443 0.360 
Note: six out of twenty-five patients were not evaluable for the food effect due to vomiting on day 1 at cycle 1 and two additional 
patients were not evaluable for SN-38. 
Abbreviations: Cmax' peak plasma concentration; AUC, area under the plasma concentration-time curve; Cl, confidence interval. 
Pharmacokinetics 
After oral administration, irinotecan and SN-38 achieved peak plasma 
concentrations within 2 to 4 hours (Table 5). Typical concentration-time profiles 
for SN-38 are shown in Figure 1. The mean AUC accumulation-ratio on day 5 versus 
day 1 for irinotecan was 117% (90% confidence interval (CI), 86-160%) (P = .40), 
suggesting no accumulation of the parent drug. For SN-38, this ratio was 85% (90% 
Cl, 61-119%) (P = .43). For the entire population, the mean AUC ratio of SN-38-to-
irinotecan was approximately 13%. This metabolic ratio was dose-independent, 
and substantially higher than the ratio of about 3% measured after intravenous 
administration [381. This indicates extensive presystemic biotransformation of 
irinotecan (i.e., in the gastrointestinal tract and/or during first-pass extraction). 
As expected, the 24-hour urinary excretion of both irinotecan and SN-38 was 
low, and accounted for less than 3% and 1% of the dose, respectively. The AUC-
ratio for fed-to-fasting was approximately 1.13 for irinotecan and 1.17 for SN-38 
(both not statistically significant; Table 6), indicating no change in absorption of 
irinotecan after a high-fat meal. 
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Figure 1. Mean [ + SD] plasma concentration-time curves of SN-38 on day 1 [01] 
and day 5 [D5] at cycle 1 [N = 20] and on day 1 [D1] at cycle 2 [N = 16] after oral 
administration of irinotecan at dose level 70 mg/m2/ day 
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Polymorphism 
UGT1A1*28a 
CYP_3A4*3 
CYP3A4*17 
CYP3A4*18 
CYP3A5*3 
ABCB1 3435 C>T 
-...,J 
0 
Description No. of samples 
promoter 23 
M445T 9 
F189S 17 
L293P 20 
splice variant 22 
E1143E 22 
Chapter 2 
Genotype frequencies 
wild-type heterozygous homozygous 
variant 
13 8 
8 1 0 
17 0 0 
20 0 0 
0 1 21 
,-
2 8 12 
Note: a TA6 /TA6 is defined as wild-type, TA6/TA7 as heterozygous, TA/TA7 as homozygous variant, and TA5/TA6 as other. 
Abbreviation: no., number. 
other 
25 
I 
::i' 20 E 
...... 
l)ll 
5.. 
co 
M 
:Z 
Vl 
..... 15 0 
c: • 0 
:;:::; 
• • r:! -..... c: Cll 
• u c: 10 0 
• u til 
.....L • E • ")( I ra I ::E 5 
I 
0 
TA5/TA6 TA6/TA6 TA6/TA7 TA/TA7 
Figure 2. UGT1A1*28 polymorphism [N = 23] related to maximal concentration 
of SN-38 [ng/ml] 
Pharmacogenetics 
Five SNPs and one dinucleotide repeat were analyzed in four genes of putative 
relevance for the irinotecan absorption and disposition (Table 7). One patient 
had an extra TA repeat in both alleles ((TA)7TAA) of the UGT1A1 gene promoter 
(UGT1A1*28), whereas another patient had one TA repeat less in one of both 
alleles (TAsfTA6). The genotype frequency for TA/TA6 (N = 13) and TA/TA7 
(N = 8) were comparable with previously reported estimates in European 
Caucasians [391. Although the dose-normalized peak concentration of SN-38 in the 
fasted condition was significantly affected by UGT1 A 1 *28 genotype (P = . 026) 
(Figure 2), this was not associated with increased toxicity (i.e., severe diarrhea 
and/or neutropenia) in patients carrying the variant allele (data not shown). No 
statistically significant associations with SN-38 pharmacokinetic parameters were 
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observed in a total of 23 patients with variant alleles in CYP3A5*3 and ABCB1 
3435 C> T (P > .23). The AUC0_24h of irinotecan of the CYP3A4*1/*3 heterozygous 
individual was comparable with the AUC0•24h of irinotecan of CYP3A4*3 wild-type 
carriers, 379 versus 582.92 (SD ± 302.06) ng·h/ml, respectively. No CYP3A4*17 
(viz. associated with low CYP3A4 activity) nor CYP3A4*18 (viz. associated with 
high CYP3A4 activity) individuals were identified. 
Efficacy 
A 69-year-old male with metastatic colorectal cancer achieved a confirmed 
partial response lasting 4 months. A total of ten patients had disease stabilization 
for 6 (N = 5), 12 (N = 2), 18 (N = 2), and 24 weeks (N = 1). Ten patients had 
progressive disease after 2 cycles of chemotherapy and one patient had early 
progressive disease. 
Discussion 
The present phase I study indicates that oral irinotecan, formulated as a semi-
solid matrix capsules, administered daily for 5 consecutive days every 3 weeks, is 
feasible and safe. The principal DLT of this oral regimen was nonhematologic and 
consisted of delayed diarrhea and fever observed at dose level 80 mg/m2/day. 
The pattern of the delayed diarrhea is similar to that associated with intravenous 
administration of irinotecan and can be relieved by support of loperamide l40l. 
It has been suggested that the delayed diarrhea after irinotecan administration 
results from the direct effect of SN-38 on the intestinal mucosa l40l. At a daily 
dose of 80 mg/m2 I day, two of five patients experienced grade 3 diarrhea and 
grade 3 fever, which, according to the predefined criteria for the MTD, precluded 
further dose-escalation. Hematologic toxicity was mild to moderate and did not 
result in DLT in the first cycle. The recommended dose is 70 mg/m2/day for 5 
consecutive days every 3 weeks, and this dose level was tested for the feasibility 
and food effect. Nonhematologic toxicities attributed to oral irinotecan 
72 treatment, including vomiting, stomatitis, anorexia, asthenia, alopecia and 
symptoms associated with mild cholinergic syndrome, were similar to historical 
experience with intravenous irinotecan l1l. 
Substantial interpatient variability in pharmacokinetics of irinotecan and SN-38 
was observed in our study, which is in agreement with other phase I studies of 
oral irinotecan l30, 32,41 ·441, and can be linked to the complex pharmacology of the 
drug. After absorption of oral irinotecan, both the parent drug and SN-38 achieved 
peak plasma concentrations within 2 to 4 hours of administration of the drug. 
There was no statistically significant accumulation of SN-38 or irinotecan, and 
there was no statistically significant influence of food on the pharmacokinetics 
of irinotecan and SN-38. 
Furthermore, we found that the metabolic-ratio, defined as the AUC of SN-
38-to-irinotecan was higher with oral administration than with intravenous 
administration of irinotecan (13% versus 3%) [381, suggesting extensive presystemic 
metabolism of irinotecan. This is consistent with the high expression levels 
of irinotecan-converting carboxylesterases in the gastrointestinal tract and 
liver l45l. Presystemic metabolism of irinotecan was also observed in the other 
phase I studies with irinotecan administered either as a solution with CranGrape 
juice [301, as powder-filled capsules [32,41 ·431, or as semi-solid matrix capsules 
[441. The results of the six phase I studies of orally administered irinotecan are 
summarized in Table 8. 
In contrast with our study, the preliminary results of another phase I study of 
oral irinotecan formulated as semi-solid matrix capsules revealed an MTD of 60 
mg/m2/day daily-times-five every 3 weeks l44l. A mean (± SD) bioavailability of 
orally administered irinotecan of 25% ± 23% was found. Furthermore, the AUC 
of the active metabolite SN-38 following oral administration of irinotecan was 
50% of the value from an equivalent intravenous dose, implicating presystemic 
metabolism of irinotecan as well l44l. In addition, over a 5-day dosing-interval 
orally administered irinotecan produced substantially less systemic exposure to 
parent drug compared to intravenous treatment on the weekly-times-4 every 6 
weeks schedule, while maintaining comparable exposure to SN-38, suggesting 
that the oral route could be associated with less irinotecan-related toxicity l44l. 
In a phase I study of irinotecan given as 5-days continuous infusion in 36 patients, 
the recommended dose was 30 mg/m2 /day, with diarrhea as dose-limiting toxicity 
at dose 40 mg/m2 I day l46l. Large variations in clearance and half-life of irinotecan 
at the different dose levels (range 5- 40 mg/m2/day) were documented [461, and 
in this study the calculated mean metabolic ratio was only 3% to 7%. In another 
phase I study of irinotecan administered as a continuous low-dose infusion for 
14 days, the recommended dose was 10 mg/m2/day times-14 every 3 weeks [221. 73 
Diarrhea was a cumulative toxicity if doses were repeated at doses above 10 
mg/m2/day or for more than 17 days l22l. The dose intensity of this schedule 
was approximately 40% of the dose intensity obtained with 90-min intravenous 
infusion of irinotecan (350 mg/m2 once every 3 weeks). The mean metabolic 
ratio was 16% and was constant over dose range tested. In comparison with the 
short infusion of irinotecan, it was demonstrated that prolonged exposure to 
~ Chapter 2 
Oral substance Schedule No. of DLT events RD Reference [Dose range] pts. 
Pts. < 65 yrs: 
66 mg/m2/d 
SolUtion o{ IV irinotecan Once daily x 5 q3w 28 Grade 4 diarrhea x 5 q3w [30] 
mixed jn Cr~nGrape juice [20 -100 mg/m2 /day] Pts. ~ 65 yrs: 
50 mg/m2/d 
x 5 q3w 
Once daily x 5 q3w Neutropenic infection 80 mg/m2/day 
Powder-filled capsules 46 Grade 3 diarrhea [32] [30-90 mg/m2/day] Grade 4 vomiting x 5 q3w 
Once daily x 5 q3w Grade 3 nausea, vomiting: 50 mg/m2/day PoWder~fitled capsules 19 Grade 3 diarrhea ' [41] [30-60 mg/m2/day] Febrile neutropenia l: x5 q3w 
Powder-fitted capsules Once daily x 14 q3w 34 Grade 4 diarrhea 30 mg/m
2/day [42] 
[7.5-40 mg/m2/day] Grade 3 vomiting x 14 q3w 
PoWder-fitted capsules Once daily x 14 q3w 19 Grade 3-4 vomiting 30 mg/m
2/day [43] 
(7.5-40 mg/m2 /day] Grade 3 diarrhea x 14q3w 
Semi-Solid Matrix capsules Once daily x 5 q3w 43 Grade 3 - 4 diarrhea 60 mg/m
2 /day [44] 
(50- 70 mg/m2/day] Grade 4 neutropenia x 5 q3w 
Abbreviations: no., number; pts., patients; DLT, dose-limiting toxicity; RD, recommended dose; IV, intravenous; q, every; w, weeks. 
low-doses of irinotecan resulted in more efficient conversion of irinotecan in 
SN-38 l22l. Furthermore, the study showed that there was no saturation of the 
carboxylesterase or UGT enzyme systems during 14- to 21-days of infusion of 
irinotecan at the doses tested l22l, in contrast with in vivo experiments, which 
showed nonlinear pharmacokinetics of irinotecan as a result of decreased 
metabolic clearance reflected by carboxylesterase saturation l47•48l. 
As mentioned earlier, the cytotoxicity of topoisomerase I inhibitors is 
more displayed by exposure time-dependent rather than concentration-
dependent l24l. Schedule dependency as a result of the cell cycle specificity of 
the topoisomerase I inhibitors is more dependent on pharmacodynamics rather 
than pharmacokinetics l22l. The present study revealed that at the recommended 
dose the cumulative AUC of irinotecan is 69% of that after continuous low-dose 
(10 mg/m2/day) infusion of irinotecan for 14 days l22l, and about 25% of that 
after 350 mg/m2 every three weeks l20l, or 145 mg/m2 weekly for 4 weeks every 
6 weeks l49l. However, for SN-38 the mean cumulative AUC was about 70% of 
both the slow infusion and single high-dose infusion schedules and 50% of that 
in the weekly regimen. It therefore appears that both slow infusion and oral 
administration result in more efficient conversion of irinotecan into SN-38, which 
is reflected in the higher metabolic ratios observed with these schedules. 
In our study, no correlation was noted between irinotecan-associated toxicity and 
the UGT1A1*28 genotype, in contrast to previous observations l15•50l. The limited 
number of patients in this study may obscure such relationships. Nevertheless, 
there was a statistically significant trend (P = .026) showing that less dinucleotide 
repeats in the promoter correlate to a reduced peak concentrations of SN-38, 
and therefore to a higher level of activity of UGT in accordance with a previous 
study l51 l. Furthermore, no statistically significance between the genetic 
polymorphisms of CYP3A5*3 and ABCB1 3435 C> T and SN-38 pharmacokinetic 
parameters (P > .23) were found, in accordance with the results of a previous 
study on intravenous irinotecan metabolism and genetic polymorphisms l38l. 
This study confirms that oral administration of irinotecan, formulated as 
SSM capsules, is safe and feasible and may have improved pharmacokinetic 
characteristics with no statistical significant effect of food on drug absorption. 75 
The oral formulation can achieve sustained drug exposure in the absence of the 
disadvantages of intravenous delivery and thus with greater convenience for 
patients. A phase II study of this oral formulation of irinotecan in patients with 
metastatic breast cancer is scheduled. 
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Abstract 
Purpose: To assess the maximum-tolerated dose (MTD), dose-limiting toxicity 
(DLT), pharmacokinetics, and preliminary antitumor activity of oral irinotecan 
given in combination with capecitabine to patients with advanced, refractory 
solid tumors. 
Patients and Methods: Patients were treated from day 1 with irinotecan 
capsules given once daily for 5 consecutive days (dose, 50 to 60 mg/m2/day) 
concomitantly with capecitabine given twice daily for 14 consecutive days (dose, 
800- 1000 mg/m2); cycles were repeated every 21 days. 
Results: Twenty-eight patients were enrolled into the study and received 155 
cycles of therapy (median 5 cycles, range 1 - 18). At dose level irinotecan 
60 mg/m 2/day and capecitabine 2 x 800 mg/m 2/day, grade 3 delayed diarrhea in 
combination with grade 2 nausea, despite maximal anti-emetic support, and with 
grade 3 anorexia and colitis were the first cycle DLTs in two out of six patients, 
respectively. At the recommended doses (irinotecan 50 mg/m2/day; capecitabine 
2 x 1000 mg/m2/day), side effects were mostly mild to moderate and uniformly 
reversible. Pharmacokinetic analysis showed no interaction between oral 
irinotecan and capecitabine. Confirmed partial responses were observed in two 
patients with gallbladder carcinoma and in one patient with melanoma. Disease 
stabilization was noted in sixteen patients. 
Conclusion: The recommended phase II doses for oral irinotecan and capecitabine 
are 50 mg/m2/day for 5 consecutive days, and 2 x 1000 mg/m2/day for 14 
consecutive days repeated every 3 weeks, respectively. This study shows that 
the combination of oral irinotecan and capecitabine is feasible, well tolerated 
and convenient for the outpatient setting, and warrants further evaluation. 
Introduction 
lrinotecan is a semisynthetic derivative of the natural alkaloid camptothecin, and 
is a potent inhibitor of the enzyme topoisomerase-1 [1,21. It is registered for use in 
a broad range of tumor types and a variety of irinotecan including combination 
regimens continue to be investigated [3,71. 
Capecitabine is an oral fluoropyrimidine carbamate, which is preferentially 
converted into 5-fluorouracil (5-FU) in tumors through a cascade of three 
enzymes, carboxylesterase, cytidine deaminase, and thimidine phosphorylase 
(dThdPase) [81. After oral intake of capecitabine, the parent drug passes mainly 
unchanged from the gastrointestinal tract and is metabolized in the liver by 
carboxylesterases to 5' -deoxy-5-fluorocytidine (5' -DFCR), then by cytidine 
deaminase to 5' -deoxy-5-fluorouridine (5' -DFUR) in the liver and tumor tissues 
and finally by dThdPase to 5-FU in tumors. This minimizes the exposure of healthy 
tissues to systemic active 5-FU. 
In randomized phase Ill studies capecitabine has demonstrated essentially 
equivalent survival with decreased toxicity compared to intravenous 5-FU 
regimens [91, and currently irinotecan administered intraveneously is being 
investigated in combination with capecitabine [6, 7• 101. The development of 
oral irinotecan raises the possibility of using this agent with capecitabine in an 
all-oral regimen, possibly increasing the convenience of therapy and therefore 
potentially improving patient's quality of life. 
Against this background, we performed a phase I study to evaluate the combination 
treatment of irinotecan capsules and capecitabine given concomitantly once daily 
for 5 consecutive days and twice daily for 14 consecutive days every 3 weeks, 
respectively, in patients with refractory solid tumors. The objectives of this trial 
were (a) to determine the maximum-tolerated dose (MTD) and dose-limiting 
toxicities (DLTs) of this combination, (b) to characterize the pharmacokinetics 
of irinotecan, its metabolite SN-38, capecitabine, and its major metabolites, to 
assess a potential interaction between the compounds, and (c) to document any 
evidence of antitumor activity. 
Patients and methods 
Eligibility Criteria 
Patients with a histologically confirmed diagnosis of a malignant solid tumor 
refractory to conventional chemotherapy or for whom no effective therapy 
existed were eligible. Other eligibility criteria included the following: age 
;:: 18 years; World Health Organization performance status 0 - 2; estimated 85 
life expectancy of ;:: 12 weeks; no previous anticancer therapy for at least 4 
weeks (6 weeks for nitrosoureas or mitomycin-C); and adequate hematopoietic 
(absolute neutrophil count (ANC) ;:: 2,000/j.IL, platelet count;:: 100 x 109/L and 
hemoglobin ;:: 10.0 g/dl (or 6.2 mmol/L)), hepatic (serum total bilirubin within 
the normal institutional ranges, and serum aspartate transaminase (ASAT), 
alanine transaminase (ALAT), alkaline phosphatase ::;. 3.0 times the institutional 
upper normal limit (UNL) (s 5.0 times UNL in case of liver metastases), and renal 
(serum creatinine concentration s 1.5 mg/ dl (s 135 !Jmol!L)) function. Specific 
exclusion criteria included prior treatment with irinotecan, capecitabine or 5-FU 
(except as a bolus), concomitant treatment with cytochrome P450 3A inhibitors or 
inducers (wash-out period of at least 7 days since last intake), symptomatic brain 
metastases or leptomeningeal involvement, active inflammatory bowel disease, 
bowel (sub )obstruction, chronic diarrhea, known chronic malabsorption or total 
colectomy or other major abdominal surgery that might result in substantial 
alteration in transit or absorption of oral medication. The institutional Ethical 
Boards approved the study protocol. All patients gave written informed consent 
before study entry. 
Treatment and Dose-escalation 
lrinotecan was provided as semi-solid matrix capsules, containing 5, 20 or 50 
mg of the active drug substance, and stored at room temperature. The capsules 
contained also lecithin and lauroyl macrogolglycerides as inactive ingredients 
and a yellowish waxy mass. The drug was supplied by Aventis Pharma (Antony, 
France) in 30 ml bottles, containing 20 capsules of the 50 mg dosage form and 40 
capsules of the 5 mg and 20 mg dosage form. 
Capecitabine was provided as film-coated, oblong-shaped tablets containing 150 
and 500 mg of active substance. The tablets were already packed for the study 
in high density polyethene bottles, whereby the 150 mg tablet was packed in 
bottles containing 28 tablets and the 500 mg tablets in bottles containing 56 
tablets. Capecitabine was provided by Hoffmann-La Roche (Basel, Switzerland). 
lrinotecan and capecitabine were concomitantly administered orally during the 
first 5 days of each cycle, and afterwards treatment with capecitabine continued 
for 9 additional consecutive days. lrinotecan capsules were taken once daily in 
the morning, at the same time of the day, with about 180 ml of water after an 
overnight fasting for at least four hours prior to the daily oral dose and one hour 
following dosing. 
Capecitabine tablets were taken twice daily at the end of a meal (i.e., breakfast 
86 and dinner), in the morning two hours after intake of irinotecan capsules and 
approximately 10 to 12 hours later, for 14 consecutive days with a glass of water. 
Cycles were repeated every 3 weeks. Compliance with the scheduled treatment 
was assessed at the end of each cycle by counting the used and returned capsules 
and tablets. With the exception of days 5, 6, 14, and 15 of the first cycle, in 
which patients were hospitalized for pharmacokinetic sampling, patients were 
treated on an outpatient basis. 
Prophylactic anti-emetics (either metoclopramide or a serotonin receptor 
antagonist) were allowed one hour before irinotecan dosing and up to two 
additional times daily if necessary during all cycles of treatment. 
For irinotecan induced delayed-type diarrhea, high-dose loperamide therapy was 
administered orally consisting of a starting dose of 4 mg at the first episode of 
diarrhea followed by 2 mg every 2 hours for at least 12 hours. The patient was 
allowed to stop loperamide only after a 12-hour diarrhea free interval. If the 
diarrhea persisted for more than 48 hours despite the recommended loperamide 
treatment, a seven days prophylactic oral antibiotic therapy (ciprotloxacine 
500 mg b. i.d.) was added during subsequent cycles. 
In case of severe acute cholinergic symptoms, patients were treated curatively 
and as secondary prevention with either orally or subcutaneously administered 
atropine. 
The starting doses for irinotecan and capecitabine were 50 mg/m2/day given 
once daily and 800 mg/m2 given twice daily. The starting dose of irinotecan was 
based on results of a previous phase I study with single agent oral irinotecan and 
was 20 mg/m2/day lower than the single agent MTD [11 1. 
Further dose-escalations were based on the prior dose level toxicity. If no DLT was 
observed during the first cycle at a given dose level, then the dose was escalated 
to the next higher dose level with 10 mg/m2/day increments for irinotecan. After 
the determination of the MTD for oral irinotecan with 2 x 800 mg/m2/day of 
capecitabine, the dose of capecitabine was increased to 1000 mg/m2 given twice 
daily for 14 consecutive days and the dose of irinotecan tapered to the next 
previous dose in combination with capecitabine 800 mg/m2 twice daily. 
At least three patients were entered at each dose level. If one of three patients 
experienced DLT at the first cycle, three additional patients were entered at 
that dose level. The MTD was defined as one dose level below the dose that 
induced DLTs in 2 out of 6 patients during the first cycle, DLTs were defined 
as National Cancer Institute Common Toxicity Criteria version 2.0 (NCI-CTC) 
grade 3 neutropenia before day 7, or grade 4 neutropenia during the treatment 
cycle, or grade 4 neutropenia lasting 2: 5 days, neutropenic fever (defined as 
grade 4 neutropenia with fever 2: 38.5°C), neutropenic infection (defined as 87 
grade 3 - 4 neutropenia with 2: grade 3 infection or documented infection), 
thrombocytopenia less than 25 x 109 /L, 2: grade 3 diarrhea, despite maximal 
intensive loperamide support, 2: grade 2 nausea or vomiting, despite maximal 
oral antiemetic therapy, or vomiting leading to discontinuation of the study 
drugs intake 2: 3 days, other 2: grade 3 nonhematological toxicities (e.g., grade 
3 stomatitis, grade 3 palmar-plantar erythrodysesthesia (hand-foot syndrome)), 
and treatment delay due to toxicities attributed to the study drugs for more than 
2 weeks (12). lntrapatient dose-escalation was not allowed. The treatment was 
resumed when the neutrophil count had recovered to 2:: 1 . 5 x 1 09 I L, the platelet 
count to 2:: 100 x 109 /L, diarrhea was absent, and any other treatment-related 
toxicities were ::; grade 1. 
Treatment Assessment 
Before initiating therapy, a complete medical history was taken and a physical 
examination was performed. A complete blood cell (CBC) count, including 
hemoglobin, white cells with differential count, platelets, and serum 
biochemistry was performed, as were ECG, and chest X-ray. Weekly evaluations 
included history, physical examination, CBC, and toxicity assessment according 
to the NCI-CTC. CBC was done twice weekly throughout cycle 1 and weekly 
thereafter, serum biochemistry were done on days 8 and 15 of cycle 1 and 
weekly thereafter until recovery, and every 3 weeks at every subsequent cycle. 
Tumor evaluation was performed after every two cycles and response assessed 
according to RECIST [13]. Patients were treated for at least two cycles of therapy 
unless disease progression or unacceptable toxicity was encountered. 
Sample Collection and Drug Analysis 
For pharmacokinetic analysis, a total of 34 blood samples (total volume of 
-170 ml) (corresponding to 11 samples for irinotecan and 23 samples for 
capecitabine) were obtained from an indwelling intravenous canula and 
collected into heparin-coated tubes for irinotecan and into EDTA-containing 
tubes for capecitabine, respectively, on days 5 (irinotecan and capecitabine) and 
14 (capecitabine only) of the first cycle. The samples were taken immediately 
prior to intake of irinotecan and at 0.5, 1, 1.5, 2, 2.25, 2.50, 3, 4, 5, 6, 7, 8, 10, 
12, 18 and 24 hours after administration on day 5 at cycle 1. Samples were also 
taken immediately prior to intake of capecitabine, and at 0.25, 0. 50, 1, 2, 3, 4, 
5, 6, 8 and 10 hours after the morning intake of capectabine on day 14 of cycle 
1. After sampling, all blood specimens were immediately put in an ice-water 
88 bath (4°C} until centrifugation at 2000 rpm for 15 minutes at 4°C. Plasma samples 
were stored frozen at a temperature below -20°C, until analysis. 
Concentrations of irinotecan and its active metabolite SN-38 were quantified as 
total drug (i.e., the total of lactone and carboxylate forms) with a validated high-
performance liquid chromatographic (HPLC) assay with fluorescence detection 
following solid-phase extraction of 50-iJL samples. The lower limit of quantitation 
was 1 ng/ml. The accuracy of the assay was defined as the present difference 
between the nominal and the mean measured concentrations of quality controls, 
ranged from -2.1% to 5.4% for irinotecan, and from -0.11 to 1.2% for SN-38 in 
plasma over the analysis period. The precision of the assay, established by the 
coefficients of variation (CVs) of the quality controls, was lower than 6.5% for 
both compounds. Concentrations of capecitabine and its metabolites 5' -DFCR, 
5' -DFUR, 5-FU, and a-fluoro-]3-alanine (FBAL) were determined by HPLC with 
tandem mass-spectrometric detection. The lower limits of quantitation were 
50 ng/ml for 5' -DFUR, 11.3 ng/ml for FBAL, 10 ng/ml for capecitabine and 5'-
DFCR, and 2 ng/ml for 5-FU). The accuracy of the assay ranged from -4.3 to 3.3% 
for 5-FU, and from -5.8 to 4.0% for FBAL. The precision of the assay was lower 
than 8%, 13%, 6.2%, 11%, and 16% for capecitabine, 5'-DFCR, 5'-DFUR, 5-FU, and 
FBAL, respectively. 
Pharmacokinetic Data Analysis 
Pharmacokinetic parameters were calculated by standard non-compartmental 
methods using WinNonlin software version 3.3 (Pharsight Corp., Mountain 
View, CA, USA). The following parameters were determined for irinotecan, 
capecitabine, and their metabolites in the dosing interval (-r): peak concentration 
(CmaJ, time to Cmax (T max), area under the curve (AUC), half-life of the terminal 
phase (T y,), and the metabolic ratio of AUCs of SN-38 and irinotecan. 
Statistical Analysis 
The effect of capecitabine on irinotecan pharmacokinetics was assessed by 
comparing Cmax and AUC on day 5 of this study (concomitant combination 
step) with day 5 of monotherapy with oral irinotecan (single agent step; 
[11 l). The comparison was made with 25 patients treated at 70 mg/m2 /day or 
80 mg/m2 I day for 5 days with the single agent. The statistical analysis was 
carried out on dose-normalized Cmax and AUC(0•24h) of irinotecan and SN-38 and 
after log-transformation. The Proc-Mixed procedure of SAS software version 8.2 
(SAS Institute Inc., Cary, NC, USA) was used with treatment (concomitant intake 
of irinotecan and capecitabine versus oral irinotecan monotherapy) taken as 
fixed effect. For comparison of the metabolic ratios, Student's t-test was used. 89 
To assess a possible influence of irinotecan and SN-38 on the pharmacokinetics 
of capecitabine, a Proc-Mixed procedure was applied on log-transformed Cmax 
and AUC(0.10h) of capecitabine and its metabolites at day 5 (concomitant intake of 
irinotecan with capecitabine) versus day 14 (intake of capecitabine only) taken 
as fixed effect and patient as random effect. Of note, 1 0 hours corresponds to 
the time between the first and second daily intake of capecitabine. All tests 
results with a P < .05 were considered statistically significant. 
Results 
Patient Characteristics and Treatment administration 
Twenty-eight patients (14 male and 14 female), with a median age of 54 years, 
received 155 cycles of treatment at three dose levels. The median number of 
cycles administered per patient was five (range, 1 - 18). All patients were eligible, 
but one was not evaluable for DLT. This patient received only 4 days of treatment 
due to very rapid progressive melanoma. All but five patients had received prior 
chemotherapy and/ or radiotherapy. A total of 26 patients was assessable for 
response. The two patients not assessable for response withdrew from the study 
due to adverse events before the first scheduled tumor reassessment and not 
proper tumor assessment, respectively. Patient characteristics are listed in Table 
1. Dose levels studied were irinotecan 50 mg/m2 I day, and 60 mg/m2 I day daily-
times-five every 3 weeks, and capecitabine 800 and 1000 mg/m2 twice daily-
times-fourteen every 3 weeks. 
Dose-limiting toxicity 
Grade 3 colitis associated with grade 3 anorexia and grade 3 delayed diarrhea 
with grade 2 nausea, despite maximal anti-emetic support with a serotonin 
antagonist, were the DLTs in the first cycle at the second dose level irinotecan 
60 mg/m2/day and capecitabine 800 mg/m2 twice daily in two out of six patients 
(Table 2). Three additional patients were entered at the next lower dose level, 
i.e. the study starting dose level (irinotecan 50 mg/m2/day and capecitabine 
2 x 800 mg/m2/day). No DLTs were observed in the first cycle in these patients. 
Subsequently, the dose level irinotecan 50 mg/m2 I day and capecitabine 1000 
mg/m2 twice daily was explored. No DLTs were observed in the first 6 patients at 
this dose level. Since capecitabine 1000 mg/m2 twice daily is the most commonly 
used combination dose, it was unlikely that a higher dose in combination with 
irinotecan would be feasible, therefore the dose of capecitabine was not further 
escalated. Hence, the recommended dose for phase II trials of the oral irinotecan 
and capecitabine combination was set at 50 mg/m2/day for 5 consecutive days 
90 (i.e., total dose of 250 mg/m2) and 1000 mg/m2 twice daily for 14 consecutive 
days every 3 weeks, respectively. Thirteen additional patients were treated 
at this dose level to confirm its feasibility. Ultimately, two out of 16 patients 
experienced DLTs in the first cycle, viz. grade 3 delayed diarrhea, grade 2 nausea 
despite maximal anti-emetic supportive treatment, and grade 3 fatigue, thereby 
confirming the recommended dose level. 
Characteristic 
No. of Patients 
Total 
Assessment 
For Dose-Limiting Toxicity 
For Efficacy 
No. of cycles/patient 
Median 
Range 
Gender, male : female 
Age, years 
Median 
Range 
WHO performance status 
0 
2 
Previous therapy 
Chemotherapy 
s 2 prior regimens 
2 3 prior regimens 
Radiotherapy only 
Both 
None 
Tumor types 
Gastro-intestinal tract, including: 
Esophageal 
Gastric 
Gallbladder 
Cholangiocarcinoma 
Melanoma 
Renal cell 
Miscellaneous 
5 
1 - 18 
54 
20-74 
Abbreviations: no., number; WHO, World Health Organization. 
No. of Patients 
28 
27 
26 
14: 14 
5 
20 
3 
16 
5 
0 
8 
5 
11 
3 
4 
3 
1 
9 
2 
6 
Cl 
::r-
0 
"0 
....,. 
'1l 
...., 
w 
91 
Dose level 
\,() 
N 
{rng/m2/ day] 
lrinotecan Capecitabine 
50 2 x800 
60 2 X 800 
.50 2 X 1000 
TOTAL 
1' 
' 
No. of Patients 
No. of With 
pts. one dose 
reduced 
6 1a 
6 0 
16C 2d 
28 3 
Chapter 3 
Patients with DLT 
With one No. of 
cycle 
cycles First cycle All cycles , DLT Events at 1st cycle delayed 
2 33 0/6 2/6 
grade 3 diarrhea and 
grade 2 nausea b [N=1]; 
2 29 216 216 grade 3 diarrhea, grade 3 
anorexia and grade 3 colitis 
[N=1] 
grade 3 diarrhea and 
7 93 2/15 5/15 grade 2 nausea b [N=1]; 
grade 3 asthenia [N=1] 
11 155 
Note: a 25% dose-reduction of capecitabine due to grade 3 hand-food syndrome at 9th cycle, b grade 2 nausea despite maximal 
anti-emetic support, cone patient was not assessable for DLT, d 25% dose-reduction of capecitabine due to above-mentioned dose-
limiting toxicities. 
Abbreviations: no., number; pts., patients. 
Hematologic Toxicity 
Worst grade hematologic toxicities per patient are listed in Table 3. Overall, 
hematologic toxicity was mild to moderate across all dose levels with no grade 
4 observed. Although grade 3 leukocytopenia and grade 3 neutropenia were 
observed in four patients at doses of irinotecan 50 mg/m2/ day and capecitabine 
2 x 1000 mgfm2fday, this was not considered a DLT because the adverse event 
occurred after the first cycle and the grade 3 myelosuppression occurred after 
day 7 of the cycle. Grade 3 anemia was seen in two patients at the feasibility 
dose level irinotecan 50 mg/m2/day and capecitabine 2 x 1000 mg/m2/day, 
considered DLTs at subsequent cycles. 
Nonhematologic Toxicity 
Other nonhematologic toxicities were mild to moderate with no grade 4 toxicity 
observed are summarized in Table 4. Overall, gastrointestinal toxicity (i.e., 
diarrhea, nausea and vomiting) was the most common adverse event. Most 
(82%) patients experienced grade 1 to 2 nausea, and 17 out of 28 patients 
(61 %) experienced grade 1 to 2 vomiting. Prophylactic anti-emetics, either 
metoclopramide or serotonine antagonists, were used to manage nausea 
and vomiting. Grade 3 delayed diarrhea was observed in 5 (18%) patients 
across all dose levels, including one patient at the first dose level (irinotecan 
50 mg/m2/day and capecitabine 800 mg/m2 twice daily) considered a DLT 
at subsequent cycle, and two patients at the second dose level (irinotecan 
60 mg/m2/day and capecitabine 800 mg/m2 twice daily) not considered DLTs 
because of inappropriate supportive treatment with loperamide. Grade 1 and 2 
diarrhea was noted in 19 (70%) patients, and was manageable with supportive 
treatment with loperamide. Grade 2 anorexia was observed in 9 (32%) patients 
and one patient had grade 3 anorexia considered a DLT at the second dose level. 
In addition, grade 1 and 2 asthenia was seen in nine (32%) patients and one 
patient experienced dose-limiting (grade 3) asthenia in the first cycle at dose 
level irinotecan 50 mg/m2/day and capecitabine 2 x 1000 mg/m2/day after 5 
days of the treatment. Mild alopecia (grade 1) was seen in eight patients and 
moderate alopecia (grade 2) was encountered in four patients. Across all dose 93 
levels mild to moderate abdominal pain was noted in 8 (29%) and 2 (7%) patients, 
respectively. Hand-foot syndrome (palmar-plantar erythrodysesthesia), a well-
known adverse event of capecitabine, was seen in six patients (21% grade 1 to 2) 
all at the recommended dose of capecitabine (1000 mg/m2 twice daily). Grade 3 
hand-foot syndrome was observed in one patient at cycle 9 at the first dose level, 
considered a DLT at subsequent cycle. Mild to moderate conjunctivitis due 
Dose level 
[mg/m2/day] 
\0 
~ 
lrinotecan I Capecitabine 
50 2 x800 
60 2 X 800 
50 2 X 1000 
No. of!, No. of 
pts. .: cycles 
6 33 
6 29 
16 93 
Anemia 
1 2 3 1 
1 4 0 2 
2 3 0 3 
5 5 3a,b 2 
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Leukocytopenia Neutropenia Thrombocytopenia 
Grades 
2 3 4 1 2 3 4 1 2 3-4 
2 0 2 1 0 0 1 0 ' 0 
1 0 0 2 0 0 0 0 0 0 
4 3C 0 i 0 4 3C 0 1 1 0 
Note: a considered a DLT at first cycle in 1 pt., b considered a DLT at subsequent cycles in 2 pts., c not considered a DLT according to 
protocol definitions because adverse events occurred after day 7 of the cycle. 
Abbreviations: no., number; pts., patients 
Diarrhea Nausea Vomiting Stomatitis Anorexia HFS Asthenia 
Dos.e level 
Grades [mg/m2/day] No. : No. 
---~ --- - of ii of --·~ ---- -- -· -··-- -
lrinotecan Capecitabine pts. :bdes 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 
t 
1 i 0 : 0 t 0 . 0 50 2 X 800 6 33 4 1a 0 3 0 0 1 0 1a 
60 2 X 800 6 29 3 1 2b 3 2b,c 0 5 0 0 0 1 0 1 2 1C 0 0 0 0 1 0 
50 2 x100Q 16 93 2C 2 11b t 0 6 3b 3b 0 0 0 3 5 0 5 1 0 3 3 1c 
Note: a considered a DLT at subsequent cycles, b not considered a DLT due to inappropriate supportive treatment according to the 
protocol definitions, c considered a DLT at 1st cycle. 
Abbreviation: HFS, hand-foot syndrome; no., number; pts., patients. 
"' Ul [ Ja:)dDLfJ 
to capecitabine treatment was seen in two patients. Finally, mild and moderate 
increase of liver transaminases was noted in six (21%) and two (7%) patients, 
respectively, whereas mild hyperbilirubinemia was observed in 2 patients at the 
recommended dose level. All toxicities were reversible. In 39% of patients (N = 
11 ), cycles were delayed by one week or more. A total of three patients (11 %) 
required at least one dose reduction of irinotecan or capecitabine. 
Pharmacokinetics 
Blood samples were obtained from 26 patients, and complete pharmacokinetic 
profiles were available in 25 patients. The mean (± SD) irinotecan and SN-38 
pharmacokinetic parameters are summarized in Table 5. Oral irinotecan was 
rapidly absorbed and metabolized with peak plasma concentrations of irinotecan 
and SN-38 within 2 to 2.5 hours. lnterpatient variability was generally high with 
coefficients of variation of 36-48% for the AUC of irinotecan, and 34-84% for the 
AUC of SN-38. The SN-38-to-irinotecan AUC metabolic ratio was approximately 
13.2%, which is similar to previous observations with single agent oral irinotecan 
formulated as semi-solid matrix capsules [11 1. Pharmacokinetic parameters 
of capecitabine and its metabolites were also similar to previous findings 
(Table 6) [141. Statistical analysis revealed that the pharmacokinetics of irinotecan 
and SN-38 were not altered by the coadministration of capecitabine, although 
there was a trend towards a higher metabolic ratio (Table 7), and showed that 
the pharmacokinetics of capecitabine and its metabolites were similar on day 
5 and day 14, suggesting the absence of a pharmacokinetic interaction with 
irinotecan (Table 8). 
Efficacy 
Twenty-six patients were assessable for therapeutic activity. Three confirmed 
partial responses were documented, two in patients with metastatic gallbladder 
carcinoma lasting for~ 24 weeks, and one in a patient with metastatic melanoma 
lasting 42 weeks. A total of 16 patients demonstrated disease stabilization for 6 
(N = 5), 12 (N = 8), 18 (N = 2), 24 (N=2), and 30 weeks (N = 1). One patient was 
96 not evaluable for response because he went off study after the first cycle due to 
DLT, and no tumor reassessment was done at that time. 
Parameter 
Cmax [ng/mL] 
Median T max [hJ 
-- -·-·--·--
AUC(0-24h) [ng·h/ml] 
AUC(O-tJ [ng·h/ml] 
Tv, [hJ 
Me.tabolic ratio 
cmax [ng/ml} 
Median T max [h] 
AUC(0_24hl [ng·h/ml] 
Tv, [h] 
Metabolic ratio 
No. of pts. 
19 
6 
lrinotecan 
65.6 ± 37.1 [57] 
2.0 
529 ± 254 [48] 
529 ± 254 [48] 
8.15 ± 1.59 [20] 
81.5 ± 30.3 [37] 
2.0 
642 ± 231 [36] 
8.94 ± 1.21 [13.5] 
Note: Metabolic ratio is defined as the AUC ratio of SN-38-to-irinotecan. 
Dose: 50 mg/m2/day 
Dose: 60 mg/m2/day 
SN-38 
6.98 ± 5.49 [79] 
2.0 
68.9 ± 50.9 [74] 
67.4 ±.52.0 [77] 
0.131 ± 0.083[63] 
8.98 ± 5.64 [63] 
2.0 
91.7 ± 76. 9[84] 
0.133 ± 0.066 [50] 
Abbreviations: SD, standard deviation; CV, coefficient of variation; no, number; pts., patients; Cmax' peak plasma concentration; 
T max' time to Cmax; AUC, area under the plasma concentration-time curve; T h' half-life of terminal phase. 
"' "-.J [ Ja:JdDI.JJ 
Parameter 
cmax [ng/ml] 
, T max [h] 
AUC(O·tl [ng•h/ml] 
AUC<0.10hl[ng·h/ml] I 
Tv, [h] 
cmax [ng/ml] 
Tmax [h] 
AUC(O·tl [ng·h/ml] 
AUC<o-tohJ[ng·h/mL] 
Tl-l [h] 
"' 00 
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~~(~~%f~6~~n)~~~kiii;~~i~~P9i;am~t~rfi;,~f~~ape~ft~bine~s':oFeR, s~~PFUR, 5"fU, · at'ld••~aAtduri~g fhe· nrst cycle 
No.of 
_r:>ts. 
12 
12 
12 
12 
10 
13 
13. 
13 
13 
11 
Capecitabine 5'-DFCR 5'-DFUR 5-FU FBAL 
Day 
5 14 5 14 5 14 5 14 5 14 
Dose: 2 x 800 mg/m2/day 
3227 ± 2757 2402 ± 999 4513 ± 1316 3548 ± 1165 5421 ± 2703 4401 ± 1328 312 ± 194 257 ± 164 3378 ± 984 3568 ± 851 
[85] [42] [29] [33] [50] [30] [62] [64] [26] [24] 
1.00 0.50 1.21 2.00 1.71 2.00 1.21 
4128 ± 2409 3967 ± 1542 8856 ± 3126 7880 ± 2067 9664 ± 3063 8929 ± 1982 554 ± 286 
[58] [39] [35] [26] [32] [22] [52] 
4145 ± 2402!:3974 ± 15428885 ± 312817924 ± 2088 9758 ± 3081 9009 ± 1988 558 ± 284 
,. ' ' ' 
__ [58] [~2] - [35] . [26] [32] . [22] [51] 
0.59 ± 0.43 0.82• ± 0.24 0.75 ± 0.31 
[72] - [29] - [41] 
Dose: 2 x 1000 mg/m2/day 
2.00 
488 ± 222 
[46] 
491 ± 223 
. [45] 
0.79 ± 0.48 
[61] 
2.50 
19028 ± 
6674 [35] 
19028 ± 
6674 [35] 
3.00 
17921 ± 
4786 [27] 
17921 ± 
4786 [27] 
2.74 ± 0.48 
[18] 
6003 ± 5827 5651 ± 5360 5156 ± 3359 4578 ± 2090 4942 ± 2435 4906 ± 2928 210 ± 123 211 ± 130 4283 ± 1187 4419 ± 1101 
[97] [95] [65] [46] [49] [60] [58] [61] [28] [25] 
2.00 I; 
I' 
1.00 2.00 1.00 2.00 2.00 2.00 2.00 3.00 3.00 
7915 ± 5020 6797 ± 3904 11025 ± 10214 ± 10224 ± 10426 ± 417±151 430±161 22894 ± 22307 ± 
[63] [57] 3888 [35] 3672 [36] 3299 [32] 3524 [34] [36] [37] 9344 [41] 8719 [39] 
7929 ± 5021 '6810 ± 3904: 11034 ± 10299 ± 10347 ± I 10519 ± 422 ± 153 434 ± 161 22894 ± 22307 ± 
[63] [57] !, 3893 [35] 3663 [36] 3321 [32] ! 3533 [34] : [36] ' [37] 9344 [41] 8719 [39] 
0.98 ± 0.61 0.99b ± 0.17 0,81C ± 0,10 1,Q4C ± 0,57 2.80 ± 0.57 
- -[63] [17] [12] [55] [20] 
Note: AUC(O·r) = AUC<0.10h); a calculated on data from 11 pts.; b calculated on data from 13 pts.; c calculated on data from 10 pts. 
Abbreviations: 5' -DFCR, 5-deoxy-5-fluorocytidine; 5' -DFUR, 5-deoxy-5-fluorouridine; 5-FU, 5-fluorouracil; FBAL, a-fluoro-(3-alanine; no., number; pts., 
patients; AUC, area under the plasma concentration-time curve; Cmax' peak plasma concentration; T max' time to Cmax; T112 , half-life of terminal phase. 
Compound Parameters p-value Estimate [%] [90% Cl] 
----- ----
.lrinotecan cmax 0.2137 79.6 [51D~107.9] 
AUC(O,Z4h) 0.5120 88.9 [66.0-119.8] 
SN-38 cmax 0.8610 103.2 [76.2-139.9} 
AUC(O-Z4h) 0.4145 119.3 [83-170.7) 
Metabolic ratio 0.1127 133.0 [98.9-178,7} 
Note: Cmax and AUC on day 5 of the combination treatment in 25 patients were compared using SAS Proc-mixed procedure with 
those on day 5 of single agent oral irinotecan in 25 patients [11 1. Metabolic ratio defined as the AUC-ratio of SN-38-to-irinotecan. 
Abbreviations: Cl, confidence interval; AUC, area under the plasma concentration-time curve; Cmax' peak plasma concentration. 
"' 
"' 
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Compound 
0 
0 
Cap~dtabine 
5'-DFCR 
5-FU 
Parameters 
cniax 
AUCto-10hl 
cmax 
AUC<0-10hl 
Metabolic ratio 
cma~ 
AUC{O-fOb) 
Metabolic ratio 
cmax 
AUC<0-10hl 
Metabolic ratio 
(max 
AUC(o-1ohl 
MetaboUc ratio 
Chapter 3 
p-value Estimate [%] [90% Cl] 
0,56 108.6 [85.6-137.6] 
I 0.53 104.9 [92.3-119.3] I 
0.16 114.1 [97.7-133.3] 
0.30 108.0 [95.4-122.4] 
0.88 102.9 [75.4-140.5] 
0.57 106.7 [87.8-129.7] 
0.74 101.6 (93.6-110.3] 
Q.83 96.8 [76.()-123.4] 
0.62 107.1 (84.5-135.7] 
0.60 103.5 [92.7-115.6] 
0.93 98.6 [74.6-130.5] 
0.91 100.5. [93.0:-108.6] 
0.38 103.2 [97.2~109.6] 
0.93 98.3 [72.8-132.8] 
Note: Pharmacokinetic parameters on day 5 (test), i.e., after five days of concomitant treatment, were compared to day 14 
(reference), i.e., nine days after stop of irinotecan administration. Metabolic ratio is defined as AUC-ratio of the metabolite-to-
capecitabine. 
Abbreviations: 5' -DFCR, 5-deoxy-5-f\uorocytidine; 5' -DFUR, 5-deoxy-5-f\uorouridine; 5-FU, 5-f\uorouracil; FBAL, a-fluoro-~-alanine; 
Cl, confidence interval; AUC, area under the plasma concentration-time curve; Cmax' peak plasma concentration. 
Discussion 
The present phase I trial indicates that the oral combination of irinotecan, 
formulated as novel semi-solid matrix capsules, and capecitabine administered 
concomitantly daily for 5 and 14 consecutive days, respectively, every 3 weeks in 
patients with advanced solid tumor, is clinically safe, feasible and has demonstrated 
antitumor activity. lrinotecan and capecitabine have different mechanisms of 
action, and have synergistic or additive cytotoxicity in experimental models. In 
addition, both agents have only partially overlapping toxicities. 
Delayed diarrhea accompanied by nausea, anorexia and colitis were the 
principal DLTs of this combination regimen. Diarrhea was easily manageable by 
the use of loperamide. Hematological toxicity was mild to moderate and did 
not result in DLT in the first cycle. Nonhematologic toxicities attributed to the 
oral combination of irinotecan and capecitabine included nausea, vomiting, 
stomatitis, fatigue, alopecia, and hand-foot-syndrome. The recommended 
dose of this oral combination for further phase II study evaluation is irinotecan 
50 mg/m2/day given daily for 5 days and capecitabine 1000 mg/m2 given twice 
daily for 14 days, repeated every 3 weeks. 
Currently, the combination of irinotecan and capecitabine is tested in different 
schedules in phase I and phase II studies in advanced colorectal cancer, 
although only preliminary data are yet available l15·19l. In the majority of 
these studies intravenous irinotecan is used, while two studies apply flat-dose 
capecitabine l20, 21 1 and a third uses oral irinotecan for 14 consecutive days 
every 3 weeks in combination with capecitabine l22l. Two randomized phase 
II studies compared weekly to 3-weekly administration of irinotecan with 
capecitabine [6, 171. Higher incidences of diarrhea and life-threatening toxicity on 
the weekly regimen have led to the conclusion that the 3-weekly administration 
is preferable. Efficacy and safety of the 3-weekly regimen were interesting and 
have led to the design of phase Ill trials which are currently performed. 
Preclinical studies showed that the therapeutic efficacy of the combination of 
intravenous irinotecan and intravenous 5-FU is dose- and sequence-dependent 
l23-26l. The sequence of irinotecan preceding 5-FU by an interval of 24 h appeared 101 
superior. Furthermore, the toxicity associated with irinotecan could be eliminated 
by reducing the dose of irinotecan to at least 50% of its MTD while keeping dose of 
5-FU at 50- 75% of its MTD, without loss of the antitumor activity [26]. Increasing 
the dose of 5-FU did not contribute to additional therapeutic activity, but only 
resulted in increased toxicity. In this combination, doses of 5-FU are critical for 
therapeutic efficacy, whereas doses of irinotecan play a modulatory function in 
102 
sensitizing tumor cells for the subsequent 5-FU administration after 24 h [26]. 
In vitro studies in HCT-8 colon carcinoma cell lines showed that the combination 
of SN-38 and 5-FU resulted in increased deoxythymidine triphosphate levels and 
inhibition of deoxyuridine monophosphate (dUMP) synthesis [26]. This depletion 
of dUMP enhanced the 5-FU associated inhibition of thymidylate synthese, which 
explained the enhanced cytotoxicity of 5-FU after irinotecan administration [261. 
The pharmacokinetic results of oral irinotecan and SN-38 in the present study 
are in agreement with results of a previously published phase I study of single 
agent oral irinotecan [111, showing rapid absorption and metabolism of the drug 
with peak plasma concentrations of irinotecan and SN-38 within 2 to 3 hours 
after intake, high interpatient variability and the same dose-independent SN-
38-to-irinotecan AUC ratio. This ratio is substantially higher than that measured 
after oral administration of irinotecan than after intravenous administration 
of irinotecan [27, 281, suggesting significant presystemic biotransformation 
of irinotecan into SN-38 within the gastrointestinal tract and/or the liver. 
This is consistent with the high expression levels of irinotecan-metabolizing 
carboxylesterases in intestinal cells [291. These enzymes are also involved in 
capecitabine biotransformation, and a pharmacokinetic drug-drug interaction 
was thus theoretically possible. However, the pharmacokinetic analysis of the 
present study revealed no significant interaction between oral irinotecan and 
capecitabine, although there was a trend towards a higher metabolic ratio 
SN-38/irinotecan with concomitant administration. The pharmacokinetics of 
capecitabine and its metabolites either at day 5 or at day 14 were not modified 
by the 5-day coadministration of irinotecan. 
In conclusion, the oral combination of irinotecan with prolonged administration 
of capecitabine appears to be feasible. The antitumor activity observed in 
patients with various drug-refractory malignancies, including gallbladder 
carcinoma and melanoma, is encouraging and provides further impetus for the 
development of this combination in phase II trials. In addition, the convenience 
of oral administration of cytotoxic drugs brings new alternatives to current 
intravenous therapy. 
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Abstract 
Assays were developed for determination of DE-310, a carboxymethyldextran 
polyalcohol conjugate of the topoisomerase I inhibitor DX-8951 (exatecan) and 
two enzymatic products (i.e., glycyl-DX-8951 and unconjugated DX-8951) in 
human whole blood, erythrocytes and saliva. Sample pretreatment involved 
a single protein-precipitation step, followed by a thermolysin-mediated 
deconjugation for the parent molecule. Separation of the compounds was 
achieved on an lnertsil ODS-80A column (150 x 4.6 mm i.d; 5 !Jm PS), using 
isocratic elution. The column effluent was monitored at excitation and emission 
wavelengths of 375 and 445 nm, respectively. Validation results indicated that 
the methods are accurate and precise at lower limits of quantitation of 0. 5 
- 6. 9 ng/ ml. The methods was used to study the blood distribution and salivary 
concentrations in patients receiving DE-310. 
1. Introduction 
DE-31 0 comprises the active moiety DX-8951 (exatecan; [1 5, 95]-1-amino-
9-ethyl- 5-fluoro-1, 2, 3, 9, 12, 15-hexahydro-9- hydroxy-4-methyl-1 OH, 13H-
benzo[de]pyranol)-[3' ,4':6,7]-indolizino[1 ,2-b]quinoline-10, 13-dione), a hexa-
cyclic camptothecin derivative, linked to a biodegradable macromolecular 
carboxymethyldextran polyalcohol drug-delivery system via a glycyl-glycyl-
phenylalanyl-glycyl-peptidyl spacer (Figure 1) l1l. The biodegradable polymer 
portion of DE- 31 0 is designed to provide preferential tumoural uptake and 
sustained release of the active moiety within the tumour, as a result of an 
enhanced permeability and retention effect l2·4l. After entering the tumour area, 
DE-310 is taken up by tumour cells through endocytosis. The breakdown of the 
carrier is mediated by lysosomal enzymes, i.e. cathepsins, which results in two 
enzymatic products, viz. glycyl-DX-8951 (G-DX-8951) and unconjugated DX-8951 
(DX-8951 ). 
108 Currently, DE-310 is being tested in clinical trials administered as a 3 h infusion 
given once every 4 or 6 weeks l5, 6l. Preliminary pharmacokinetic analysis showed 
that the apparent plasma half-lifes of conjugated DX-8951, glycyl-DX-8951 (G-
DX-8951) and unconjugated DX-8951 (DX-8951) in humans, were in the order 
of 10 - 13 days l5l. This pharmacokinetic behavior is very distinct from that of 
other known camptothecin analogs l7l. To allow more detailed studies on the 
distribution of DE-310 and to elucidate the basis for its unique pharmacokinetic 
behavior, information of dynamic changes of free drug in vivo in different body 
compartments is essential. 
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Figure 1. The chemical structures of DE-310 [M.W. 3.4 x 105], DX-8951 
[M. W. 435.45], and G-DX-8951 
Previously, several physiologically based approaches have been put forward for 
the determination of the non-protein-bound fraction of drugs in dynamically 109 
functioning biological systems, including analysis of saliva [81, cerebrospinal fluid 
[91, and red blood cell partitioning [101. Here, we report on the development and 
validation of HPLC-based analytical methods for the determination of conjugated 
DX-8951, DX-8951 and G-DX-8951 in human whole blood, erythrocytes and 
saliva. 
2. Experimental 
2. 1. Chemicals and reagents 
Reference standards of DE-310 (batch: P-IW114B; purity, 100%), DX-8951f (batch: 
654-654-98-003; purity, 99. 9%}, which refers to the monomethanesulfonate 
dihydrate salt form of DX-8951, G-DX-8951 trifluoroacetate (batch: AR068103; 
purity, 98.8%}, and the internal standard DW-8579 (batch: AR141301; purity, 
98.2%) were supplied by Daiichi Pharmaceutical Co., Ltd. (Tokyo, Japan). 
Acetonitrile was obtained from Biosolve (Valkenswaard, the Netherlands), Tris-
hydrochloride buffer and thermolysin from Sigma (St. Louis, MO, USA), and zinc 
sulfate and calcium chloride from J. T. Baker (Deventer, the Netherlands). All 
other chemicals and HPLC solvents were of highest grade available commercially. 
Milli-Q-UF (Millipore, Bedford, MA, USA) water was used throughout. Blank 
human plasma, whole blood and saliva were obtained from healthy volunteers 
via the Central Laboratory of the Blood Transfusion Service (Amsterdam, the 
Netherlands). Unwashed erythrocytes were isolated from whole blood samples 
using MESED instruments (Kelmis, Belgium), as described previously [111. 
2.2. Sample preparation 
2.2. 1. DX-8951 and G-DX-8951 in whole blood, erythrocytes and saliva 
Aliquots of 100 !JL blood were transferred to 4. 5 mL glass tubes, followed by the 
addition of 900 !JL of human plasma, 500 !JL of acetonitrile, 100 !JL of internal 
standard DW-8579 (100 ng/mL in acetonitrile-water (1 :1, (v/v)}, and 100 !JL 
of zinc sulfate [70% (w/v) in water]). After vigorous vortex-mixing for 5 min 
on a multi-tube vortex mixer (Dade S8215-1X, Miami, FL, USA}, samples were 
centrifuged using a Hettig Universal 30RF centrifuge (TUttlingen, Germany) for 
5 min at 4000 x g. The supernatant was transferred to a clean 4.5 mL glass tube 
and partially evaporated under a gentle stream of nitrogen at 60°C for exactly 30 
min. An aliquot of 200 !JL of the residue was transferred to a low-volume insert 
of glass, and 100 !JL was injected into the HPLC system. 
Prior to extraction of erythrocyte samples, 100 !JL volumes of erythrocytes were 
110 diluted with 150 !JL of human plasma, followed by vortex-mixing on an MS2 
minishaker (IKA Works, Inc., Wilmington, NL, USA). This procedure was performed 
to achieve a uniform assay in order to interpolate the chromatographic data on a 
single standard measure line in the matrix (plasma). Aliquots of 100 !JL of plasma-
diluted erythrocytes were further prepared as blood (see above). 
Sample pretreatment for DX-8951 and G-DX-8951 in saliva was identical to that 
described for whole blood, using saliva aliquots of 250 !JL diluted with 750 !JL 
of human plasma. This procedure was performed to achieve a uniform assay in 
order to interpolate the chromatographic data on a single standard measure 
line in the matrix (plasma). At the end of the evaporation period, 250 Ill of 
the residue was transferred into a low volume insert of glass, and 200 1Jl were 
subjected to chromatography. 
2.2.2. Conjugated DX-8951 in whole blood, erythrocytes and saliva 
Aliquots of 100 1Jl of blood, plasma-diluted erythrocytes, or saliva were 
transferred to 1.5 ml polypropylene microtubes (Eppendorf, Hamburg, Germany), 
followed by the addition of 100 Ill of plasma and 600 1Jl of methanol. Following 
vigorous mixing for 1 min on the multi-tube mixer, samples were centrifuged at 
ambient temperature for 5 min at 10,000 x g. Next, 600 1Jl of the upper layer 
were transferred to a 4.5 ml glass tube and then evaporated to dryness under 
nitrogen at 60°C. The residue was reconstituted in 100 IJl of water, 200 1Jl 
Tris-hydrochloride buffer (0.1 M; pH 8.5), and 100 Ill of a thermolysin solution 
(2.0 mg/ml in 0.1 M calcium chloride). This mixture was incubated for 1 h at 
50°C in a water bath to release phenylalanylglycyl-DX-8951 (FG-DX-8951) from 
conjugated DX-8951. The reaction was stopped by adding 500 Ill of a mixture of 
0. 5 M hydrochloric acid-water (1: 1, (v /v)). The resulting solution was centrifuged 
for 5 min at 4000 x g, and 100 1Jl of the supernatant were diluted with 100 Ill of 
phosphate-buffered saline (pH 7.2), from which 100 1Jl were injected into the 
HPlC system. 
2.3. Equipment and chromatographic conditions 
Chromatographic analyses were performed using a constaMetric 3200 pump (lDC 
Analytical, Riviera Beach, Fl, USA), a 717plus autosampler (Waters, Milford, 
MA, USA) and a Jasco FP-920 fluorescence detector (Hachioji City, Japan). The 
analytical column used was packed with lnertsil ODS-BOA material (150 x 4.6 
mm i.d; 5-IJm PS) from Gl Science (Tokyo, Japan). The column temperature 
was maintained at 60°C by using a Spark Mistral column heater (Meppel, the 
Netherlands). The fluorescence detector operated at excitation and emission 
wavelengths of 375 and 445 nm, respectively, with the emission bandwidth set 111 
at18nm. 
The mobile phase for determination of DX-8951 and G-DX-8951 consisted of a 
0.1 M sodium acetate (pH 5.0, acetic acid)-tetrahydrofuran mixture (15:2, (vI 
v)), whereas that for conjugated DX-8951 was composed of 0.1 M sodium acetate 
(pH 5.0, acetic acid)-methanol (10:12, (v/v)). The mobile phases were prepared 
daily, filtered and degassed before use, and delivered isocratically at a flow rate 
of 1.0 mllmin. 
2.4. Calibration 
Separate standard stock solutions of DX-8951, G-DX-8951 and DW-8579 were 
prepared in triplicate at 1.0 mg/ml in dimethylsulfoxide and were stored at 
-80°C. The amount of compounds in the triplicate solutions was measured by 
injection aliquots of 50 ~L of 2500-fold diluted stock solutions in acetonitrile-
water (1 :1, (v/v)), followed by a 50-fold dilution in the mobile phase (all in 
triplicate) and injection into the HPLC system. The mean value of the individual 
stock solutions was within 2.0- 4.6% of each other. Stock solutions of DE-310 
were prepared at 1.0 mg/ml (equivalent to 69.0 ~g/ml of DX-8951) in water, and 
were stored at -80°C. The amount of compound in the triplicate solutions was 
measured by incubation of aliquots of DE-310 with thermolysin for 1 h in a water 
bath at 50°C, followed by injection of 10 ~L aliquots after stopping the enzyme 
reaction. 
Acquisition and integration of HPLC data was performed with Chrom-Card 
data analysis system (Fisons, Milan, Italy), running on an ICW chromatographic 
workstation. Six-point calibration curves were prepared daily in a blank matrix 
by serial dilution from the standard stock solution. For DX-8951 and G-DX-
8951, weighted 1 /x2 linear-regression analysis of the peak-height ratio of the 
compounds and the internal standard versus the concentration were used for 
the calculation of the calibration curves. For conjugated DX-8951, weighted 1 I x2 
linear-regression analysis of the peak height versus the concentration was used. 
2.5. Method validation 
The selectivity of the methods was assessed using a set of five independent blank 
(drug-free) human blood and saliva samples that were handled as described 
above. The presence of potentially interfering endogenous compounds with 
retention times similar to that of DX-8951, G-DX-8951, conjugated DX-8951, 
and/ or the internal standard was investigated by visual inspection of the 
chromatograms. 
The precision and accuracy of the analytical procedures was evaluated by 
repeat analysis of quality control (QC) samples, prepared in batch at various 
112 concentrations in each matrix and stored at -80°C, on separate occasions. QC 
samples of unwashed erythrocytes were prepared by incubation of 30 ml of 
whole blood for a period of 30 min at 37°C with DX-8951 and G-DX-8951 (each at 
a final concentration of 50 ng/ml). Subsequently, 1.5 ml aliquots of whole blood 
were transferred to 20 MESED instruments for isolation of unwashed erythrocytes. 
The remaining blood was used for the determination of DX-8951 and G-DX-8951 
concentrations, and for hematocrit measurement. 
The between-run precision (BRP) was evaluated prospectively as the percentage 
relative standard deviation obtained by one-way analysis of variance (ANOYA) 
using the run day as classification variable, calculating between-groups mean 
square (B), the within-groups mean square (W), and the grand mean (M) of the 
observed concentrations across run days. BRP was defined as: 
BRP = 100 x [(B- W) I n]0·5 I M 
The within-run precision (WRP) was estimated in a similar manner using the one-
way ANOYA as: 
WRP = 100 x [(W) 0·s I M] 
In case where W is greater than B, the resulting variance is negative, implying 
that no significant additional variation was observed on performing the assay in 
different runs. The average accuracy of the determinations were calculated as 
percentage deviation from nominal values (%DEY) and was defined as: 
%DEY= 100 x (M I nominal concentration) 
For determination of the lowest standard concentration with a definite level of 
certainty, i.e. the lower limit of quantitation (LLQ), blank samples were spiked 
with each of the analytes and subjected to repeat analysis as described for 
the QC samples. Stability of the analytes in the tested matrices was evaluated 
following (1) three freeze-thaw cycles of 15 min each, (2) at 3JCC for 24 h, and 
(3) after extraction at room temperature (autosampler stability). The extraction 
efficiency was established by comparing peak areas of samples prepared in 
plasma with those for non-processed samples prepared in mobile phase. All 
statistical analyses were performed using the software package Number Cruncher 
Statistical System v5.0 (Dr. J.L. Hintze, Kaysville, UT, USA; 1992). 
2.6. Patient samples 
The patients studied participated in a clinical phase I and pharmacokinetic study 
of DE-310 in various nonhematological malignancies [51. The DE-310 doses of 6.0 
or 7.5 mglm2 were delivered as a 3 h intravenous infusion, with treatment cycles 
repeated every 6 weeks. The protocol was approved by the Institutional Review 
Board of Erasmus University Medical Center (Rotterdam, the Netherlands) and 
written informed consent was obtained prior to treatment. 
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Blood samples were collected in sodium heparinized coated tubes before and at 
1, 2, 4, 6, 8, 24, 48, 72, 168, 240, 336, 504, 672 and 840 h after the end of the 
DE-310 infusion. After sampling, the blood specimens were immediately put in an 
ice-water bath (4°C) until centrifuged at 2000 rpm for 15 min at 4°C. Plasma was 
transferred into plastic specimen storage vials and the red blood cell fraction 
into Falcon vials, and both were stored frozen at -20°( until analysis. Saliva 
samples were collected in plastic specimen storage vials before and at 3, 7, 27, 
51, 72, 168, 240, 336, 504, 672, 840 h after the end of the DE-310 infusion and 
stored frozen at -20°( until analysis as described above. 
3. Results and discussion 
3. 1. Chromatography and detection 
Because of the pH-dependent instability of the a-hydroxy-8-lactone moiety in 
the core structure of most camptothecin analogs [121, including DX-8951, resulting 
in the ring-opened carboxylate form at high pH and the ring-closed lactone form 
at low pH, we decided to focus only on measurement of total concentrations in 
the present study, since disruption of the carboxymethyldextran polyalcohol side 
chain while maintaining the physiologic lactone-to-carboxylate ratio may not 
be feasible. In addition, for most camptothecin analogs it has been shown that 
total drug monitoring serves as an appropriate surrogate of the lactone forms 
[131. The choice of the internal standard DW-8579, which lacks the C4-methyl 
substituent as compared to DX-8951 (Figure 1 ), and the optimal fluorescence 
wavelength couple of the analytes (365/445 nm) was based on earlier work 
described for determination of DX-8951 in human plasma [141 and mouse plasma 
[151. Furthermore, no other metabolites were expected around the retention time 
of the internal standard [141. 
The choice of the lnertsil ODS-80A analytical column was based on previous 
experience during the development of an assay for total drug forms (i.e., 
lactone plus carboxylate) of the related agent topotecan in human whole blood 
114 and unwashed erythrocytes [161, and resulted in optimal selectivity factors and 
resolution. The composition and pH of the mobile phase was selected in order to 
optimize separation factors and peak shapes of the analytes. To ensure sufficient 
selectivity in our assays, tetrahydrofuran was added to the mobile phase as an 
organic modifier. 
In order to allow for convenient and inexpensive sample-pretreatment procedure 
of the biological samples, we opted for a solvent extraction, rather than taking 
recourse to solid-phase cartridges f13l. This was achieved by the use of a protein-
precipitation step in the presence of aqueous zinc sulfate f17l. This sample 
handling was also chosen for its optimal elimination of endogenous interferences, 
while maintaining a high extraction efficiency for the analytes in all matrices. 
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Figure 2A and 2B. HPLC chromatograms of internal standard [IS] DW-8579, [I] 
DX-8951 and [II] G-DX-8951 in [A] whole blood and [B] erythrocytes 
3.2. Method validation 
3.2. 1 Whole blood and erythrocytes 
Chromatograms of blank and spiked human whole blood and erythrocyte samples 
are shown in Figure 2A and 2B, respectively. The selectivity for the analytes is 
shown by the sharp and symmetrical resolution of the peaks, with no significant 
interfering peak for all compounds in drug-free specimens, obtained from five 
different individuals. The retention times of the internal standard DW-8579, 
unconjugated DX-8951 and G-DX-8951 were 16, 24, and 42 min, respectively, with 
an overall chromatographic run time of 45 min. This long run time was chosen 115 
to obtain optimal chromatographic resolution and to eluate potential interfering 
substances previous to injection of a new sample. In addition, there was no need 
for high-throughput assay because a limited number of saliva and erythrocyte 
samples per patient were expected. The calibration curves of assay of DX-8951 
and G-DX-8951 in human blood were found to be linear in the range of 5.0 - 200 
ng/ml when applying a weight factor of 1 /x2, with correlation coefficients of at 
least 0. 995 and 0. 997 for DX-8951 and G-DX-8951, respectively. 
Chapter 4 
a-
Spiked concentration Observed concentration [ng/ml] Precision [%] Number of replicate [ng/ml] observations 
Whole blood Erythrocytes Within-run Between-run 
DX-8951 
50 - 7.26 7.8 4.6 5 
50 50.6 - 1.3 0.65 2 
G~DX-8951 ,, i lc ,, 
50 - 35.1 2.6 5.3 5 
50 47.6 0.64 3.9 2 
Spiked concentration Freeze-thaw [three cycles] 24 h, 37°C Number of replicate 
[ng/ml] observations 
Observed Difference Observed Difference 
concentration [%] concentration [%] 
[ng/ml,.] [ng/ml] 
DX-8951 
20.3 20.6 1.8 19.1 -5.8 3 
74.1 72.0 -2.8 72.8 -1.7 3 
158.8 155.1 -2.3 152.2 -4.2 3 
G-DX-8951 
-- -------- --- --
-- --- - --- ------ -- - --- --
17.7 18.4 4.0 16.5 -7.0 3 
65.1 64.7 -0.7 64.8 -0.6 3 
144.2 138.8 -3.8 136.6 -6.0 3 
-.....! f7 JaJdDI.fJ 
QC samples in whole blood spiked with DX-8951 and G-DX-8951 (50 ng/ml, final 
concentration) were assayed in duplicate in four days, whereas QC samples in 
erythrocytes were assayed in quintuplicate in four days. Validation data of the 
analytical runs in terms of accuracy and precision indicated that all of samples 
were within the acceptable range (Table 1 ). The mean overall extraction 
recoveries were 118.0 and 101.0% for DX-8951 and G-DX-8951, respectively. 
Stability data for DX-8951 and G-DX-8951 in human blood indicated that both 
compounds were stable following three freeze-thaw cycles as well as after 
incubation at 37°C for 24 h (Table 2). 
400 A 150 B IS Ill 
300 
100 
> 200 E 
II 
50 
100 
0 10 15 20 25 0 2 4 6 8 10 
Retention time (min) 
Figure 3A and 38. HPLC chromatograms of [A] internal standard [IS] DW-8579, 
[I] DX-8951, [II] G-DX-8951; and [B] [Ill] FG-DX-8951 in human saliva 
Following incubation of human blood spiked with DE-310 at a concentration of 
5000 ng/ml (i.e., equivalent to DX-8951 at a concentration of 345.0 ng/ml) at 
3JCC for 30 min, no conjugated DX-8951 could be detected in the erythrocytes 
118 following their isolation in the MESED instruments. For this reason, no further 
validation characteristics could be made for conjugated DX-8951 in erythrocytes 
(data not shown). This is consistent with the high molecular weight of the 
conjugated analyte, precluding (extensive) red blood cell partitioning. 
Concentration [ng/ml} Precision [%] Accuracy[%] 
'I 
r 
Spiked I Observed Within-run Between~run 
DX-8951 
0.5 [LLQa] 0;51 6.1 3.0 101.6 
---- ---- ·-·----· ---- ----
2.5 2.43 2.7 3.1 97.2 
7.5 7.19 2.1 3.6 '95;8 
15.0 14.4 2.3 2.6 95.9 
G-DX-8951 
0.5 [LLQJ 0.48 11.5 b 95.4 
2.5 2.25 3.7 b 90.1 
-- - ----·-- -- -·---- - --
--- --- - - --------- - - --- -- ---
7.5 6.67 2.8 3.8 90.2 
- ---------
-- - ------ -
15.0 13.8 2.4 3.6 91.7 
Abbreviation: a LLQ: lower limit of quantitation. 
Note: b No additional variation was observed on performing the assay in different runs. 
"' 
p Ja:)dDLfJ 
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3.2.2. Saliva 
No chromatographic interference was noted from endogenous compounds in 
blank human saliva specimens (Figure 3A). The calibration curves for DX-8951 and 
G-DX-8951 in saliva were linear in the range of 0.5- 20.0 ng/ml, with correlation 
coefficients of at least 0.990. The retention times for DW-8579, DX-8951 and G-
DX-8951 were 9, 12 and 17 min, respectively, with an overall chromatographic 
run time of 45 min. A representative chromatogram of a QC sample containing 
DX-8951 and G-DX-8951 spiked at a concentration of 7.5 ng/ml is also shown 
in Figure 3. The LLQ samples were assayed in quintuplicate on four separate 
occasions, and indicated that 95 and 80% of the analyzed samples containing 
DX-8951 and G-DX-8951, respectively, were within the acceptable range for 
accuracy of 80 - 120%. Likewise, QC samples were analyzed in quintuplicate on 
four consecutive days and accuracy and precision data were within acceptable 
limits (Table 3). Stability data of DX-8951 and G-DX-8951 in human saliva after 
three freeze-thaw cycles (-80°(} and 24 hat 37°( are given in Table 4. These data 
suggest a minor loss of material due to instability, necessitating rapid freezing of 
clinical samples after blood collection. 
The calibration curves of the assay for conjugated DX-8951 in human saliva 
were linear in the range of 100.0 - 5000 ng/ml (equivalent to 6. 9 - 345 ng/ml 
of DX-8951 ), with correlation coefficients of at least 0. 996. The retention time 
of conjugated DX-8951 was 5.2 min, and the total run time was set at 10 min. 
A representative chromatogram of a QC sample containing DE-310 spiked at a 
concentration of 200.0 ng/ml (13.0 ng/ml of DX-8951) is shown in Figure 3B. 
All of the analyzed LLQ and QC samples fell within the range of accuracy of 80 -
120%. Because of the fact that 100% of the analyzed LLQ samples and QC samples 
were within the acceptable range of accuracy, only three analytical runs were 
performed (Table 5). Stability experiments showed that conjugated DX-8951 was 
stable during the chromatographic run when using plastic inserts and at 4°C in 
the dark, but not after three freeze-thaw cycles (-80°C} and upon storage for 24 
h at 37°C (Table 4). 
Spiked concentration Freeze-thaw [three cycles] 24 h, 37°C Number of replicate 
[ng/ml] observations 
Observed Difference Observed Difference 
concentration [%] concentration [%] 
[ng/ml] [ng/ml} 
DX-8951 
2.5 2.2 -12.0 2.1 -16.0 2 
-- ------- _,_- --- -·--
-· - -- -- ·- -· -·- --- ---- ·-· --.----
7.1 6.4 -9.8 5.9 -16.9 2 
14.3 12.7 -11.2 11.8 -17.5 2 
G-DX-8951 
2.5 2.0 -20.0 1.7 -32.0 2 
-- --- - --
7.4 5.8 -21.6 5.0 -32.4 2 
15.4 12.4 -19.5 10.4 -32.5 2 
DE-310 [DX-8951 eq.] 
---------- --
------------ - - -----------------------
11.86 12.06 1.7 9.1 -23.2 3 
- -- -· - '{ -·-- - - --· --- -
129.8 129.5 -0.3 106.7 -17.8 3 
303.3 :t 291.5 -3.9 236 .. 2 -22.1 3 
N p Ja:)dDI.JJ 
--
N 
N 
Concentration [ng/ml] 
Spiked 
100.0 [6.0 ng eq, DX-8951] 
-- --·-
200:0[13;8 ng eq. DXc8951] 
- ---
1000.0 [69.0 ng eq. DX-8951] 
2.000.0 [138 ng eq. DX-8951] 
Observed 
98.4 
204.2 i i 
940.0 
1879.6 
Chapter 4 
Precision [%] Accuracy [%] 
Within-run Between-run 
7.5 2.2 98.3 
3.8 4.2 102,0 
3.4 3.1 94.6 
3.8 5.1 93.6 
3.3. Pharmacokinetics 
The suitability of the developed methods for the clinical use was demonstrated 
by the determination of DE-31 0 and its enzymatic products in human erythrocytes 
and saliva obtained from eight patients with different advanced solid tumours, 
treated with DE-310 at dose levels 6.0 or 7.5 mg/m2 once every 6 weeks. In all 
analyzed samples of erythrocytes and saliva, the concentration of DE-31 0, G-DX-
8951, and DX-8951 were below lower limit of quantitation (< 0.5 ng/mL). This 
would fit with the hypothesis of preferential drug uptake in tumour tissue, but 
not in other tissues. 
In conclusion, we have developed and validated HPLC methods with fluorescence 
detection for DE-31 0 and two major metabolites in human whole blood, 
erythrocytes, and saliva. The methods were shown to meet the current 
requirements as to the validation of bioanalytical methods, providing good 
accuracy and precision. The results obtained from the analysis of patient 
samples revealed that DE-310, G-DX-8951, and DX-8951 are neither distributed 
to erythrocytes, nor excreted in saliva, which makes the biodistribution of this 
topoisomerase I inhibitor substantially different from that of topotecan [11 1, or 
irinotecan and its metabolite, SN-38 [181. 
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Abstract 
Purpose: To assess the maximum-tolerated dose (MTD), toxicity and pharma-
cokinetics of DE-310, a macromolecular prodrug of the topoisomerase I inhibitor 
exatecan (DX-8951f), in patients with advanced solid tumors. 
Patients and Methods: Patients received DE-310 as a 3-h infusion once every 2 
weeks (dose, 1.0 to 2.0 mg/m2) or once every 6 weeks (dose, 6.0 to 9.0 mg/m2). 
Conjugated DX-8951 (the carrier linked molecule), and the metabolites DX-8951 
and glycyl-DX-8951 were assayed in various matrices up to 35 days post first and 
second dose. 
Results: Twenty-seven patients were enrolled into the study and received a total 
of 86 administrations. Grade 4 neutropenia and grade 3 thrombocytopenia, and 
grade 3 hepatotoxicity with vena-occlusive disease (VOD), were dose-limiting 
toxicities. Other hematological and nonhematological toxicities were mild 
to moderate and reversible. The apparent half-life of conjugated DX-8951, 
glycyl-DX-8951, and DX-8951 was 13 days. The area under the curve ratio for 
conjugated DX-8951-to-DX-8951 was 600. No drug concentration was detectable 
in erythrocytes, skin and saliva, although low levels of glycyl-DX-8951 and DX-8951 
were detectable in tumor biopsies. One patient with metastatic adenocarcinoma 
of unknown primary achieved a histologically proven complete remission. One 
confirmed partial remission was observed in a patient with metastatic pancreatic 
cancer and disease stabilization was noted in 14 additional patients. 
Conclusion: The recommended phase II dose of DE-310 is 7.5 mg/m 2 given once 
every 6 weeks. The active moiety DX-8951 is released slowly from DE-310 and 
over an extended period, achieving the desired prolonged exposure to this 
topoisomerase I inhibitor. 
128 Introduction 
DE-31 0 is a novel macromolecular drug-delivery system for the topoisomerase 
I inhibitor DX-8951f (exatecan mesylate), in which each molecule is linked 
via a glycyl-glycyl-phenylalanyl-glycyl-peptidyl spacer to a biodegradable 
carboxymethyldextran polyalcohol polymer. This carrier part of DE-310 is 
intended to provide passive accumulation in tumor tissue and sustained 
release of the active moiety DX-8951 within the tumor, which occurs as result 
of enzymatic cleavage of the peptidyl spacer by cathepsin B and cathepsin L, 
thereby enhancing its activity and reducing its systemic toxicity [11. The main 
chain is acid-labile, suggesting that it is biodegradable and can be depolymerized 
after endocytosis in a lysosomal acidic-environment (Figure 1) [11. 
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Figure 1. Schematic representation of intracellular drug release by cleavage 129 
of the peptidyl linker by lysosomal enzymes. After internalization of the 
macromolecular carrier DE-310 [MW 3.4 x 105] by endocytosis, the macromolecule 
is transferred to the lysosomal compartment, where it is exposed to lysosomal 
enzymes [i.e., cathepsin B and cathepsin L]. Both glycyl-DX-8951 and free DX-
8951 [MW 435.48] are liberated intracellularly. The biodegradable polymer is 
metabolized and afterwards excreted renally. 
The cytotoxicity of topoisomerase I inhibitors in animal models increases with 
duration of exposure, and long-term exposures to low concentrations are more 
effective than short-term exposures to high concentrations l2l. The concept 
behind the development of DE-310 is that the macromolecular carrier will 
accumulate and be retained preferentially in tumor tissue by an enhanced 
permeability and retention (EPR) effect [3·51. 
Preclinical studies have revealed that the macromolecular carrier is stable in 
plasma and is resistant to clearance by the reticuloendothelial system. DE-
31 0 showed antitumor activity in various tumor models by single and repeated 
administration l1l, and antitumor activity was noted at lower doses than with 
DX-8951. The two DE-310 breakdown products, DX-8951 and glycyl-DX-8951, 
were found to exert antitumor activity in vivo, whereas the CYP3A4 and 
CYP1A2-mediated DX-8951 metabolites referred to as UM-1 and UM-2 were 
less potent [6, ?, 91. 
Previous phase I clinical studies with various administration schedules of DX-
8951f have shown reversible, noncumulative, and dose-dependent neutropenia 
and sometimes thrombocytopenia l10-15l. Other side effects included mild to 
moderate gastrointestinal toxicity (nausea, vomiting, stomatitis, diarrhea), 
fatigue, asthenia and alopecia l10-15l. Reversible, noncumulative, neutropenia 
was the dose-limiting toxicity (DLT) in all schedules [10-141, as well as transient 
and reversible liver dysfunction l11 , 131, or stomatitis in advanced leukemia l15l. 
The objectives of this phase I study were (a) to determine the maximum-tolerated 
dose (MTD) and dose-limiting toxicities (DLTs) of DE-31 0 when administered 
intravenously once every 2 or 6 weeks, (b) to characterize the pharmacokinetics 
of DE-31 0 (as conjugated DX-8951) and its metabolites DX-8951 and glycyl-DX-
8951, and (c) to evaluate preliminary antitumor activity. 
Patients and methods 
Eligibility Criteria 
130 Patients with a histologically confirmed diagnosis of a malignant solid tumor 
refractory to conventional chemotherapy or for whom no effective therapy 
existed were eligible. Other eligibility criteria included the following: age .2 18 
years; Eastern Cooperative Oncology Group performance status 0 - 2; estimated 
life expectancy of .2 8 weeks; no previous anticancer therapy for at least 4 
weeks (6 weeks for nitrosoureas, mitomycin-( or carboplatin); and adequate 
hematopoietic (absolute white blood cell count (WBC) > 3,000/!JL, absolute 
neutrophil count (ANC) > 1,500/jJL, platelet count> 100 x 109/L and hemoglobin 
> 8.5 g/dl (or 5.2 mmol/L)), hepatic (serum total bilirubin < 1.5 mg/dl (25.6 
!Jmol/L), serum aspartate transaminase (ASAT), and alanine transaminase (ALAT) 
< 2.5 times the institutional upper normal limit (UNL) (< 5.0 times UNL in case 
of liver metastases)), and renal (serum creatinine concentration< 1.5 mg/dl or 
if raised between 1.5 - 2.0 mg/ dl, then a creatinine clearance of > 60 mllmin) 
function. Specific exclusion criteria included symptomatic brain metastases, 
active or uncontrolled infection, known allergy to camptothecin derivatives, 
concomitant treatment with CYP 3A4 inhibitors or inducers (wash-out period of 
at least 7 days since last intake), or diarrhea (more than 2 - 3 stools/ day above 
normal frequency during the past 4 weeks). The institutional Ethical Board 
approved the study protocol. All patients gave written informed consent before 
study entry. 
Treatment and Dose-escalation 
DE-310 for injection (37.9 mg of conjugated DX-8951 (i.e., equivalent to 2.5 mg 
of DX-8951) and 165 mg maltose-monohydrate per 5 ml vial) was provided as a 
lyophilized powder, and was stored in a refrigerator at 2- 8 OC and protected from 
light in a closed package. The drug was supplied by Daichii Pharmaceutical Co., 
Ltd. (Tokyo, Japan). DE-31 0 was reconstituted with 5 ml of 0. 9% sodium chloride 
to obtain a concentration of 0.5 mg DX-8951 equivalent/ml solution and then 
filtered. The appropriate volume of stock solution needed to yield the required 
dose was diluted in a polyvinylchloride infusion bag with 0. 9% sodium chloride to 
250 ml. This dilution was stable for at least 24 hours when protected from light. 
The diluted drug product was administered protected from light over a period 
of 3 hours, using a programmed peristaltic pump system. With the exception 
of the first and second administration of the first and second cycle of the q2w 
schedule and the first and second cycle of the q6w schedule, respectively, in 
which patients were hospitalized for pharmacokinetic blood sampling, patients 
were treated on an outpatient basis. Prophylactic therapy was prohibited for 
the first administration, but could be given from the second administration if 
treatment was delayed (> 24 h) or when constant nausea and vomiting occurred. 131 
Prophylactic growth factors were not allowed. 
The starting dose of DE-310 was 1.0 mg/m2, and each infusion was followed by a 
two weeks recovery period for every 28 days of treatment (q2w schedule), and 
was based on 1/6 of the highest non-severe toxic dose found in the dog. In the 
q2w schedule, cycles were repeated every 28 days. After protocol amendment to 
a six-weekly schedule, based upon available information from a parallel phase I 
study using an every four-weeks schedule l16l, the dose of DE-310 was escalated 
to 6.0 mg/m2, followed by a six-weeks recovery period (q6w schedule). Further 
dose-escalations were based on the prior dose level toxicity. 
At least three patients were entered at each dose level. If one of three patients 
experienced DLT, three additional patients were to be entered at that dose 
level. The MTD was defined as one dose level below the dose that induced DLTs 
in at least 2 out of 6 patients, defined as the National Cancer Institute Common 
Toxicity Criteria version 2.0 (NCI-CTC) grade 4 neutropenia lasting for ~ 5 
days, neutropenic fever (defined as grade 4 neutropenia with fever ~ 38.5°C), 
thrombocytopenia less than 25 x 1 09 /L, any other clinically significant grade 
4 hematological toxicity, grade 3 or 4 vomiting despite maximum supportive 
care, any other grade 3 or 4 nonhematological toxicity, and for the q2w 
schedule inability to start the second administration of the first cycle or to 
start a second cycle after a 1-week delay because of unresolved toxicity l17l. 
Unresolved toxicity was defined as WBC < 3.0 x 109 /L, ANC < 1. 5 x 1 09 /L, platelet 
count< 100 x 109/L, and all associated nonhematological toxicities (excluding 
alopecia) not yet recovered to grade 0 to 1. lntrapatient dose-escalation was not 
allowed. The treatment was resumed when the neutrophil count had recovered 
to~ 1.5 x 109/L, the platelet count to~ 100 x 109 /L, and any other treatment-
related toxicities were ::; grade 1 . 
Treatment Assessment 
Before initiating therapy, a complete medical history was taken and a physical 
examination was performed. A complete blood cell count (CBC), and serum 
biochemistry were performed, as were ECG, urinalysis, and chest X-ray. Weekly 
evaluations included history, physical examination, toxicity assessment according 
to the NCI-CTC, serum biochemistry and urinalysis. CBCs were determined twice 
weekly throughout every cycle. Tumor evaluation was performed after every 
two cycles in the q2w schedule, and after every cycle in the q6w schedule, 
respectively, according to RECIST l18l. 
132 Sample Collection and Drug Analysis 
For pharmacokinetic analysis, a total of 40 blood samples (-6 ml each) over a 
period of 8 weeks for the q2w schedule, and over a period of 12 weeks for the 
q6w schedule, respectively, was obtained from an indwelling intravenous canula 
and collected into a heparin-containing tube. In the q2w schedule, samples 
were taken immediately prior to drug administration of DE-310, at the end of 
infusion, and at 1, 2, 4, 6, 8, 24, 48, 96, and 144 hours post-end of infusion. In 
the q6w schedule, samples were taken immediately prior to drug administration 
of DE-310, and at 1, 2, 4, 6, 8, 24, 48, 72, 168,240,336, 504,672 and 840 hours 
post-end of infusion. Blood specimens were immediately put in an ice-water 
bath (4°C) until centrifugation at 2000 rpm for 15 minutes at 4°C. Plasma was 
transferred into plastic specimen storage vials and stored frozen at -20°C until 
analysis. Also, urine was collected for pharmacokinetic analysis over a 24-hour 
period on days 1 - 8 in the first 2 cycles of the q2w schedule and over a 24-hour 
period on days 1-2, and over a 12-hour period on days 3, 7, 14, 21, 28, 35, and 
42 in the first two cycles of the q6w schedule. Urine samples were stored frozen 
at -20°C until analysis. 
The plasma concentrations of conjugated DX-8951, glycyl-DX-8951 and DX-8951 
were quantified by a validated liquid chromatographic method (MDS Pharma 
Services, Montreal, Canada). Concentrations of conjugated DX-8951 were 
determined using a thermolysin enzymatic reaction and fluorescence detection. 
Samples of saliva and erythrocytes, normal skin, and superficial tumor tissue, 
if possible, were obtained from patients at the dose levels 6.0 and 7.5 mg/m2• 
Saliva was obtained during the first cycle prior to drug administration, at the end 
of infusion, 4 hours post-end of infusion, and once a day on days 2, 3, 4, 8, 11, 
15, 22, 29, and 36. Samples of erythrocytes were collected at the time points 
indicated for plasma. The concentrations of conjugated DX-8951, glycyl-DX-8951 
and DX-8951 in saliva, erythrocytes and ascites were quantified by a validated 
method as described previously [191. Normal skin and tumor tissue was obtained 
on day 8 or 9 of the first cycle and analyzed as described for plasma (Shin-Nappon 
Biomedical Laboratory Ltd., Kainan, Japan). 
Pharmacokinetic and Pharmacodynamic Data Analysis 
Pharmacokinetic parameters were calculated by standard non-compartmental 
methods using WinNonlin software version 3.3 (Pharsight, Mountain View, CA, 
USA), and included time to peak concentration (T max), peak concentration (Cmax), 
terminal half-life (Ty,), and area under the curve (AUC). Urine excretion was 
calculated in percentage of the dose administered. Pharmacokinetic parameters 
are provided as mean values with the percent coefficient of variation, and the 133 
level of significance (P) for statistical tests was set at 0.05. 
Results 
Patients and Treatment 
A total of twenty-seven patients (16 males and 11 females) with a median age 
of 57 years was enrolled into the study (Table 1 ). All patients were eligible and 
assessable for toxicity. A total of 61 cycles (i.e., 86 administrations) of treatment 
was given at dose-levels of 1.0 mg/m2 (q2w), 2.0 mg/m2 (q2w), 6.0 mg/m2 (q6w), 
7.5 mg/m2 (q6w), and 9.0 mg/m2 (q6w). Twenty-five patients were assessable for 
response; one patient died due to massive pulmonary embolism before scheduled 
tumor reassessment, and another patient withdrew because of rapid disease 
progression and was replaced (i.e., dose-level 6.0 mg/m2). 
Dose-Limiting Toxicity 
At the starting dose of 1.0 mg/m2 , the cohort was expanded to 6 patients because 
of the initial classification of DLT due to prolonged grade 1 thrombocytopenia in 
one patient, delaying the second administration of DE-310 of the first cycle. In 
retrospect, this mild thrombocytopenia was related to occult gastrointestinal 
bleeding from cirrhosis induced esophageal varices. No further DLTs were 
observed with this schedule. Since pharmacokinetics revealed a drug terminal 
half-life exceeding the 2 weeks administration interval, the protocol was 
amended to a 6 weeks interval between administrations. 
The initial 3 patients at the q6w schedule were treated at a dose of 6.0 mg/m2 
and experienced no DLTs. Subsequently, a dose of 9.0 mg/m2 was explored, 
where two patients developed DLT. A female patient with metastatic pancreatic 
cancer had grade 4 leukocytopenia, and grade 4 neutropenia with fever on 
day 8, as well as grade 3 thrombocytopenia, grade 2 anemia, and grade 3 
hepatotoxicity (elevated transaminases). All side effects were reversible. The 
second and third cycles were given at a dose of 6.0 mg/m2, and were uneventful. 
A second female patient with metastatic adenocarcinoma of unknown primary 
(ACUP) had an uncomplicated first cycle, but on day 11 of her second cycle she 
developed grade 3 thrombocytopenia, grade 3 neutropenia, grade 2 anemia, 
134 grade 3 hepatotoxicity (i.e., hyperbilirubinemia and elevated transaminases). 
An ultrasound guided liver biopsy revealed veno-occlusive liver disease (VOD). 
Hyperbilirubinemia persisted for 7 weeks and subsequently recovered but no 
further DE-310 was given. In view of the DLTs observed at 9.0 mg/m2, the cohort 
of 6.0 mg/m2 was further expanded with 3 additional patients, none of whome 
experienced DLTs. 
Characteristic 
No. of Patients 
Total 
Assessment 
For Dose-Limiting Toxicity 
For Efficacy 
Gender, male : female 
Age, years 
Median 
ECOG performance status 
2 
Previous therapy 
Chemotherapy only 
Median no. of regimens 
Range 
Radiotherapy 
Both 
None 
Tumor types· 
Gastro-intestinal tract, including: 
Colorectat cancer 
Esophageal cancer 
Pancreatic cancer 
Melanoma 
Lu.~~.~ancer .(~5~~9 
Soft tissue sarcoma 
Unknown primary adenocarcinoma 
Miscellaneous 
Note: 'Two patients had double tumors. 
57 
31 - 78 
2 
1 - 4 
No. of Patients 
27 
27 
25 
16 : 11 
19 
2 
3 
12 
6 
3 
3 
5 
Abbreviations: no., number; ECOG, Eastern Cooperative Oncology Group; NSCLC, non 
small cell lung cancer. 
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Subsequently, an intermediate dose of 7.5 mg/m2 was explored. At this dose 
level, one out of six patients developed DLT consisting of grade 3 hepatotoxicity 
(i.e., hyperbilirubinemia and elevated transaminases) occurring on day 15 of the 
second cycle. An ultrasound guided liver biopsy again revealed VOD, which was 
fully reversible within 15 weeks. The recommended dose for phase II trials of DE-
310 was set at 7.5 mg/m2 once every 6 weeks. 
Hematologic and Nonhematologic Toxicity 
A summary of the worst grade hematologic toxicities per patient is provided 
in Table 2. In addition to the dose-limiting toxicities, the other observed 
nonhematologic toxicities were only mild to moderate and consisted of nausea, 
vomiting, stomatitis, anorexia, asthenia, and alopecia (Table 3). Fifty-one 
percent of patients experienced short lasting nausea, and 37% experienced 
incidental vomiting. Prophylactic anti-emetics were not given. Reversible 
increase of the liver transaminases was encountered in 12 out of 27 patients 
(44%) across all dose levels, except 1.0 mg/m2 (Table 4). 
Pharmacokinetics 
Pharmacokinetic analysis was performed in all patients. Across the various 
dose levels, the apparent terminal half-lives of conjugated DX-8951, glycyl-
DX-8951, and DX-8951 were 13, 12, and 13 days, respectively (Table SA and 
5B). Consequently, plasma concentrations of all compounds conjugated were 
sustained for several weeks. This parallel decline suggests that the terminal 
phase seen with the DE-310 metabolites (i.e., glycyl-DX-8951 and DX-8951) is 
not due to real elimination-processes but due to their much slower formation 
from conjugated DX-8951. At the recommended dose of 7.5 mg/m2, substantial 
interindividual variability was observed (coefficient of variation, up to 92%). The 
AUC ratio of conjugated DX-8951-to-DX-8951 was approximately 600, a similar 
value seen as predicted by preclinical studies l1l. The AUCs of conjugated DX-
8951, glycyl-DX-8951, and DX-8951 appeared to increase in near proportion with 
an increase in dose. 
136 Urinary excretion was very slow, and total drug recovery over the entire sampling 
period amounted to less than 1%. In line with the small distribution volume of 
conjugated DX-8951, concentrations of conjugated DX-8951, glycyl-DX-8951, 
and DX-8951 were not detectable in erythrocytes and saliva, further pointing to 
limited distribution outside the plasma compartment. In tumor biopsies of four 
patients, concentrations of both glycyl-DX-8951 and DX-8951 were detectable 
at low levels, whereas in normal skin biopsies of nine patients concentrations of 
DX-8951 remained below the detection limit (Table 6). 
Anemia Leukocytopenia Neutropenia Thrombocytopenia 
-- ---------------
Grades 
Dose No. No. of No. of 1 2 1 2 3 4 1 2 3 4 1 2 3 [mg/m2] of pts. cycles adm. 
1.0 6 13 24 0 1 0 0 0 0 0 0 0 0 2 0 0 [q2w] i 
2.0 4 16 30 0 2 0 0 0 0 0 0 0 0 0 0 0 [q2w] 
6;0 
7 17 17 1 2 2 i 0 0 0 2 0 0 0 1 0 0 [q6w] ' 
7.5 6 10 10 2 3 0 1 0 0 0 0 1 0 0 [q6wJ 
9.0 4 5 5 0 2 2 1 0 1a 2 ' 0 1 1a 0 0 2a i [q6w] 
Note: a considered DLTs in 2 patients at dose level 9.0 mg/m2 [q6w] in the first and second cycle, respectively. 
Abbreviations: no., number, pts., patients, adm., administrations; q, every; w, weeks . 
..... 
w 
"'-l ~ JaJdDI.JJ 
Dose 
[mg/m2] 
1.0 
[q2w] 
2.0 
[q2w] 
6.0 
[q6w] 
7.5 
[q6w] 
9.0 
[q6w] 
No. 
of pts. 
6 
4 
7 
6 
4 
I 
I 
...... 
w 
00 
Nausea 
No. of No. of 1 2 
cycles adm. 
13 24 1 0 
16 30 2 1 
17 17 5 0 
10 10 2 1 
5 5 2 0 
Vomiting Stomatitis Anorexia 
Grades 
1 2 1 2 1 2 
I 1 0 0 0 0 !, 0 I 
__ j 
2 1 0 0 0 0 
0 3 2 1 1 3 1 
0 1 1 0 3 0 
2 0 0 0 ', 1 0 
Abbreviations: no., number, pts., patients, adm., administrations; q, every; w, weeks. 
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Fatigue Alopecia 
1 2 1 2 
2 1 0 0 
1 2 1 0 
5 2 1 0 
6 0 1 0 
2 1 1 0 
ALAT ASAT Total bilirubin 
Grades 
Dose No. of No. of No. of 1 2 3 1 2 3 1 2 3 [mg/m2] pts. cycles adm. 
1.0 6 13 24 0 0 0 0 0 0 0 0 0 [q2w] 
2.0 4 16 30 0 1 0 1 1 0 1 0 0 [q2w] 
6.0 7 17 17 2 0 0 4 0 0 0 0 0 [q6w] 
7.5 6 10 10 0 2 1a 0 1 2a 1 1 1a [q6w] 
---,--- - --- -------
9.0 4 5 5 1 0 2b 1 1 2b 0 0 1a [q6w] 
Note: a considered a DLT in 1 patient at dose level 7.5 mg/m2 [q6w], and in 1 patient at dose level 9.0 mg/m2 [q6w] in the second 
cycle; b considered a DLT in 1 patient at dose level 9.0 mg/m2 [q6w] in the first cycle. 
Abbreviations: ALAT, alanine transaminase; ASAT, aspartate transaminase; no., number, pts., patients, adm., administrations; 
q, every; w, weeks. 
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~ Chapter 5 
0 
Mea.ri[C:.:V%JR~arl11acokinetiC: garameters ofconjugatedDX-8951, gtycyl-DX-8951, and DX-8951 of 1st administration at 
in q2VI/ schMule and at 1st course. in q6w. schedule. 
Conjugated DX-8951 Glycyl-DX-8951 DX-8951 
[mg/m2] AU Co-t . AUCo-336h i Cmax . T max T;., AU Co-t AUCo-336h Cmax T max T;, AU Co-t AUCa-336h Cmax T max T * 
[ng·h/mL] · [ng·h/mL]i [ng/mL]i [h] [h] [ng·h/mL] [ng·h/ml] [ng/ml]. [h] [h] : [ng·h/mL] [ng·h/mL]: [ng/ml] [h] [h] 
q2w 
mean: 38402.0• 460.8 5.3 · 238.5 1.54 132.0 158.6 0.87 135.0 
n/a n/a n/a 1 n/a n/a n/a 
CV% 67.7 53.8 47.6 67.8 71.7 51.9 72.5 71.7 44.6 
mean 61104.0b 582.6b 1A.Ob 515.8c 2.23b 99.oa. 366.6c 1.6 87.0 
n/a n/a n/a n/a n/a n/a 
CV% n/a n/a n/a 130.2 123.7 39.6 111.7 100.7 52.8 
q6w 
661924.4 498855d 3344.7 5.0 243.4 1731.2 929.2d 6.71 1251.0348.4 960.4 642.8d 3.2 150.4:260.8 
45.5 36.0 17.5 38.3 40.8 55.5 60.0 93.3 78.9 47.0 39.2 34.7 56.6 50.8 21.1 
1124472.3 793120.2 5706.3 4.7 i 338.8 3907.2 2492.4 11.6 123.0 330.2 1781.1 1168.6 5.2 151.0. 302.0 
19.4 20.1 18.9 50.1 18.3 90.1 92.6 93.7 42.7 78.5 78.9 83.6 84.5 68.5 54.0 
902743.5 629527.3 4218.9 5.5 309.5 3178.7 2299.6 12.6 183.0 186.3: 2062.8 1479.0 6.9 135.0 169.5 
60.3 56.5 33.8 54.5 37.3 71.5 89.9 118.0 71.4 16.2 53.2 56.3 66.8 65.7 18.4 
Note: AUC0_t: AUC calculated from time 0 to the last non-zero concentration; AUC0_336h: AUC calculated from time 0 to the concentration at time 336h 
post end of infusion, where possible. Since the distribution phase of glycyl-DX-8951 and DX-8951f from conjugated DX-8951 and the glycyl-DX-8951 
and DX-8951 elimination phase could be simultaneously occurring over the dosing interval, a true terminal elimination phase cannot be accurately 
characterized using non-compartimental methods. An apparent elimination phase half-life [T y, app.] is therefore reported here; a calculated on data 
from 4 pts.; b calculated on data from 1 pt.; c calculated on data from 3 pts.; d calculated on data from 6 pts. 
Abbreviations: CV, coefficient of variation; AUC, area under the plasma concentration-time curve; Cmax' peak plasma concentration; T max' time to 
Cmax; T112, half-life of terminal phase; q, every; w, weeks; n/a, not available; pts., patients. 
Conjugated DX-8951 Glycyi-DX-8951 DX-8951 
Dose 
[mg/m2] AU CO-t AUCo.J36h (max Tmax Tli i AUCO-t AUCo-336h (max 'Tmax Tli AUCO·t AUCiJ-336h (max Tmax Tli 
[ng·h/ml] [ng·h/mL] [ng/mLJ [h) [hJ [ng·h/mLJ [ng·h/ml] [ng/mL} [h] [h] ' [ng·h/ml] [ng·h/ml] [ng/ml] [h] [h] 
q2w 
i 31256.5 324.9 3.8 321.7 3.8 ! 36.5 321.8 4.9 51.0 :mean 
n/a -- --- n/a n/a n/a n/a -" ----- n/a 
CV% 114.8 72.9 25.5 111.5 134.4 66.7 98.5 66.6 
2.0 mean i 221846.0 1230.3 ' 3.5 834.5a 4.oa 292• 631.0• 3.1a 326a 
[N=3] n/a n/a n/a 'n/a · n/a n/a CV% 75.1 42.8 16.5 93.9 112.7 143.1 86.2 115.7 119.9 
q6w 
6.0 imean 750514.6 519098.0 3541.4 6.0 295.8 2989.8 1540.0 7.5 1247.8 i226.2 1202.7 727.3 2.9 180.6210.2 
[N=5J CV% 32.6 25.6 22.0 47.1 19.7 100.4 72.4 98.4 64.8 36.7 68.5 54.1 54.8 38.3 25.9 
- -- -,i -- --- ! -;--- - --,---
7.5 mean. 1180980.0 813841.0 5081.0 6.3 :418.3. 13080.3 6324.2 33.4 1179.01152.7 4032.8 2484.3 10.5 163.0210.7 I 
[N=3] CV% 42.7 39.0 13.2 63.8 38.2 102.8 98.0 110.9 87.2 7.7 66.7 61.8 56.2 51.7 4.8 
9.0 !mean 131375.1 i 920467.3 '4868.5 15.0 267.0 13893C 3814,9C 36.5C 339c 616C 7039.3C 2811,5C ! 19,8C 339c 181C 
- b I [N-2] CV% 71.7 73.8 55.7 113.1 4.2 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
Note: AUC0_t: AUC calculated from time 0 to the last non-zero concentration; AUC0_336h: AUC calculated from time 0 to the concentration at time 
336h post end of infusion, where possible. Since the distribution phase of glycyl-DX-8951 and DX-8951f from conjugated DX-8951 and the glycyl-
DX-8951 and DX-8951 elimination phase could be simultaneously occurring over the dosing interval, a true terminal elimination phase cannot 
be accurately characterized using non-compartimental methods. An apparent elimination phase half-life [T Yz app.] is therefore reported here; 
a calculated on data from 3 pts.; b dose reduction from 9.0 to 6.0 mg/m2 [q6w] for 1 pt. in course 2; c calculated on data from 1 pt. 
Abbreviations: CV, coefficient of variation; AUC, area under the plasma concentration-time curve; Cmax' peak plasma concentration; T max' time to 
Cmax; T 112, half-life of terminal phase; q, every; w, weeks; n/a, not available; pts., patients. 
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Patient 
[Tumor type] 
19 [Sarcoma] 
20 [Colorectal] 
21 .[Melanoma] ! 
22 [Melanoma] 
23 [Melanoma] i 
24 [NSCLC] 
25 [ACUP] 
26 [Sarcoma] 
27 [Melanoma] ! 
Jl. 
N 
Dose 
[mg/m2] 
[q6w] 
6.0 
6.0 
6.0 
7.5 
7.5 
7.5 
-- --' 
7.5 
7.5 
7.5 
1 
Time of biopsy Normal Biopsy of 
at first cycle VS Tumor 
[day] Tumor type 
8 Normal 
8 Normal 
Normal 
9 I 
Tumor Melanoma 
Normal 
9 
Tumor Melanoma 
Normal 
8 
Tumor Melanoma 
8 Normal 
9 Normal 
8 Normal 
9 Tumor Sarcoma 
8 Normal 
Chapter 5 
Weight Conjugated 
of sample DX-8951 G-DX-8951 DX-8951 [mg] 
5.8 BLQ BLQ BLQ 
9.8 BLQ 62.731 BLQ 
32.7 BLQ 1 24.524 BLQ 
153.5 166.159 134.457 8.037 
18.9 BLQ 53.448 BLQ 
2294.1 303.557 155.276 4.188 
15.9 BLQ 59.173 BLQ 
2223.0 222.019 119.103 4.157 
9.3 BLQ 10.870 BLQ 
9.2 BLQ 
- -L 
I 5.617 BLQ 
27.2 BLQ ' 8.419 BLQ !' 
414.2 160.690 54.202 2.159 
29.1 BLQ 10.199 6.613 
Abbreviations: G-DX-8951, glycyl-DX-8951; vs, versus; q, every; w, weeks; BLQ, below limit of quantitation; NSCLC, non small cell 
lung cancer; ACUP, adenocarcinoma unknown primary. 
Plasma Ascites 
--- ----
Cycle Day Conjugated G·DX-8951 DX-8951 Conjugated G-DX-8951 DX-8951 DX-8951 DX-8951 
2987.9b 2.333C 0,545C n.d. n.d. n.d. 
15 424.3 1.974 0.448 1401.97 3.66 0.61 
1 29 119.3 0.610 0.149 382.18 0.46 0.11 
---- ;---
36 BLQ 0.352 0.084 232.82 BLQ BLQ 
39 n.d. n.d. n.d. 197.51 BLQ BLQ 
1 4067.1a 2.643C 0;785C 172.49 BLQ BLQ 
4 1759.9 7.912 1.578 3164.66 6.74 0.67 
2 18 n.d. n.d. n.d. 572.32 1.64 0.21 
22 305.9 0.948 0.181 466.62 1.10 0.18 
30 BLQ 0.321 0.073 103.1 BLQ BLQ 
Note: maximum concentration at •z, b4, and cz4 hrs. post end of infusion. 
Abbreviations: G-DX-8951, glycyl-DX-8951; q, every; w, weeks; n.d., not determined; BLQ, below limit of quantitation (for ascites< 
0.5 ng/ml). 
--"' 
J:>. ~ Ja:)dDl.fJ w 
During the first and second cycle at 6.0 mg/m2 the concentrations were also 
assessed in ascites of a patient with metastastic pancreatic cancer (Table 7). 
Efficacy 
A histologically proven complete remission, confirmed by surgery and still 
persisting at a follow up duration of more than 1 year, was documented in a 56-
year old female with lymph node metastases of ACUP, who experienced DLT at 
dose level 9.0 mg/m2 and only received 2 cycles. 
A partial response lasting 3 months was achieved in a 46-year old female with 
liver metastases from pancreatic cancer initially treated at 9.0 mg/m2 during the 
first cycle, and treated at 6.0 mg/m2 during the second and third cycle. While 
according to actual measurements, another partial remission of liver metastases 
was seen in a 58-year old female with metastatic ovarian cancer, treated at 2.0 
mg/m2 for 7 cycles, we downstaged this response to stable disease since the 
liver metastases were small and difficult to measure. Progression occurred in this 
patient after 8 months. A total of 14 patients demonstrated disease stabilization 
for 6 weeks (wks) (N=1; fibrous histiocytoma), 8 wks (N=1; colorectal cancer 
(CRC) ), 10 wks (N=1; CRC), 12 wks (N=5; pancreatic cancer (N=2), CRC, ACUP and 
melanoma (each N=1), 16 wks (N=1; urothelial cancer), 18 wks (N=2; NSCLC and 
leiomyosarcoma uteri), 24 wks (N=2; CRC and alveolar soft part sarcoma), and 32 
wks (N=1; ovarian cancer). 
Discussion 
We performed this study to assess the safety, tolerability, MTD, and 
pharmacokinetics of DE-310, a macromolecular prodrug of the topoisomerase 
I inhibitor exatecan (DX-8951f), administered as a 3-hour intravenous infusion 
once every 2 or 6 weeks. 
The present study showed that prolonged concentrations of DX-8951 were 
achieved by only single short infusion of DE-310 given every 6 weeks, which 
144 confirmed the pharmacokinetic proof of principle yielding the extended exposure 
to the topoisomerase I inhibiting active moiety. 
Because of the long half-life, which approximated a 2 weeks administration 
interval and largely exceeded the half-life expected based on preclinical data, 
further exploration of the q2w schedule was considered illogical in view of the 
potential for drug accumulation, and therefore the study protocol was amended 
to a 6 weeks schedule. The pharmacokinetics showed near dose proportionality 
of conjugated DX-8951, glycyl-DX-8951, and DX-8951. 
Reversible grade 4 myelosuppression and grade 3 hepatotoxicity with VOD were 
the principal DLTs and were observed at dose levels 9.0 mg/m2 (2 out of 4 patients) 
and 7.5 mg/m2 (1 out of 6 patients), respectively. It is of interest to note that 
the AUCs of conjugated DX-8951, glycyl-DX-8951 and DX-8951 were 1 0-fold higher 
in the second cycle of the two patients with resulting VOD compared to the other 
patients at the same dose levels. The reason for this large interpatient variation 
in pharmacokinetics remains to be elucidated. The recommended dose for 
phase II studies is 7.5 mg/m2 once every 6 weeks. At this dose and schedule, 
circulating concentration of the active moiety DX-8951 after a single infusion of 
DE -310 were similar to those achieved at the MTD of a 21-day continuous infusion 
of DX-8951f at 0.15 mg/m2 /day (Figure 2) [201. 
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Figure 2. Comparative exposure of 21-day continuous infusion of 0.15 mg/m2 / 
day of DX-8951f [exatecan] [201 versus single 3-hour infusions of increasing doses 
of DE-310 
Other nonhematalogic toxicities attributed to the treatment of DE-310 included 145 
mild to moderate nausea, vomiting, stomatitis, anorexia, asthenia, and 
alopecia, a toxicity profile similar to that of single agent exatecan mesylate 
(DX-8951f) [10-141. 
The observed myelosuppression was an expected side effect, known to be 
a class-effect of topoisomerase I inhibitors. The nadirs of ANC and platelets 
were reached at 22 days (range, 18 - 29 for ANC, and 11 - 36 for platelets) post 
infusion. 
Myelosuppression was always fully reversible after a median of 14 days 
(range, 3- 23) post nadir. In view of the presence of circulating active drug moiety 
at the time of nadir, and the conceptual likelihood that colony-stimulating growth 
factors could thus actually increase severity and duration of myelosuppression by 
stimulating stem cells while exposed to cytotoxics, the administration of agents 
like G-CSF was specifically avoided. 
The other DLT was hepatotoxicity consisting of reversible increases in liver 
transaminases and bilirubin, and in 2 patients correlated with presence of 
hepatic VOD. Hepatic VOD results from toxic injuries to the hepatic sinusoids 
(zone 3 of the liver acinus), followed by a series of biologic processess that lead 
to circulatory compromise of centrilobular hepatocytes, fibrosis, and obstruction 
of liver blood flow l21 , 221. Histology showed diffuse damage in the centrilobular 
zone of the liver, in combination with sinusoidal fibrosis, necrosis of pericentral 
hepatocytes, narrowing and fibrosis of central veins. Although drug-induced 
VOD is most frequently observed following stem cell transplantations with 
high-dose busulfan and cyclofosfamide, it can occur after various regimens of 
chemotherapy at conventional doses (e.g., actinomycin D, dacarbazine, cytosine 
arabinoside, mitramycin, and 6-thioguanine), combination chemotherapy, or 
(total body) irradiation. It has been suggested that drugs or toxins can induce 
depletion of glutathione leading to cell death and yielding increased activity of 
matrix metalloproteinases, resulting in degradation of the extracellular matrix 
and loss of sinusoidal endothelial cells from the space of Disse l21 , 221. 
Hepatotoxicity was also reported in a phase I study of N-(2-hydroxypropyl)-
methacrylamide (HPMA) copolymer conjugates of doxorubicine (PK1) l23l, but 
not for MAG-camptothecin (MAG-CPT) l24l, and the phase I study of pegylated-
camptothecin (PEG-CPT) l25l. It therefore remains unclear if the carrier is 
responsible for this phenomenon, or whether both carrier and active drug are 
responsible. While VOD is a severe side effect, the fact that even the most severe 
cases of hepatotoxicity in our trial showed full reversibility indicates that with 
proper monitoring the drug DE-310 can be safely used at the recommended dose 
of 7.5 mg/m2 every 6 weeks. 
146 Concentrations of conjugated DX-8951, glycyl-DX-8951, and DX-8951 were 
determined in ascites samples in a patient with advanced pancreatic disease 
treated at dose level 6.0 mg/m2• These data indicated significant exposure of 
the peritoneal cavity to conjugated DX-8951, glycyl-DX-8951, and DX-8951 at 
concentrations exceeding those in simultaneously obtained plasma samples. 
The results of studies assessing DE-310, glycyl-DX-8951 and DX-8951 in normal 
skin, erythrocytes, and saliva would seem to fit with the long circulation times 
combined with the formation rate-limited elimination and the hypothesis of 
preferential drug uptake by tumor tissue and not in other tissues. However the 
sample size and available data are too limited to draw definitive conclusions. 
Notwithstanding, it can be concluded that the biodistribution of this polymerized 
agent is substantially different from that of the registered topoisomerase I 
inhibitors topotecan [261, and irinotecan and its metabolite SN-38 [271. 
In summary, by employing a polyalcohol carrier with cleavable linking peptide 
as a drug-delivery system, the pharmacokinetics profile of the topoisomerase 
I inhibitor DX-8951f seems to be improved, providing slow release of the 
active moiety over a very extended period. This together with the presence of 
discernable drug levels in tumor and the below limits of quantitation drug levels 
in normal tissues provides supportive evidence to the validity of the concept of 
using macromolecular carriers to enhance the potential efficacy and diminish the 
toxicity of topoisomerase I inhibitors and warrants further evaluation in phase II 
studies. 
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Abstract 
The purpose of this weekly schedule phase I study of liposome encapsulated 
paclitaxel (LEP) was to define the maximum-tolerated dose (MTD), the 
recommended dose (RD), the dose-limiting toxicities (DLTs), the pharmacokinetic 
profiles, and to evaluate preliminary antitumour effects in patients with 
refractory solid malignancies. LEP was administered as an intravenous infusion 
over 45 minutes once every week for 6 out of 8 weeks. Fourteen patients were 
treated at doses ranging from 90 to 150 mg/m 2/week. In one patient DLT was 
observed at dose level 150 mg/m2/week, who received less than 70% of the 
intended cumulative dose. No cumulative toxicities were observed. Stabilization 
of disease for 8 weeks was documented in two patients. The whole blood 
clearance of total paclitaxel was similar for LEP (15.3 ± 8.98 L/h/m2) and Taxol® 
(17.5 ± 3.43 L!h/m2), and the extraliposomal-to-total-drug ratio increased 
rapidly to unity at later sampling time points. The trial was discontinued upon 
completion of enrolment of the 150 mg/m2 /week cohort because an assessment 
of the pharmacokinetics and clinical data suggested that LEP was unlikely to 
have any advantages over Taxol®. It is concluded that this formulation of LEP is 
unlikely to provide improvements over taxanes currently in clinical use. 
1. Introduction 
Paclitaxel, a complex diterpenoid natural product derived from the bark of the 
Western yew tree, Taxus brevifolia, belongs to the class of anti-microtubule 
agents and is active in a broad variety of human malignancies, including breast, 
ovarian and non-small cell lung cancer. Due to the agent's poor solubility in 
aqueous solutions, paclitaxel is formulated for clinical use in a mixture of 
Cremophor ELand ethanol (Taxol®). Previous work has indicated that Cremophor 
EL contributes to the nonlinear pharmacokinetic behavior of paclitaxel and to 
severe hypersensitivity reactions in humans observed after the administration of 
Taxol®[1, 21. The incidence of these severe hypersensitivity reactions is 
approximately 41% despite the use of pre-medication with corticosteroids 
and antihistamines (see: http:/ /www.taxol.com). It has been proposed 
that the hypersensitivity reaction to Taxol ® is caused by a Cremophor EL-
mediated activation of the complement system [31. The clinical formulation of 
Taxol® has also been associated with other side effects, including peripheral 
neurotoxicity [41. To overcome the problems associated with the current 
formulation of paclitaxel, several chemical, pharmaceutical, and/ or biological 
strategies are being explored to optimize chemotherapeutic treatment with 
paclitaxel [5l. One of the strategies is delivery of the drug by the use of liposomes 
(size ranging from 10 nm to 20 11m) consisting of an aqueous core surrounded 
by one or more membranes consisting of naturally or synthetic phospholipids 
arranged in a bilayer configuration [6, 7l. These spherical vesicles can encapsulate 
various therapeutic agents, including anticancer agents [8l. One rationale for 
encapsulating cytotoxic drugs in liposomes is based on the hypothesis that 
macromolecular (liposomal) carrier leakage will occur in tumour tissue due to its 
enhanced permeability and retention (EPR) effect [9,10l. This EPR effect is caused 
by discontinuation of the endothelium of tumour blood vessels, as a result of 
structural and functional anomalies, and the co-existing lack of a fully functional 
system of lymphatic drainage [11 l. The interplay between these characteristics of 
tumour tissue can result in the extravasation and retention of liposomes within 
the tumour interstitium, with the potential for providing more active drug to 
tumour with less exposure to normal tissue. 
Since liposome encapsulation is suitable for the intravenous delivery of poorly 
water soluble compounds, paclitaxel has also been proposed for administration 
in liposomes [8l. A liposome formulation (without Cremophor EL) could have 
considerable potential given the substantial liabilities associated with Cremophor 
EL. Several liposome-based formulations of paclitaxel have been tested in 
vivo for antitumour activity in various models [12·15l, and for various liposome 
formulations the maximum-tolerated dose (MTD) was 2- to 7-fold greater than 
for Taxol® [12l. 
The encapsulation of cytotoxic agents into liposomes (e.g., anthracyclines) has 
been shown to substantially modulate the pharmacokinetic behavior of these 
drugs [1l. This approach may enhance the efficacy of anticancer drugs and reduce 
their systemic toxicity through a lower exposure to the drug of normal tissues. 
The aim of this study was to define the MTD, RD, DLTs, pharmacokinetic profiles, 
and evaluate preliminary antitumour effects of a weekly schedule of LEP in 
patients with refractory solid malignancies. 
2. Patients and methods 
2. 1 Patient selection 
Patients with a histologically confirmed diagnosis of a malignant solid tumour 
refractory to conventional chemotherapy or for whom no effective therapy 
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existed were eligible. Other eligibility criteria included the following: age 
;:: 18 years; Eastern Cooperative Oncology Group performance status ::; 1; no 
previous anticancer therapy for at least 4 weeks (6 weeks for nitrosourea or 
mitomycin-C); and adequate haematopoietic (absolute neutrophil count (ANC) 
;:: 1,500/IJL, platelet count;:: 100 x 109/L and hemoglobin ;:: 10.0 g/dl (or 6.2 
mmol/L), hepatic (serum total bilirubin ::; 1.5 mg/dl, and serum aspartate 
transaminase (ASAT), alanine transaminase (ALAT) ::; 2.5 times the institutional 
upper normal limit (UNL) (::; 5.0 times UNL in case of liver metastases), and renal 
function (serum creatinine concentration ::; 1.5 mg/ dl). Prior surgery or radiation 
therapy (irradiation field encompassing < 25% of bone marrow) was acceptable 
as long as it had been completed at least 4 weeks before study registration. 
Specific exclusion criteria included known hypersensitivity to Cremophor EL 
and/or paclitaxel-containing regimens, known brain metastases, spinal cord 
compression, and/or carcinomatous meningitis. The study protocol was approved 
by the institutional Ethical Board, and all patients gave written informed consent 
before study entry. 
2.2 Treatment and dose-escalation 
LEP was provided in vials containing 25 mg of paclitaxel per vial, and was 
supplied by the Pharmacia (Nerviano, Italy) as a freeze-dried product. The vials 
also contained cardiolipin, egg phosphatidyl choline, cholesterol, d-a-tocopheryl 
acid succinate (vitamin E), and mannitol as inactive ingredients. The addition of 
mannitol as a cryoprotectant to this liposomal formulation of paclitaxel ensured 
that sonication before the administration of the drug was not required. The vials 
were stored at 5° C in the dark, and were kept at room temperature for at least 2 
hours before reconstitution. After that, 25 ml of 0. 9% sodium chloride injection 
per 25 mg of paclitaxel were added to the LEP vials. The solution was injected in 
the middle of the lyophilized cake using a 50 ml sterile and pyrogen free syringe. 
The vials were gently shaken for 2 to 3 minutes. The reconstituted product was 
a sterile dispersion, and in-line filters were not used for administration. The 
content of the reconstituted vials was transferred to an infusion bag using a 
154 syringe, and the infusion bag was gently turned for 30 seconds before infusion. 
LEP was given as a 45-minute infusion, preceded by pre-medication consisting of 
20 mg dexamethasone, 2 mg clemastine, and 50 mg ranitidine, each administered 
intravenously 30 minutes before the initiation of LEP infusion. Prophylactic anti-
emetics were not given. The treatment was administered every 7 days for 6 
out of 8 weeks, unless the patient did not recover adequately from treatment-
related adverse events of prior infusions. A period of 8 weeks was defined as one 
cycle. The starting dose of LEP was 90 mg/m2 /week. This dose and schedule was 
selected on the basis of both clinical and pharmacokinetic data regarding weekly 
paclitaxel and from a phase I study of a sonicated preparation of LEP given as a 
single agent once every 3 weeks (unpublished data, Pharmacia). Subsequent dose 
levels scheduled were: 120 mg/m2 /week (33% dose increment), 150 mg/m2 /week 
(25%), and 180 mg/m2 /week (20%). 
At least three patients were entered at each dose level. The MTD was defined 
as one dose level below the dose that induced DLTs during the first cycle in :::: 2 
out of 6 patients. DLTs were defined using the National Cancer Institute Common 
Toxicity Criteria (NCI-CTC) version 2.0 and included: grade 4 neutropenia > 
7 days, grade 4 haematological toxicity of any duration (except for grade 4 
neutropenia), febrile neutropenia, non-haematological toxicities ?: grade 3, 
severe hypersensitivity reaction suggestive of an anaphylactic reaction, and 
receiving less than 70% of the intended cumulative dose of LEP [171. If grade 2 
neutropenia and/ or grade 2 thrombocytopenia occurred during treatment, the 
dose of LEP was decreased by 50% for the subsequent administration. In case 
of grade ?: 3 neutropenia and/ or thrombocytopenia, treatment with LEP was 
omitted for that week and then decreased by 50% for subsequent administrations 
when the neutrophil count had recovered to ?: 1500/iJL and the platelet count to 
?: 75 x 1 09 I L. I ntrapatient dose-escalation was not allowed. 
2.3 Treatment assessment 
Before initiating therapy, a complete medical history was taken and a physical 
examination was performed. A complete blood cell (CBC) count, including 
haematology tests (hemoglobin, WBC with differential count, and platelets), 
and serum biochemistry, (sodium, potassium, calcium, magnesium, chloride, 
creatinine, total protein, albumin, total bilirubin, alkaline phosphatase, ASAT, 
ALAT, and gamma-glutamyltransferase) were performed, as were urinalysis 
(pH and albumin), ECG, and chest X-ray. Weekly evaluations included physical 
examination, toxicity assessment according to the NCI-CTC criteria, and 
haematology tests. Urinalysis was performed at week 1, 3 and 5 before 155 
administration of LEP. Tumour evaluation was performed after every cycle 
of 8 weeks and response was assessed according to RECIST [181. Patients were 
discontinued from treatment in the case of disease progression, unacceptable 
toxicity, or patient request. 
2.4 Sample collection and drug analysis 
The pharmacokinetic of LEP was evaluated by following the time concentration 
profile of paclitaxel, measured both as total paclitaxel in blood (liposome-
associated plus non-liposome-associated) and extraliposomal paclitaxel in 
plasma (non-liposome-associated, bound and unbound to plasma proteins). The 
pharmacokinetics of extraliposomal and total paclitaxel after LEP administration 
were evaluated in all patients enrolled into the study during the first cycle of 
treatment. A total of 33 blood samples (about 7 ml) were drawn from each 
patient during the first and last week of the first cycle of treatment at pre-dose, 
end of infusion and at 5, 15, 30 min and 1, 2, 4 h, any time between 8 and 16 h, 
24, 48, 72 and 168 h (this latter only at the sixth week) post-infusion. In addition, 
blood samples were also collected at pre-dose and end of infusion at the second, 
third, fourth, and fifth week of treatment. Blood samples were collected in 
precooled (ice-water, 4 ° C) vials containing lithium heparin as anticoagulant. An 
aliquot of blood (2 ml) was frozen at -20°C and used for the analysis of total 
paclitaxel; the remaining amount of blood was centrifuged (1200 x g for 15 min 
at 4°C) and the harvested plasma was frozen at -20°( and used for the analysis 
of extraliposomal paclitaxel. 
Concentrations of total paclitaxel (i.e., the sum of liposome-associated and non-
liposome-associated paclitaxel) and extraliposomal paclitaxel (i.e., the non-
liposome-associated, protein-bound and unbound) were determined in blood and 
plasma, respectively, with validated methods based on liquid chromatography 
with tandem mass-spectrometric detection (MS/ MS). For the quantitation of 
total paclitaxel, Triton X-100 (5%, (v/v)) was added to whole blood and an 
aliquot (1 00 1-JL) of blood was extracted using tert-butyl methyl ether (MTBE). 
To determine extraliposomal concentrations of paclitaxel in human plasma 
(250 1-JL), liposomes were separated from plasma proteins using a solution 
containing dodecantungstophosphoric acid and magnesium chloride; an aliquot 
of supernatant (1 00 IJL) was extracted with MTBE. For both methods, paclitaxel 
was separated using a Zorbax C18 column and eluted under gradient conditions 
with a mobile phase containing acetonitrile and 2 mM ammonium acetate 
156 buffer (pH 5). MS/MS detection was conducted with a PE-Sciex API 3000 mass 
spectrometer using a turbo ionspray source and multiple reaction monitoring in 
a positive ion mode. The lower limits of quantitation were 5 ng/ml and 1 ng/ml 
for total paclitaxel in blood and extraliposomal in plasma, respectively. 
Analysis of the protein-unbound fraction of the extraliposomal paclitaxel 
concentrations was attempted but could not be determined separately due to 
interference in the equilibrium dialysis method l19l. 
2.5 Pharmacokinetic analysis 
Pharmacokinetic parameters were calculated by standard non-compartmental 
methods using WinNonlin version 3.1 (Pharsight, Mountain View, CA, USA). The 
area under the plasma concentration-time curve (AUC) was calculated up to the 
last detectable concentration (C(t,zJ), using the linear trapezoidal rule. Other 
parameters, including volume of distribution at steady state (V55 ) and clearance 
(CL) were estimated using standard equations. The AUC was extrapolated to 
infinity by addition of C(t,z/k, where k is the terminal rate constant, which was 
estimated from a log-linear regression analysis of the terminal disposition phase. 
The half-life of the terminal phase was calculated as ln(2)/k. 
3. Results 
A total of 14 patients was entered into the study and received at least one 
dose of LEP. All patients were assessable for toxicity and response. Patient 
characteristics are listed in Table 1. Four patients did not complete the first 
cycle; one patients with adenocarcinoma of the duodenum, developed tumour 
related haematemesis and three patients had disease progression. The total 
number of assessable cycles was 16. The median number of cycles per patient 
was 1 (range, 1 - 2). 
3. 1 Dose-limiting toxicity 
At 150 mg/m2/week, one patient experienced DLT by receiving less than 70% of 
the intended cumulative dose of LEP. The patient received the first two doses 
as planned. The third and fourth infusions were omitted because of grade 3 
and grade 4 neutropenia, respectively, and the patient received no subsequent 
therapy because of disease progression. In view of this single DLT, the cohort was 
expanded without observing further DLTs. Dose-escalation to 180 mg/m2 /week 
did not take place because of discontinuation of the study (see below). For this 
reason, the MTD and RD were not determined. 
3.2 Haematological toxicity 
Haematological toxicities per patient over the entire cycle of treatment are 
summarized in Table 2. One patient experienced grade 3 neutropenia at the 
120 mg/m2 /week dose level and one patient at the 150 mg/m2/week dose level 
experienced grade 3 and grade 4 neutropenia. At the 150 mg/m2 /week dose level, 
haematological side effects generally lasted less than 7 days. Mild to moderate 
anemia and thrombocytopenia was documented at all dose levels tested. 
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Characteristic 
No. of Patients 
Total 
Assessment 
For Dose-Limiting Toxicity 
For Efficacy 
No. of cycles/patient 
Median 
Range 
Gender, male ; female 
Age, years 
Median 
Range 
ECOG performance status 
0 
Previous therapy 
Chemotherapy only 
Radiotherapy 
Surgery 
Tumour types 
Colorectal 
Gastro-intestinal tract, including: 
Esophageal 
Gastric 
Gallbladder 
Pancreatic 
Unknown primary tumour 
Miscellaneous 
,, 
! 
1 . 2 
54 
30. 66 
No. of Patients 
14 
13 
12 
8: 6 
4 
10 
11 
3 
9 
3 
8 
1 
2 
2 
2 
3 
Abbreviations: no., number; ECOG, Eastern Cooperative Oncology Group. 
Dose No. No. 
[mg/m2/week} of pts. of cycles 
90 3 3 
120 4 4 
150 7 9 
Abbreviations: no., number; pts., patients. 
_.. 
Ul 
..0 
Anemia 
1-2 3-4 
0 
2 0 
5 0 
Leucocytopenia Neutropenia Thrombocytopenia 
Grades 
1-2 3 4 1-2 3 4 1-2 3 4 
2 0 0 1 0 0 1 0 0 
2 0 0 1 1 0 2 0 0 
3 3 0 3 1 1 2 0 0 
9 JaJdDI.JJ 
3.3 Non-haematological toxicity 
Gastrointestinal toxicities of mild to moderate severity were observed at all 
dose levels tested, and consisted of nausea [grade 1 (N = 7), grade 2 (N = 1 ), 
grade 3 (N = 1 )], diarrhea [grade 1 (N = 8), grade 2 (N = 1 ), grade 3 (N = 1 )], and 
vomiting [grade 1 (N = 3)]. Mild hypersensitivity reactions, consisting mainly of 
a facial flush and shortness of breath, were documented in four patients at the 
150 mg/m2/week dose level. All of these reactions had a rapid onset within the 
first minutes after the start of the LEP infusion and promptly recovered after 
stopping of the infusion and intravenous administration of 2 mg clemastine and 
100 mg hydrocortisone. After rechallenging, none of these patients experienced 
a repeat of the infusion reaction. In two patients, a transient grade 1 to 2 skin 
reaction was documented. Mild alopecia (grade 1) was observed in 1 patient and 
neurotoxicity was not observed, but particularly the latter should be interpreted 
with caution in view of the very small number of cycles evaluated per patient. 
3.4 Pharmacokinetics 
Pharmacokinetic analysis was performed on all the 14 patients enrolled in this 
study. The pharmacokinetic parameters for total and extraliposomal paclitaxel 
during the first and sixth week of the LEP treatment are summarized in Tables 3 
and 4. After the administration of LEP at dose levels 90, 120, and 150 mg/m2 / 
week, the levels of total and extraliposomal paclitaxel reached the maximum 
value near the end of infusion on both the first and sixth week of treatment. 
After the administration of 90, 120 and 150 mg/m2 /week, the mean(± SD) peak 
concentration of extraliposomal paclitaxel was 190 ± 94 and 186 ± 70 ng/mL, 
363 ± 241 and 224 ng/ mL, and 424 ± 166 and 326 ± 120 ng/ mL, after the first 
and sixth week, respectively. The corresponding values of total paclitaxel were 
2787 ± 1262 and 3083 ± 807 ng/mL, 3918 ± 1325 ng/mL and 2020 ng/mL, and 
5004 ± 2334 and 5032 ± 3527 ng/mL, after the first and sixth week, respectively, 
at the 90, 120 and 150 mg/m2/week dose level. After the end of infusion, blood 
levels of total paclitaxel and plasma levels of extraliposomal paclitaxel declined 
polyexponentially with an apparent terminal half-life ranging between 77 and 
160 195 h, and 80 and 144 h, respectively. Total paclitaxel exhibited a relatively slow 
clearance from whole blood (range, 9 to 26 L/h/m2), with a steady-state volume 
of distribution ranging from 120 to 2189 L/m2• There was large interpatient 
variation in both drug clearance and volume of distribution at a coefficient of 
variation of approximately 60%. 
1st week 6th week 
Dose No. of cmax TVz,z AUCO-t(last) AUCO-oo CL v,, No. of cmax TVz,z AUCO-t{tast) 
'[mg/m2/week]' patients [ng/mL] [h] [ng·h/ml] [ng·h/ml] [L/h/m2] [l/m2] patients [ng/ml] [h) [ng·h/mL] 
- -·- --·--- -·-· --
90 3 2787 135 6444 8035 11 ± 2 1004 3 3083 
195a 12494 
± 1262 ± 67 ± 12 ± 1111 ± 506 ± 807 ± 61 ± 5194 
3918 .na 6566 7611 618 i 120 4 
± 1325 ± 68 ± 3231 ± 2492 17 ± 5 ± 316 1 2020 112 5731 
150 7 5004 118 10609 12539 13 ± 6 1036 5 5032 
145b 13759 
± 2334 ± 83 ± 2852 ± 3260 ± 824 ± 3527 ± 125 ± 5143 
Note: aN = 2, bN = 3. 
Abbreviations: SD, standard deviation; no., number; Cmax' peak plasma concentration; T112 z' half-life of the terminal disposition 
phase; AUC0_t(tast)' area under the plasma concentration-time curve up to the last time poin't with measurable levels; AUC0 __ , AUC 
extrapolated to infinity; CL, total clearance; V,,, steady-state volume of distribution. 
0' 9 Jt3JdDlJJ 
Dose 
[mg/m2/week] 
90 
120 
150 
"' N 
No. of 
patients 
3 
4 
7 
Note: aN = 1, bN = 3, eN = 2. 
1st week 
em ax T~,z AUCO-t(last) : 
[ng/mL] [h] [ng·h/mL] • 
190 ± 94 8oa 910 
± 171 
363 ±241 ! 138b ± 74 .l 1357 
± 287 
424 ± 166 126b± 32 2410 
± 704 
Chapter 6 
6th week 
No .. of (max Ty,,z AU Co-t (last) 
patients [ng/mL] [h] [ng·h/ml] 
-----'~--
N/A 3 186 ± 70 135 ± 67 4242 
± 2658 
2119 
1. 224a N/A 2826 
± 576 
3031 5 326 ± 120 144C ± 48 3967 
± 839 ± 1321 
Abbreviations: SD, standard deviation; no., number; Cmax' peak plasma concentration; T112,z, half-life of the terminal 
disposition phase; AUC0_t(tast)' area under the plasma concentration-time curve up to the last time point with measurable levels; 
AUC0 __ , AUC extrapolated to infinity; N/ A, not available. 
After the first week of treatment, the levels of total and extraliposomal 
paclitaxel increased in direct proportion with the dose, suggesting linear 
pharmacokinetics. Furthermore, over the tested dose range, total blood 
clearance was dose-independent (P = 0.490, Kruskal-Wallis one-way ANOVA, 
corrected for ties), supporting the above observation of a linear kinetics for 
total paclitaxel. Pharmacokinetic information obtained during the sixth week 
indicated on average an one- to two-fold accumulation, which is in reasonable 
agreement with the half-life of the apparent terminal disposition phase. 
10000 
:g 1000 
....... 
Oil 
c: 
c: 
0 
:c; 
~ 
...... 
c: 
QJ 
u 
c: 
0 
u 
100 
10 
0 30 60 90 120 150 
Time [h] 
Figure 1. Plasma concentration time profiles of total paclitaxel in whole blood 
[closed symbols] and extraliposomal paclitaxel in plasma [open symbols] in 
patients receiving LEP at a dose of 150 mg/m2/week. Data are presented as mean 
values [symbols] ± standard deviation [SD] 163 
Assuming an equal distribution between plasma and blood for extraliposomal 
paclitaxel following administration of LEP [20l, extraliposomal paclitaxel 
represented only a minor portion of the total paclitaxel [i.e., the sum of 
liposome-associated and non-liposome-associated paclitaxel] in the systemic 
circulation. The proportion of extraliposomal and total paclitaxel changed 
with time and among patients, ranging from 3 to 14% of the total paclitaxel at 
the first time point to about 23 to 100% at the final sampling time points. On 
average, considering the overall exposure, extraliposomal paclitaxel in plasma 
accounted for approximately 14 to 49% of the total paclitaxel exposure. The 
mean extraliposomal paclitaxel plasma concentrations and the total paclitaxel 
concentrations in blood versus time curves observed at the 150 mg/m2/week 
dose level are displayed in Figure 1 and 2. 
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Figure 2. Plasma concentration time profiles of total paclitaxel in whole blood 
[closed symbols], extraliposomal paclitaxel in plasma [open symbols] in patients 
receiving LEP at a dose of 150 mg/m2 /week, and total paclitaxel in plasma [open 
164 lozenges] in 14 patients receiving Taxol® at a dose of 150 mg/m2 [3-hour infusion]. 
Data are presented as mean values [symbols] ± standard deviation [SD] 
3.5 Antitumour efficacy 
At the 150 mg/m2/week dose level, disease stabilisation for 8 weeks was 
documented in two patients with liver metastases of an adenocarcinoma 
of unknown primary and with pleural and peritoneal metastatic esophageal 
carcinoma, respectively. Other patients had progressive disease after either the 
tumour assessment at 8 weeks, and 2 patients were discontinued because of 
early progression after the first and fourth administration of LEP, respectively. 
4. Discussion 
The current study was performed to explore the safety, feasibility, and 
pharmacokinetics of a new liposomal formulation of paclitaxel administrated 
as a 45-minute intravenous infusion once weekly for 6 out of 8 consecutive 
weeks. A previous formulation requiring a cumbersome sonication step just 
prior to infusion had been tested in a phase I trial using a single dose given 
every 21 days. The new, freeze-dried formulation has the same composition 
as the previously tested LEP formulation with the exception of the addition of 
mannitol as a cryoprotectant. The non-sonicated formulation was developed 
with the objectives of improving the overall profile of the drug. Real-time 
pharmacokinetics complimented clinical findings indicating that LEP was unlikely 
to offer significant advantages over taxanes currently employed in the clinic. 
With the new formulation, myelosuppression was seen at the 150 mg/m2/week 
dose level, suggesting that a possible recommended phase II dose using a weekly 
schedule would be in the range of 150- 180 mg/m2/week. However, the current 
results do not allow any conclusions regarding long-term or cumulative toxicity, 
including the critical neurotoxicity. 
To be effective as a carrier a liposome must be able to efficiently balance stability 
in the circulation with the ability to make the drug available at the tumour [8]. In 
order to achieve the optimum efficacy for a drug-delivery system, it is necessary 
to encapsulate the maximum possible quantity of a drug [71. Comparison of the 
encapsulation efficiency of the drug in liposomes with the therapeutic dose 
indicates whether liposomes can be used as a suitable drug-delivery system [71. 
The retention of the encapsulated drug is determined by the physicochemical 
characteristics of the drug itself and by the lipid composition and number of 
concentric membranes of the liposomal vesicle [21 , 221. Highly hydrophobic drugs, 165 
like paclitaxel, tend to associate mainly with the bilayer compartment of the 
liposome, resulting in lower entrapment stability due to faster redistribution of 
the drug to plasma components [91. 
In comparison with small molecules, the volume of distribution of the drug 
encapsulated in liposomes is usually significantly reduced [91, and when a drug is 
stably encapsulated within the liposomal matrix it displays the pharmacokinetic 
profile of the intact liposome rather than that of the encapsulated agent l11 1. In 
general, this should achieve a significant increase in the AUC in the circulation 
and possibly in tumour tissue, and mimicking the effect of administering cytotoxic 
drugs as continuous intravenous infusion, without the inconvience of intravenous 
devices and toxicities associated with systemic drug exposure l11 1. Likewise, the 
clearance of anticancer drugs encapsulated in liposomes is usually reduced, 
and the elimination half-life prolonged l231, as has been shown previously for 
anthracyclines l241, vincristine l251, and lurtotecan l261. 
The pharmacokinetics of total paclitaxel when administered as LEP appeared to 
be dose-independent, providing further evidence of the previous supposition that 
the non-linearity of paclitaxel disposition following the administration of Taxol ® 
is caused by its excipient Cremophor EL l11. However, as compared to Taxol®, the 
interpatient variation in paclitaxel pharmacokinetic parameters following the 
administration of LEP was large (up to 60%). In contrast to that expected for a 
liposomal formulation, the clearance of total paclitaxel in whole blood following 
LEP (15.3 ± 8. 98 Llh/m2) was very similar to that reported after administration 
of Taxol® (17.5 ± 3.43 L/h/m2 ) l271. The observed values for volume of distribution 
at steady state of total paclitaxel in patients receiving LEP was very high 
(about 1000 Llm2). Furthermore, in the systemic circulation, most paclitaxel 
was associated with the liposomes, since the extraliposomal paclitaxel AUC 
accounted only for 14- 49% of the total paclitaxel AUC; however, the proportion 
of extraliposomal drug in plasma and total drug in whole blood increased with 
the time, reaching unity at the end of the sampling time period. 
Previous work has shown that the plasma protein binding of the fraction of 
unbound paclitaxel in plasma in the absence of formulation excipients is 
approximately 85% in humans l11. Assuming this value of plasma protein binding 
also for paclitaxel after LEP administration, at the 150 mg/m2/week dose level, 
the predicted AUC0·t(last) is 362 ± 106 ng·h/ml, which is similar to 397 ± 69.7 ng·h/ 
ml observed for Taxol® at the recommended weekly dose of 100 mg/m2 l281. This 
clearly suggests that at approximate equitoxic doses, exposure to the clinical 
relevant pharmacokinetic parameter is comparable for both formulations, and 
166 that LEP provides no pharmacologic advantages over Taxol ®. 
The release of complement fragments C3a and C5a can cause a hypersensitivity 
reaction, called complement activation-related pseudoallergy (CARPA), by 
release of anaphylatoxins and a cascade of cellular mediators of inflammation 
l3,29 ,301. Activation of complement can rapidly induce a pallet of symptoms, 
including pain (e.g., chest-pain, low back pain, headache), chills, choking, 
nausea, confusion, skin toxicity (e.g., erythema, pruritus, urticaria), symptoms 
of respiratory distress (e.g., bronchospasm, dyspnea), and severe cardiac 
arrhythmias [3,291. The frequency of CARPA due to intravenous infusion of 
conventional or pegylated liposomes ranged from 3 to 7% in several studies. 
Symptoms were observed within 5 to 10 min after the start of the first infusion. 
In most patients symptoms disappeared shortly after stopping of the infusion 
l3l. The rapid induction of this event seems to indicate that minimal amounts of 
liposomes can induce these side effects l30l. In the present study, hypersensitivity 
reactions were observed shortly after the intravenous infusion of the first LEP 
treatment in 3 patients. Rechallenge of the LEP infusion after treatment of 
corticosteroids and antihistamines was possible in all 3 patients without any new 
reaction or other complications. While the frequency of reactions was relatively 
low, LEP did not distinguish itself from currently used taxanes, since all patients 
received standard premedication with dexamethasone and antihistamines. 
Collectively, the results of pharmacokinetic data supported the 
decision to terminate the study prior to reaching the primary objective of 
determining the MTD and RD and strengthened the importance of performing 
real-time pharmacokinetic analysis during a phase I study in order to bring as 
much as relevant information as possible to guide the decisions for further 
development. 
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This thesis includes phase I clinical and pharmacological studies on second 
and third generation topoisomerase I inhibitors, either administered orally, 
or intravenously as a macromolecular drug-delivery system, and on the anti-
microtubulin agent, paclitaxel encapsulated in liposomes, to investigate the 
suitability of prolonged exposure of these anti-cancer agents and formulations. 
These studies were performed since in preclinical models, the cytotoxicity 
of both topoisomerase I inhibitors and paclitaxel increases with duration of 
exposure. 
In Chapter 1 we review the semi-synthetic camptothecin analogs currently 
registered or under clinical development as well as novel derivatives in 
preclinical development. In order to increase antitumor activity and to 
reduce toxicity, a variety of different strategies is being used to modulate 
the systemic delivery of these analogs. Three principal approaches are being 
discussed, (a) pharmaceutical modulation of formulation vehicles, structural 
alterations, and the search for more aqueous soluble prodrugs, (b) modulation 
of routes of administration and considerations on infusion duration, and (c) both 
pharmacodynamic and pharmacokinetic biomodulation. 
Oral administration of irinotecan is a more patient convenient approach to 
mimic continuous drug-delivery facilitating prolonged exposure of the agent. 
In Chapter 2 a phase I and pharmacokinetic, food effect, and pharmacogenetic 
study on oral irinotecan given as semi-solid matrix (SSM) capsules to patients 
with solid tumors is presented. The purpose of the study was to characterize 
the maximum-tolerated dose, recommended dose, toxicity and pharmacokinetic 
profile of orally administered irinotecan once daily for 5 consecutive days 
repeated every 3 weeks with the drug being taken in fasted condition. Patients 
were randomly assigned to take the drug along with high-fat and high-calorie 
breakfast for the first administration at day 1 of the first or second cycle. Twenty-
five assessable patients received 101 cycles (median 2 cycles, range 1 - 15) at 
dose levels 70 and 80 mg/m2/day. Grade 3 delayed diarrhea in combination with 
172 grade 3 fever were dose-limiting toxicities (DLTs) at 80 mg/m2/day in three out 
of five patients. Exposure to the active metabolite SN-38 was relatively high 
compared to intravenous infusion, but no relevant accumulation was observed. 
Food had no significant effect on irinotecan pharmacokinetics. One confirmed 
partial remission and ten disease stabilizations were observed in previously 
pretreated patients. No association was found between UGT1A1*28 genotype and 
the risk of severe irinotecan-induced toxicity (i.e., diarrhea and neutropenia). 
The recommended dose is 70 mg/m2/day for 5 consecutive days every 3 weeks. 
The study confirms that oral administration of irinotecan is feasible and may 
have improved pharmacokinetic characteristics as compared to intravenous 
administration of the drug. 
In general, combination chemotherapy is more effective than single agent 
treatment. lrinotecan and capecitabine have different mechanisms of 
action, and have synergistic or additive cytotoxicity in experimental models. 
Furthermore, both agents have only partially overlapping toxicities. Against 
this background, we performed a phase I and pharmacokinetic study on oral 
irinotecan in combination with capecitabine in patients with solid tumors as 
described in Chapter 3. Twenty-eight patients were enrolled into the study 
and received 155 cycles of therapy (median 5 cycles, range 1 - 18). They were 
treated with irinotecan SSM capsules given once daily for 5 consecutive days 
(dose, 50- 60 mg/m2/day) concomitantly with capecitabine given twice daily for 
14 consecutive days (dose, 800 - 1000 mg/m2), cycles repeated every 21 days. 
At dose level irinotecan 60 mg/m2/day and capecitabine 2 x 800 mg/m2/day, 
grade 3 diarrhea in combination with grade 2 nausea, despite maximal anti-
emetic support, and with grade 3 anorexia and colitis were noted as DLTs in the 
first cycle in two out of six patients, respectively. At the recommended doses 
(irinotecan 50 mg/m2/day; capecitabine 2 x 1000 mg/m2/day), side effects 
were mostly mild to moderate and uniformly reversible. Pharmacokinetic 
analysis showed no interaction between both agents. Three confirmed partial 
responses and 16 disease stabilizations were observed. The study showed that 
the combination of oral irinotecan and capecitabine is a feasible, well tolerated 
all oral regimen, especially convenient for the outpatient setting and warrants 
further evaluation. 
An alternative approach for continuous drug administration is using a 
macromolecular drug-delivery system, which can comprise an active 
topoisomerase I inhibitor linked to a polyalcohol polymer. Macromolecular 
carriers will accumulate and be retained preferentially in tumor tissue by a 173 
phenomenon, termed enhanced permeability and retention (EPR) effect, that is 
thought to be due to tumor vasculature displaying a discontinuous endothelium, 
which allows macromolecular extravasation into tumor tissue, and also the lack 
of effective lymphatic drainage in tumors, which prevents efficient clearance of 
such accumulated macromolecules. Macromolecular carriers have been shown 
to alter drug pharmacokinetics at the whole organism and cellular level and 
facilitate controlled drug release at the tumor site. 
DE-310 is a novel macromolecular prodrug of the topoisomerase I inhibitor 
exatecan (DX-8951f). To study the biodistribution of this macromolecular carrier 
and its two major enzymatic products (i.e., glycyl-DX-8951 and DX-8951 ), high 
liquid chromatographic assays in human whole blood, erythrocytes and saliva 
were developed and validated as described in Chapter 4. Sample pretreatment 
involved a single protein-precipitation step, followed by a thermolysin-mediated 
deconjugation for the parent molecule. Separation of the compounds was 
achieved on an lnertsil ODS-80A column (150 x 4.6 mm i.d.; 5 IJm PS), using 
isocratic elution. The column effluent was monitored at excitation and emission 
wavelengths of 375 and 445 nm, respectively. Validation results indicated that 
the methods are accurate and precise at lower limits of quantitation of 0.5 
- 6. 9 ng/ml. The suitability of the developed methods for the clinical use 
was demonstrated by the determination of DE-310 and its enzymatic products 
in human erythrocytes and saliva obtained from eight patients with different 
advanced solid tumors, treated with DE-310 at dose levels or 7.5 mg/m2 (q6w). 
In all analyzed samples of erythrocytes and of saliva the concentration of DE-
310, glycyl-DX-8951, and DX-8951 were below lower limit of quantitation (< 
0.5 ng/ml). This would fit with the hypothesis of preferential drug uptake in 
tumor tissue, but not in other tissues. Therefore, the biodistribution of DE-310 is 
substantially different from other topoisomerase I inhibitors, such as irinotecan 
and topotecan. 
In Chapter 5 we reported a phase I and pharmacokinetic study of DE-310 
administered as a 3 hours intravenous infusion once every 2 or 6 weeks in 
patients with advanced solid tumors. Twenty-seven patients were treated 
and received a total of 86 administrations (i.e., 61 cycles). Initially, patients 
were treated once every 2 weeks in a 4-weekly schedule at doses ranging from 
1.0- 2.0 mg/m2 (q2w). Because of the long half-life, which approximated the 2 
weeks administration interval and largely exceeded the half-life expected based 
on preclinical data, further exploration of the q2w schedule was considered 
illogical in view of the potential risk for drug accumulation, and therefore the 
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weeks at doses ranging from 6.0 - 9.0 mg/m2 (q6w). Grade 4 myelosuppression 
and grade 3 hepatotoxicity with vena-occlusive disease (VOD) were the principal 
dose-limiting side effects. Other hematological and nonhematological toxicities 
were mild to moderate and reversible. Pharmacokinetics could performed in 
all patients. Across the various dose levels, the apparent terminal half-lives of 
conjugated DX-8951 (the carrier linked molecule), glycyl-DX-8951, and DX-8951 
were 13, 12, and 13 days, respectively. Consequently, plasma concentrations of 
all compounds conjugated were sustained for several weeks. This parallel decline 
suggests that the terminal phase seen with the DE-310 metabolites (i.e., glycyl-
DX-8951 and DX-8951) is not due to real elimination-processess but due to their 
much slower formation from conjugated DX-8951. Substantial interindividual 
variability was observed (coefficient of variation, up to 92%) at dose level 
7.5 mg/m2• The AUC ratio of conjugated DX-8951-to-DX-8951 was approximately 
600. The AUCs of conjugated DX-8951, glycyl-DX-8951, and DX-8951 appeared to 
increase in near proportion with an increase in dose. In tumor biopsies of four 
patients, concentrations of both glycyl-DX-8951 and DX-8951 were detectable 
at low levels, whereas in normal skin biopsies of nine patients concentrations of 
DX-8951 remained below the detection limit. During the first and second cycle 
at 6.0 mg/m2 the concentrations of the three compounds were also assessed 
in ascites of a patient with metastastic pancreatic cancer. One patient with 
metastatic adenocarcinoma of unknown primary achieved a histologically 
proven complete remission. One confirmed partial remission was observed in a 
patient with metastatic pancreatic cancer and disease stabilization was noted in 
fourteen additional patients. The recommended phase II dose is 7.5 mg/m2 given 
once every 6 weeks. The study showed that prolonged concentrations of DX-8951 
were achieved by only single short infusion of DE-31 0 given every 6 weeks, which 
confirmed the pharmacokinetic proof of principle yielding the extended exposure 
to the topoisomerase I inhibiting active moiety. 
Liposomes are macromolecular vehicles for drug delivery which are able to 
leak in tumor tissues according to the proposed EPR effect. We conducted a 
phase I and pharmacokinetic study of liposome encapsulated paclitaxel (LEP) 
as described in Chapter 6. Fourteen patients were treated at doses ranging 
from 90 - 150 mg/m2/week with LEP administered as an intravenous infusion 
over 45 minutes once every week for 6 out of 8 weeks. In one patient DLT was 
observed at dose-level 150 mg/m2/week, who received less than 70% of the 
intended cumulative dose. No cumulative toxicities were observed. Stabilization 
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clearance of total paclitaxel was similar for LEP (15.3 ± 8.98 L/h/m2) and Taxol® 
(17.5 ± 3.43 L/h/m2), and the extraliposomal-to-total-drug ratio increased 
rapidly to unity at later sampling time points. The trial was discontinued upon 
completion of enrolment of the 150 mg/m2/week cohort because an assessment 
of the pharmacokinetics and clinical data suggested that LEP was unlikely to 
have any advantages over Taxol®. It was concluded that this formulation of LEP is 
unlikely to provide improvements over taxanes currently in clinical use. 
Final conclusions and Future perspectives 
In conclusion, in preclinical models prolonged exposure to low concentrations 
of cytotoxic agents, especially suitable for topoisomerase I inhibitors and 
taxanes due to their unique mechanisms of action, shows more antitumor 
efficacy compared with bolus administration. However, the optimal treatment 
and dosing regimens, such as continuous intravenous infusion, long-term oral 
delivery, liposomal encapsulation, or polymerized drug formulations have to 
be more crystallized in further clinical investigations. So far, current insights, 
albeit only derived from phase II clinical trials, suggested that prolonged drug 
exposure may be at least as effective and less toxic than more conventional 
schedules of intermittant administration of higher doses given as short bolus 
intravenous infusion. Traditionally, continuous intravenous infusion of cytotoxic 
agents is suitable for this concept, but this way of administration poses several 
disadvantages (e.g., catheter-related infections). For a variety of reasons 
oral regimens of anticancer drugs are more convenient for continuous drug 
administration and more preferred by patients, provided the efficacy of the drug 
is not compromised. 
From a pharmacological point of view, the use of oral irinotecan has to overcome 
some disadvantages. These include maintenance absorption through the 
biochemical barrier of efflux pumps (i.e., drug transporters), and modulation 
by cytochrome P-450 isoenzymes in the epithelium of the intestine, the first 
pass effect in the liver and the excretion in the bile, that all influence the 
relatively low, and highly variable, bioavailability of the drug. In addition, the 
narrow therapeutic index offers a potential risk of an accidental overdose and 
consequently unpredictable excessive toxicity, or suboptimal exposure and 
hence lower efficacy. But on the other hand, a higher metabolic ratio, defined as 
the AUC ratio of SN-38-to-irinotecan, was determined after oral treatment of the 
drug compared with the metabolic ratio estimated after intravenous infusion of 
irinotecan, suggesting extensive presystemic metabolism due to high expression 
levels of irinotecan-converting carboxylesterases in the gastrointestinal tract 
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more efficient conversion of irinotecan into SN-38. 
Macromolecular drug-delivery systems are an alternative approach to achieve 
prolonged exposure to anti-cancer agents. It is suggested that a key factor in 
the success of polymer-based cancer therapies is the unique blood vasculature 
within solid tumors. Compared with the blood vessels in normal tissue, those 
of tumors are frequently more leaky to circulating marcomolecules allowing 
them easy access to the interior of tumor tissues. Furthermore, macromolecules 
will accumulate and be retained in tumor tissues due to anomalous lymphatic 
drainage. 
The question which has to be answered is, is there enough evidence for the 
proposed EPR effect? Likely, the prolonged exposure of high molecular weight 
macromolecules relates by the impossibility to diffuse passively in and out of cells 
like low molecular weight drugs do. Their uptake by cells elapses by the process 
of endocytosis. Afterwards, intracellular lysosomal enzymes need to release the 
active drug. This means that the polymer-drug conjugate will circulate longer 
in the general circulation, because the molecular weight is above the renal 
excretion treshold. Due to temporary inactivation of the active moiety, by linking 
to the conjugate, the longer systemic exposure of the macromolecular carrier 
is possible without increasing side effects associated with the active cytotoxic 
agent. 
The design of novel tailor-made synthetic biodegradable polymers (e.g., 
dendrimers) will be necessary in the next years and this development needs a 
multidiscplinary approach with collaborations from the field of biology, chemistry, 
pharmacology, and medicine. 
Although the expectations of the potential benefit for improving therapeutic 
activity from liposomal drug carriers are still high, today's reality in application 
of novelliposomal drug carriers demands comprehensive knowledge of liposome 
technology to understand its limitations in the design of efficacious drug 
carriers. 
From a pharmacokinetic point of view, the volume of distribution of liposomes 
is significantly reduced in comparison with small molecules, and when a drug is 
stably encapsulated within the a liposomal matrix it displays the pharmacokinetic 
profile of the liposome rather than of the parental unencapsulated agent. In 
general, this should achieve a significant increase in the area under the plasma 
concentration-time curve in the circulation and tumor tissue, and mimick the 
effect of administering cytotoxic drugs as continuous intravenous infusion, 
without the inconvience of intravenous devices and toxicities associated with 
systemic drug exposure. In addition, the maximum plasma concentration and 177 
plasma clearance of the liposomes are reduced, and its elimination half-life is 
prolonged. In theory, all these factors may contribute to an increased therapeutic 
index of liposomal formulations of cytotoxic drugs. 
After an intravenous administration of liposomes, opsonizing blood proteins 
rapidly associate with the liposome surface. The liposome-protein bound 
interactions alter the physiochemical properties of liposomes, thereby resulting 
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in altered stability and clearance properties of liposomes. This opsonization 
process triggers recognition and liposomes uptake by macrophages of the 
reticuloendothelial system (RES) through receptor-mediated phagocytosis or 
endocytosis and clearance by the liver, spleen or lung. The complement system is 
responsible for the elimination of liposomes from blood circulation, presumably 
as a consequence of opsonization by activated complement C3 fragments and 
the membrane attack complex (MAC), i.e., the assembly of CSb-9 complexes 
that produces a lytic pore, which induce the release of the liposomal contents. 
The circulation time of pegylated-liposomes (e.g., Caelyx®) is longer than 
conventional liposomes because the stealth characteristics take more time to 
be attacked by macrophages. This means that broad suitability of liposomes 
vehicles as passive targeting for cytotoxic agents in oncological practice may 
have limited benefits. 
Samenvatting en conclusies 
In dit proefschrift worden de resultaten besproken van klinische en 
farmacologische fase I studies, die enerzijds met tweede en derde generatie 
topoisomerase I remmers en anderzijds met het cytostaticum (antikankermiddel) 
liposomaal geformuleerd paclitaxel zijn verricht. De topoisomerase I remmers 
irinotecan en exatecan werden respectievelijk oraal als capsule en intraveneus als 
polymeer - door koppeling aan een biologisch afbreekbare polyalcoholstructuur 
- toegediend. Het antimicrotubulaire cytostaticum paclitaxel werd intraveneus 
als een liposomale formulering toegediend. Het doel van dit proefschrift was 
om de toepasbaarheid van verlengde expositieduur van deze cytostatica en 
formuleringen te onderzoeken. Deze studies werden uitgevoerd op basis van 
de resultaten van preklinisch onderzoeken, waarbij aangetoond werd dat de 
effectiviteit van celdoding door zowel topoisomerase I remmers als paclitaxel 
grater werd naarmate de expositieduur van deze middelen kon worden 
verlengd. 
In Hoofdstuk 1 wordt een overzicht gegeven van semi-synthetische 
camptothecine analoga, die inmiddels zijn geregistreerd voor dagelijkse 
klinische toepassing of die zich nog in een (pre- )klinisch ontwikkelingsstadium 
bevinden. Ten einde antitumoractiviteit te vergroten en bijwerkingen te 
verminderen, zijn verschillende strategieen toegepast om de systemische 
toepassing van deze analoga te verbeteren. Drie manieren van aanpak worden 
hierbij besproken, (a) de farmaceutische wijziging van formuleringsvehikels en 
structuurformule en het maken van meer wateroplosbare prodrugs, (b) wijziging 
van toedieningsroutes en van infusieduur, en (c) de biomodulatie van de 
farmacodynamiek en farmacokinetiek. 
Het oraal innemen van irinotecan is een patientvriendelijke benadering om de 
continue intraveneuze toediening van dit cytostaticum na te bootsen ten einde 
een verlengde expositieduur van dit antikankermiddel te bewerkstelligen. In 
Hoofdstuk 2 worden de resultaten van een klinische en farmacokinetische fase 179 
I studie met oraal toegediend irinotecan, geformuleerd als semi-solid matrix 
(SSM) capsules, bij kankerpatienten beschreven. In deze studie werd eveneens 
het effect van voedselinname op de biologische beschikbaarheid onderzocht, 
alsmede farmacogenetische aspecten van irinotecan. Het doel van deze studie 
was om de maximaal verdraagbare dosering, de aanbevolen dosering voor verder 
onderzoek in fase II studies, het bijwerkingen- en het farmacokinetische profiel 
van irinotecan vast te stellen. lrinotecan werd door de patienten 's ochtends op 
de nuchtere maag eenmaal daags gedurende vijf achtereenvolgende dagen in een 
periode van drie weken ingenomen. Eenmalig werd het cytostaticum ingenomen 
na een vet- en koolhydraatrijk ontbijt om het effect daarvan op de biologische 
beschikbaarheid van het cytostaticum vast te stellen. Randomisatie hiervoor 
vond plaats om te bepalen of de medicatie met het ontbijt tijdens de eerste of de 
tweede kuur moest worden ingenomen. Aan vijfentwintig patienten werden 101 
kuren (mediaan 2 kuren, interval 1 - 15) toegediend. De toegepaste doseringen 
war en 70 en 80 mg/m2 I dag. Ernstige diarree (graad 3) en koorts (graad 3) waren 
de dosis-limiterende bijwerkingen (DLT) bij de dosering van 80 mg/m2 I dag in drie 
van vijf patienten. In vergelijking met intraveneuze toediening van irinotecan is 
de blootstelling aan de actieve metaboliet SN-38 relatief hoog, maar er werd 
geen relevante accumulatie van SN-38 in onze studie vastgesteld. Het gelijktijdig 
innemen van de irinotecan capsules met voedsel had geen significant effect op 
de farmacokinetiek van irinotecan. In de patientengroep, die eerdere behandeld 
was geweest met andere cytostatica, werd bij een patient een partiele remissie 
vastgesteld, terwijl bij tien patienten stabilisatie van de ziekte als respons werd 
waargenomen. Tussen UGT1 A 1 *28-genotypering en het risico op het onstaan 
van ernstige bijwerkingen door irinotecan (i.h.b. diarree en neutropenie) kon 
in onze studie geen verband worden vastgesteld. De aanbevolen dosering is 
70 mg/m2 /dag gedurende vijf achtereenvolgende dagen tijdens een periode 
van drie weken. De studie bevestigt dat de orale toediening van irinotecan 
goed haalbaar is en mogelijk verbeterde farmacokinetische kenmerken heeft in 
vergelijking met intraveneuze toediening van dit cytostaticum. 
In het algemeen geldt, dat een combinatie van cytostatica effectiever is 
dan monotherapie met een cytostaticum. lrinotecan en capecitabine hebben 
verschillende werkingsmechanismen en tonen synergistische en toegevoegde 
effectiviteit van celdoding in experimentele diermodellen. Verder hebben 
beide middelen slechts gedeeltelijk overlappende bijwerkingsprofielen. 
Tegen deze achtergrond, hebben wij een klinische en farmacokinetische fase 
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kankerpatienten, zoals beschreven in Hoofdstuk 3. Achtentwintig patienten 
kregen in totaal 155 kuren (mediaan 5 kuren, interval 1 - 18) toegediend. Zij 
kregen eenmaal daags gedurende vijf achtereenvolgende dagen irinotecan SSM 
capsules (dosering 50 - 60 mg/m2 /dag) gelijktijdig met capecitabine (dosering 
800 - 1000 mg/m2) tweemaal daags gedurende veertien achtereenvolgende 
dagen. Een kuur werd elke drie weken herhaald. Bij de dosering van irinotecan 
60 mg/m2/dag en capecitabine 2 x 800 mg/m2/dag waren ernstige diarree (graad 
3) in combinatie met braken (graad 2), ondanks maximale bescherming met anti-
emetica, alsmede in combinatie met ernstige eetlustverlies (anorexie) (graad 3) 
en colitis (graad 3), dosis-limiterende bijwerkingen (DLT) tijdens de eerste kuur 
in twee van zes patienten. De bijwerkingen op het niveau van de aanbevolen 
dosering (c.q. irinotecan 50 mg/m2/dag en capecitabine 2 x 1000 mg/m2/dag) 
waren over het algemeen mild tot matig en reversibel. Farmacokinetische 
analyse toonde geen interactie tussen irinotecan en capecitabine. Drie patienten 
hadden een partiele remissie als respons en zestien patienten behielden 
stabilisatie van hun ziekte tijdens deze behandeling. De studie toont aan dat de 
combinatiebehandeling van orale irinotecan en capecitabine haalbaar is en goed 
verdragen wordt. De behandeling met orale cytostatica geeft de mogelijkheid 
om patienten poliklinisch te behandelen. Mede daarom is het aan te bevelen om 
deze combinatie verder te onderzoeken in fase II studies. 
Een andere benadering om meer continue expositie aan een cytostaticum te 
bereiken, vormt het toepassen van een zogenaamd 'macromolecular drug-
delivery system' (macromoleculair geneesmiddelafleveringssysteem), waarbij 
bijvoorbeeld een actief werkzame topoisomerase I remmer wordt gekoppeld 
aan een polyalcoholstructuur (i.e., polymeer). Er wordt verondersteld dat 
macromoleculen bij voorkeur in tumorweefsel kunnen accumuleren door een 
fenomeen, genaamd enhanced permeability and retention (EPR) effect, dat 
wordt veroorzaakt door de gewijzigde structuur van bloedvaten in tumorweefsel, 
waarbij het endotheel niet als een continue aaneengesloten laag is aangelegd, 
maar daartussen grote porien bevat. Als gevolg hiervan zouden macromoleculen 
gemakkelijker in tumorweefsel kunnen lekken dan in normale weefsels. 
Bovendien voorkomt de gebrekkige aanleg van lymfvaten in tumorweefsel dat 
macromoleculen daar efficient uit kunnen worden geklaard. Ten gevolge van 
deze beide tumorweefselkarakteristieken wordt verondersteld dat accumulatie 
van een 'macromolecular drug-delivery system' in tumorweefsel plaatsvindt en 
dat hiermee een hogere concentratie van een actief werkzaam cytostaticum in 
de tumor kan worden bereikt. 181 
DE-31 0 is een nieuwe macromoleculaire prod rug van de topoisomerase I remmer 
exatecan (DX-8951f). Om de distributie van deze macromoleculaire prodrug en 
zijn enzymatische afsplitsingsmetabolieten (i.e., glycyl-DX-8951 en DX-8951) 
te bestuderen, werden hoge druk vloeistofchromatografie (HPLC) bepalingen 
in menselijk bloed, rode bloedcellen en speeksel ontwikkeld en gevalideerd, 
zoals beschreven in Hoofdstuk 4. De voorbehandeling van de monsters bestond 
uit een enkelvoudige onteiwitingsstap, gevolgd door een deconjugatie van het 
hoofdmolecuul. Scheiding van de verschillende componenten werd bereikt 
door gebruik te maken van een HPLC methode met een reversed-phase kolom 
en isocratische elutie. De kolomeffluent werd gemonitored door middel van 
fluorescentie. De laagst adequaat en precies meetbare concentraties bij 
deze methode was 0.5 ng/ml voor glycyl-DX-8951 en DX-8951, alsmede 6. 9 
ng/ml voor geconjugeerd DX-8951 (i.e., het aan de polyalcoholstructuur 
gekoppelde molecuul). De toepasbaarheid van de methode voor klinisch gebruik 
werd aangetoond door de bepaling van DE-310 en de twee enzymatische 
afsplitsingsprodukten in rode bloedcellen en speeksel afkomstig van acht 
kankerpatienten, die behandeld werden met DE-310 gedoseerd met een dosis 
van 7.5 mg/m2 eenmaal per 6 weken. De concentraties van DE-310, glycyl-DX-
8951 en DX-8951 in alle geanalyseerde monsters van de rode bloedcellen en 
speeksel waren lager dan de laagst adequaat en precies meetbare concentratie. 
Deze bevinding komt overeen met de hypothese van preferentiele opname van 
macromoleculen in tumorweefsel en niet in normale weefsels. Op grond hiervan 
kan worden gesteld, dat de biodistributie van DE-310 wezenlijk anders is dan van 
andere topoisomerase I remmers, zoals irinotecan en topotecan. 
In Hoofdstuk 5 rapporteren wij een klinische en farmacokinetische fase 
I studie met DE-31 0, intraveneus toegediend als een 3-uur durend infuus 
eenmaal per 2 of 6 weken bij kankerpatienten. Zevenentwintig patienten 
werden behandeld en er werden in totaal 86 toedieningen (overeenkomend 
met 61 kuren) gegeven. Aanvankelijk werden de patienten eenmaal per 
2 weken in een 4-wekelijks toedieningsschema behandeld (doseringsinterval 1.0 
- 2.0 mg/m2). In verband met de lange halfwaardetijd, die bijna gelijk bleek 
aan het toedieningsinterval en veellanger was dan de verwachte halfwaardetijd 
op basis van preklinisch onderzoek, was verder onderzoek van dit 2-wekelijkse 
toedieningsschema niet meer opportuun wegens het te verwachten risico op 
accumulatie dit cytostaticum. Derhalve werd het studieprotocol geamendeerd 
tot een 6-wekelijks toedieningsschema (doseringsinterval6.0- 9.0 mg/m2). Zeer 
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gepaard gaande met vena-occlusive disease (VOD), waren de belangrijkste dosis-
limiterende bijwerkingen. Overige hematologische en niet-hematologische 
bijwerkingen waren mild tot matig en waren reversibel. Farmacokinetische 
analyse kon in alle patienten worden verricht. De halfwaardetijden van 
geconjugeerd DX-8951, glycyl-DX-8951 en DX-8951 waren respectievelijk 13, 12 
en 13 dagen over het gehele doseringstraject. De plasmaconcentraties van alle 
componenten konden gedurende enkele weken worden aangetoond. De parallel 
verlopende verlaging van de concentraties van de metabolieten suggereert dat 
de eindfase niet gerelateerd is aan een werkelijke uitscheiding van de DE-31 0-
metabolieten, maar bepaald wordt door de langzame enzymatische afsplitsing 
van DE-31 0. Aanzienlijke interindividuele variabiliteit (met variatiecoefficient 
tot 92%) werd waargenomen bij een dosering van 7.5 mg/m2• De verhouding van 
de oppervlakte van de curve, die het verloop tussen de plasmaconcentratie en 
de tijd weergeeft (AUC; area under the curve), van geconjugeerd DX-8951 en van 
DX-8951 was ongeveer 600. De AUC's van geconjugeerd DX-8951, glycyl-DX-8951 
en DX-8951 bleken in goede verhouding te staan met toename van de dosering. 
Glycyl-DX-8951 en DX-8951 konden in lage concentraties worden aangetoond 
in tumorbiopten afkomstig van vier patienten, terwijl in normale huidbiopten 
afkomstig van negen patienten geen DX-8951 kon worden aangetoond. Bij een 
patient met gemetastaseerd pancreascarcinoom, die behandeld werd met DE-310 
in een dosis van 6.0 mg/m2 (q6w), konden concentraties van de drie componenten 
in ascites worden aangetoond. Een patient met gemetastaseerd adenocarcinoom 
van onbekende primaire origine bereikte een histologisch bewezen complete 
remissie met een follow-up duur van ruim een jaar. Een partiele remissie werd 
vastgesteld bij een andere patient, terwijl stabilisatie van ziekte als respons werd 
waargenomen bij veertien andere patienten. De aanbevolen dosering van DE-310 
voor fase II studies is 7.5 mg/m2 eenmaal per 6 weken intraveneus toegediend. De 
studie toonde aan dat langdurige concentraties van de topoisomerase I remmer 
exatecan (DX-8951) konden worden verkregen door middel van een eenmalige 
korte infusie van de macromoleculaire prodrug DE-310, dat slechts eenmaal per 
6 weken hoeft te worden toegediend. Vanuit farmacokinetische gezichtspunt 
kon hiermee het principe van langdurige expositieduur van een topoisomerase I 
remmer bevestigd worden. 
Liposomen zijn macromoleculaire vehikels om geneesmiddelen te transporteren. 
Ook liposomen zijn in staat om in tumorweefsel te lekken als gevolg van 
het eerdergenoemde EPR effect. Een klinische en farmacokinetische fase 
I studie met paclitaxel geformuleerd (c.q. ingepakseld) in liposomen (LEP; 183 
liposome encapsulated paclitaxel) werd door ons uitgevoerd zoals beschreven 
in Hoofdstuk 6. Veertien kankerpatienten werden behandeld met LEP 
(doseringsinterval 90 - 150 mg/m2/week), waarbij het cytostaticum zesmaal 
wekelijks als kortdurend infuus van 45 minuten werd toegediend in een totale 
periode van acht weken. Een patient kreeg een dosis-limiterende bijwerking op 
het doseringsniveau van 150 mg/m2/week, ten gevolge van het feit dat minder 
dan 70% van de bedoelde cumulatieve dosering aan deze patient kon worden 
gegeven. In deze studie werden geen cumulatieve bijwerkingen vastgesteld. In 
twee patienten werd stabilisatie van hun ziekte gedurende 8 weken als respons 
waargenomen. De klaring van totaal paclitaxel uit bloed was identiek voor LEP 
(15.3 ± 8.98 L/h/m2 ) als voor Taxol® (17.5 ± 3.43 Llh/m2). Op latere tijdstippen 
van de farmacokinetische bloedafnames kon geen onderscheid meer gemaakt 
worden tussen extraliposomaal paclitaxel en totaal paclitaxel. Deze studie 
werd voortijdig beeindigd na voltooiing van de patienteninstroom voor het 
doseringscohort 150 mg/m2/week, op basis van farmacokinetische en klinische 
resultaten, die suggereerden dat LEP geen voordeel zou hebben ten opzichte 
van Taxol®. Derhalve werd geconcludeerd dat deze liposomale formulering van 
paclitaxel (LEP) niet zou kunnen voorzien in verbeteringen ten opzichte van de 
taxanen, die momenteel klinisch worden toegepast. 
Eindcondusies en toekomstperspectieven 
In preklinische modellen laat verlengde expositie aan lage concentraties 
van cytostatica - een concept dat vooral toepasbaar is voor topoisomerase 
I remmers en paclitaxel, vanwege hun unieke werkingsmechanismen - een 
betere antitumoractiviteit zien in vergelijking met korte expositie aan hoge 
concentraties cytostatica, die als bolus werden toegediend. Echter, de optimale 
behandeling en doseringsschema's, zoals bijvoorbeeld door middel van continue 
intraveneuze infusie, langdurige orale toediening, toediening via liposomale of 
gepolymeriseerde formuleringen, dient nog nader te worden uitgekristalliseerd 
in meer onderzoeken. Tot nu toe suggereren de gegevens, ofschoon slechts 
afkomstig van klinische fase II studies, dat verlengde expositie aan cytostatica 
tenminste even effectief en minder toxisch kan zijn dan conventionele schema's 
met intermitterende, intraveneuze toediening van hoge doseringen cytostatica als 
een bolus. Traditioneel wordt continue intraveneuze infusie van cytostatica voor 
dit concept toegepast, echter deze toedieningsvorm heeft een aantal nadelen, 
184 zoals bijvoorbeeld catheter-gerelateerde infecties. De orale toedieningsvorm 
is in principe een mogelijkheid voor continue toediening van cytostatica en de 
meerderheid van patienten geeft hieraan de voorkeur, mits de effectiviteit van 
het cytostaticum door de orale toedieningsvorm niet wordt verminderd. 
Vanuit een farmacologisch gezichtspunt gezien, heeft het gebruik van oraal 
irinotecan een aantal nadelen. Tot deze nadelen behoren o.a. het behoud van 
absorptie van het cytostaticum door de dunne darm tegen een biochemische 
barriere van efflux-pompen (i.e., drug transport-eiwitten) in, wijziging van het 
cytostaticum door cytochroom P-450 isoenzymen in het dunne darmepitheel, 
het 'first pass' -effect in de lever en de uitscheiding in de gal. Deze factoren 
beYnvloeden de relatief lage en hoog variabele biologische beschikbaarheid van dit 
cytostaticum. Bovendien zorgt de smalle therapeutische breedte enerzijds voor 
een potentieel risico van incidentele overdose ring en daarmee de mogelijkheid van 
onvoorspelbare ernstige bijwerkingen, en anderzijds van suboptimale expositie 
van het cytostaticum en daarmee een kans op vermindering van de effectiviteit. 
Aan de andere kant wordt een hogere metabole ratio, gedefinieerd als de 
AUC-verhouding van SN-38 ten opzichte van irinotecan, waargenomen na orale 
toediening van irinotecan in vergelijking met de metabole ratio na intraveneus 
toegediende irinotecan. Deze verhoogde metabole ratio wordt veroorzaakt 
door uitgebreide presystemische metabolisatie van irinotecan ten gevolge van 
hoge expressie in de darmen en in de lever van carboxylesterases, enzymen die 
irinotecan kunnen metaboliseren. Op grand hiervan kan verondersteld worden 
dat de orale toediening van irinotecan resulteert in efficientere omzetting van 
irnotecan in zijn actieve metaboliet SN-38. 
Met het gebruik maken van macromolecular drug-delivery systems wordt een 
andere manier om verlengde expositieduur van cytostatica te bewerkstelligen 
toegepast. In de literatuur wordt gesuggereerd dat een sleutelfactor in het 
succes van op polymeren-gebaseerde antikankerbehandelingen wordt bepaald 
door de unieke structuur van de bloedvaten van tumorweefsels. In vergelijking 
met bloedvaten in normale weefsels zijn de bloedvaten in tumorweefsels meer 
doorlaatbaar voor circulerende macromoleculen. Hierdoor zijn macromoleculen in 
staat om in tumorweefsel te accumuleren. Bovendien kunnen de macromoleculen 
daarna niet uit tumorweefsel worden geklaard in verband met de gebrekkige 
aanleg van lymfvaten in tumorweefsels. 
De vraag die beantwoord dient te worden, is of er voldoende bewijs is om aan 
te nemen dat het zogenaamde EPR effect bestaat? De verlengde expositieduur 
van macromoleculen met een hoog moleculair gewicht wordt bereikt door de 
onmogelijkheid van deze macromoleculen om passief in cellen te diffunderen 
zoals stoffen met een laag moleculair gewicht dat wel kunnen doen. De opname 185 
van macromoleculen geschiedt via het proces van endocytose. lntracellulair 
wordt de actief werkzame stof vrijgemaakt van de polymeerstructuur met behulp 
van lysosomale enzymen. Dit tijdkostende opnameproces van macromoleculen in 
cellen impliceert dat de macromoleculen langdurig in de bloedsomloop blijven 
circuleren, mede gelet op het feit dat macromoleculen, vanwege hun hoge 
moleculaire gewicht, niet door de nieren kunnen worden uitgescheiden. 
Een actief werkzaam cytostaticum dat aan een polymeerstructuur gekoppeld is, 
is hierdoor tijdelijk inactief gemaakt en geeft daardoor minder bijwerkingen bij 
verblijf in de bloedsomloop. 
Het antwerp van nieuwe op maat gemaakte synthetische biologisch afbreekbare 
polymeren (bijvoorbeeld dendrimeren) zal in de komende jaren noodzakelijk zijn 
en een succesvolle ontwikkeling hiervan noopt tot intensieve multidisciplinaire 
samenwerking vanuit verschillende disciplines, o.a. biologie, biochemie, 
farmacologie en geneeskunde. 
Hoewel de verwachtingen van het potentii:He voordeel voor het bereiken van een 
verbeterde therapeutische activiteit door liposomen nog steeds hoog gespannen 
zijn, eist de realiteit dat het toepassen van liposomen als vehikels voor 
cytostatica een uitgebreide kennis van de liposomentechnologie noodzakelijk 
maakt, om de beperkingen van liposomen als effectieve vehikels van cytostatica 
te kunnen begrijpen. 
Vanuit een farmacokinetisch gezichtspunt gezien, is het verdelingsvolume van 
liposomen significant verminderd in vergelijking met kleine moleculaire stoffen. 
Het farmacokinetische profiel wordt weerspiegeld door het liposoom zelf en niet 
door het erin opgenomen cytostaticum, indien dit cytostaticum stabiel genoeg 
in de liposomale matrix is opgenomen. In het algemeen wordt een significante 
stijging van de AUC in de bloedsomloop en in tumorweefsel bereikt, waarmee 
het effect van een continue infusie van een cytostaticum kan worden nagebootst 
zonder het ongemak van langdurige intraveneuze infusie of bijwerkingen ten 
gevolge van de systemische blootstelling van het cytostaticum. Bovendien zijn de 
maximale plasmaconcentratie en plasmaklaring van liposomen verminderd en is 
de halfwaardetijd verlengd. In theorie dragen al deze farmacokinetische factoren 
bij tot een verhoogde therapeutische breedte van liposomale formuleringen voor 
cytostatica. 
Na intraveneuze toediening van liposomen, wordt het liposomale oppervlak 
snel door bloedeiwitten geopsoniseerd. Deze liposomale-eiwitbindinginteracties 
wijzigen de fysicochemische eigenschappen van liposomen, resulterend in 
gewijzigde stabiliteit en klaring van de lipsomen. Dit proces van opsonisatie 
186 zorgt ervoor dat liposomen worden herkend en opgenomen door macrofagen van 
het reticuloendotheliale systeem (RES) door middel van receptoren-gemedieerde 
fagocytose en vervolgens door de lever, milt en longen worden geklaard. Het 
complement systeem is verantwoordelijk voor de eliminatie van liposomen uit 
de bloedsomloop, voornamelijk als een gevolg van opsonisatie door geactiveerd 
complement C3-fragmenten en het 'membrane attack complex' (MAC), i.e., 
de verzameling van C5b-9 complementcomplexen. Het MAC zorgt ervoor dat 
een porie in het liposoom kan ontstaan, als gevolg waarvan het vrijkomen van 
de liposomale inhoud wordt bewerkstelligd. De circulatietijd van pegylated-
liposomen (bijvoorbeeld Caelyx®) is langer dan van conventionele liposomen, 
vanwege het feit dat macrofagen meer tijd nodig hebben om pegylated-liposomen 
te fagocyteren. Een en ander impliceert dat de brede toepasbaarheid van 
liposomen als vehikels voor passief transport van cytostatica in de oncologische 
praktijk slechts beperkt mogelijk is. 
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Wie getroffen is door kanker en gaandeweg ervaart dat "Het Leven altijd 
een ongelijke dans van schijnbare kans en scheve rechtvaardigheid is" (Leo 
Vroman), kan - zodra kansrijke standaardbehandelingen in de reguliere 
geneeskunde ontbreken - de keuze maken om te participeren in een Fase I 
geneesmiddelenonderzoek met experimentele cytostatica. 
In bepaalde opzichten kan men bij zo'n Fase I geneesmiddelenonderzoek een 
parallel trekken met het bereiden en serveren van een nog niet eerder beproefde 
maaltijd. Het benodigde keukengerei en de afzonderlijke ingredienten om zo'n 
maaltijd te bereiden zijn vooraf genoegzaam bekend, maar de uitkomst van de 
samenstelling tot een nieuw eetbaar concept, varierend van een eenvoudige 
ltaliaanse pasta tot een uiterst gecompliceerde Japanse tafel, is telkens een 
nieuwe uitdaging. Stapsgewijs worden proefpersonen voorzichtig blootgesteld 
aan hogere doses van een nieuw produkt, totdat de maximale dosering van de 
smaak gevonden is, waarbij het optreden van misselijkheid, braken of diarree 
niet geheel uitgesloten kan worden. 
Op de afdeling Interne Oncologie van het Erasmus MC - Daniel den Hoed bevindt 
zich een dergelijke keuken, waar sinds enkele tientallen jaren verschillende 
van deze 'proefmaaltijden' - met meer of minder succes - worden bereid en 
geserveerd. De afgelopen 4 jaren heb ik mij verdienstelijk mogen maken in het 
pionierswerk van deze buitengewone gastronomie, daarbij gesteund door de 
multidisciplinaire samenwerking met vele medewerkers, waarvoor ik hen allen 
zeer hartelijk dank. lk zal U rondleiden in dit bijzondere etablissement en U nader 
voorstellen aan enkelen van hen ..................................................... . 
De Stamgasten, patienten, ieder met hun eigen levensverhaal in een ongewisse 
tijd op het einde van hun levenspad, wekelijks, geduldig aanschuivend aan de 
lange tafels op de polikliniek, ben ik bijzonder erkentelijk voor hun moed en 
vertrouwen om een dergelijke proefmaaltijd te proberen. lmmers, "the proof of 
the pudding is the eating". Soms werden zij extra op de proef gesteld door het 
nuttigen van een vet- en zwaar koolhydraatrijk ontbijt op de nuchtere maag. 
196 De Restaurateur, Prof. dr. Gerrit Stater, nestor van de afdeling en de klassieke 
Nederlandse keuken tot in de finesse beheersend, dank ik zeer voor zijn 
gastvrijheid en de geboden mogelijkheden in deze culinaire carriere. Ook dank 
ik je voor het feit dat je een van mijn promotoren wil zijn. 
Le Chef de Cuisine, Prof.dr.Jaap Verweij, promotor, createur en culinaire coach 
in het bereiden van diverse maaltijden met internationale faam en Michelin-ster. 
Heel veel dank dat ik de afgelopen tijd jouw keukenhulp mocht zijn. Het smaakt 
eigenlijk nog steeds naar meer ..................................... . 
La Gerante, dr.Maja de Jonge, Ladychef van formaat, bedankt voor al jouw 
wijze lessen in de uitgebreide kookboekreceptuur. lk heb het als een voorrecht 
beschouwd, om zolang met jou samen de Fase I polikliniek te mogen doen. 
The Executive Chief, dr.Alex Sparreboom, thuis in vele kookstijlen, is na 
jarenlange trouwe dienst begonnen aan zijn eigen culinaire avontuur onder 
Amerikaanse vlag. Heel veel dank voor de snelle beoordelingen van het gehele 
driegangenmenu en jouw bereidheid om voor de promotie naar Nederland terug 
te komen. 
De disgenoten, Leden van de Kleine en Grote Promotiecommissie, Prof.dr.Alex 
Eggermont, Prof.dr.Allan van Oosterom, Prof.dr.Pieter Sonneveld, Prof.dr.Curt 
Burger en Prof.dr.Sjoerd Rodenhuis, "met Hoge Heren is het kwaad kersen 
eten", dank ik allen zeer voor hun snelle beoordeling van alle hoofdgerechten op 
de grote kaart en hun deelname aan de promotiecommissie. 
Het bedienend personeel, alle senior- en junior-internisten, thuis in alle 
keukengeheimen, bedankt voor de plezierige en collegiate samenwerking de 
afgelopen jaren. 
De liefdevolle serveersters, "de meisjes van 80-Zuid", ofwel een "Gouden team" 
onder bezielende leiding van Bogdana, ben ik zeer dankbaar voor de prettige 
samenwerking in de afgelopen periode en de nauwgezette en uitstekende wijze, 
waarop alle - soms zelfs in aluminiumfolie verpakte - proefmaaltijden werden 
geserveerd en de gasten daarbij op en top werden verwend en begeleid. De 
secretaresses, Willy en Jeanne, bedank ik voor het accurraat verzorgen van 
het gastenboek; de afspraken en reserveringen waren altijd op tijd en correct 197 
gemaakt. Bimla, bedankt voor al je hulp bij het afdraaien van de bloedmonsters 
in de echte keuken. Bovendien heeft jouw dagelijkse bezorging van de koffie om 
stipt 2 uur 's middags zijn Pawlow-reflex niet gemist. Alle verpleegkundigen en 
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hoofdstukken en jullie kritische commentaren op de manuscripten. 
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198 Assadourian, Christian Boeuf, Patricia Lefebvre, Dorothee Semiond and Ger-Jan 
Sanderink (Aventis, Paris, France}, I thank you all very much for the pleasant 
collaboration to the different Phase I trials of this PhD thesis. 
De leveranciers, de bibliothecaressen, Marijke Westerhout-Kersten en Kerstin 
van der Veen, ben ik zeer erkentelijk voor hun snelle service en hulp bij het 
verzamelen van alle keukenrecepten c.q. literatuurgegevens. De radiologen, 
dr.Hein de Bruin, drs.Monica Piskorz, dr.Anca Ciurea en dr.Cees van Dijke, heel 
veel dank voor jullie bereidheid om die lastig terug te vinden retroperitoneale of 
mediastinale lymfkliermetastasen nog eens aan te wijzen. 
Ten slotte ... , mijn ouders, grote waardering heb ik voor hen, vanwege hun 
onvoorwaardelijke liefde, hun morele ondersteuning en relativeringsvermogen 
tijdens studie en promotietijd. Dat pappa in de afrondingsfase van dit 
proefschrift zo getroffen werd door een ernstige ziekte had niemand kunnen 
vermoeden. Vanaf dit moment kan ik alleen maar hopen dat zijn gezondheid hem 
zal toestaan, dat hij de promotieplechtigheid nog persoonlijk kan bijwonen. 
Dulce ca ?i mierea, mijn geliefde, drs. Mirella, samen hebben we in korte tijd al 
heel veellol beleefd, ik verheug me op wat de toekomst zal brengen, dank voor 
al jouw liefde, begrip en steun. 
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